Drug, bio-affecting and body treating compositions inventions 08/08

20080207486 - Compositions and methods for the therapy and diagnosis of breast cancer: Compositions and methods for the therapy and diagnosis of cancer, particularly breast cancer, are disclosed. Illustrative compositions comprise one or more breast tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides.... Agent: Seed Intellectual Property Law Group Pllc

20080207484 - Hybrid proteins with erbb4 extracellular domain and neuregulin heparin-binding domain for targeting: Polypeptides of the neuregulin (NRG) heparin binding domain (N-HBD) and nucleic acids coding therefor are disclosed. In particular, fusion polypeptides are produced that comprise, as a targeting structure, a N-HBD polypeptide, fragment, homologue or functional derivative and a protein to be targeted. This is fused to a polypeptide or peptide... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20080207487 - Manufacturing process for the production of polypeptides expressed in insect cell-lines: The present invention provides a manufacturing method for polypeptides that are produced in insect cells using a baculoviral expression system. In one example, the insect cell culture is supplemented with a lipid mixture immediately prior to infection (e.g., one hour prior to infection). The polypeptides are isolated from the insect... Agent: Morgan, Lewis & Bockius LLP (sf)

20080207488 - Method for detecting peptides comprising a cross-b structure: The invention relates to the field of compositions comprising a protein, more specifically to pharmaceutical compositions. More specifically, the invention relates to the detection and/or removal of conformationally altered proteins and/or molecules comprising a cross-β structure from a pharmaceutical composition or any of its constituents comprising a protein. The present... Agent: Trask Britt

20080207483 - Methods and compositions for diagnosis and therapy of cancer based on hyper-mutated tumor genes: The present invention provides novel methods and compositions for the diagnosis and treatment of cancers. The invention also provides methods of identifying inhibitors of tumorigenesis.... Agent: Stefano Volinia

20080207485 - Mhc oligomer and method of making the same: The invention discloses MHC oligomers and methods for making the same comprising at least two functional MHC complexes having a peptide binding groove, each MHC complex having a peptide bound in the peptide binding groove of the MHC complex, wherein each peptide has a modification which allows highly specific oligomersation... Agent: Foley And Lardner LLP Suite 500

20080207489 - Use of ccn5 for treatment of smooth muscle proliferation disorders: The invention provides methods for treating a smooth muscle cell disorder such as asthma, vascular injury, persistent pulmonary hypertension in the newborn, pulmonary hypertension in adults, megaureter, pyloric stenosis, uterine fibroids, lymphangioleiomyomatosis (LAM), cervical incompetence, or cancer, and methods for assessing smooth muscle tissue remodeling in a mammal by expressing... Agent: Lawson & Weitzen, LLP

20080207490 - Glucose uptake modulator and method for treating diabetes or diabetic complications: The present invention relates to an glucose uptake modulator, a pharmaceutical composition comprising the glucose uptake modulator, and a method of treating a diabetes or diabetic complications in a mammal in need thereof, which comprises administering to said mammal an effecting amount of a glucose uptake modulator.... Agent: Lexyoume Ip Group, Llc

20080207491 - Method and composition for treatment and/or prevention of antibiotic-resistant microorganism infections: The present invention relates to a new composition, use and method to improve the cure of infections caused by antibiotic resistant microbial pathogens, in particular beta-lactam resistant microorganisms. Lactoferrin (LF) or Lactoferricin (LFC) can be administrated alone or in combination with antibiotic to affect growth, physiology and morphology of targeted... Agent: Wood, Phillips, Katz, Clark & Mortimer

20080207492 - Amphipathic glycopeptides: Glycopeptides which are amphipathic and capable of crossing the blood-brain-barrier are provided. The glycopeptides are useful for treating a variety of neurological an behavioral disorders.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.c.

20080207493 - Compounds for use in the treatment of obesity: The present invention relates to novel peptide compounds which are effective in modulating one or more melanocortin receptor types, to the use of the compounds in therapy, to methods of treatment comprising administration of the compounds to patients in need thereof, and to the use of the compounds in the... Agent: Novo Nordisk, Inc. Intellectual Property Department

20080207494 - Cyclosporin compositions: Cyclosporin A compositions are disclosed herein comprising an oil and a surfactant. These are useful in the treatment of dry eye disease.... Agent: Allergan, Inc.

20080207495 - Cyclosporin compositions for ocular rosacea treatment: Disclosed herein are methods of treating ocular rosacea with cyclosporin A. Compositions and medicaments related thereto are also disclosed.... Agent: Allergan, Inc.

20080207496 - Organic compound: A combination which comprises (a) a staurosporine derivative and (b) an agent effective in preventing, delaying or treating transplant rejection in which the active ingredients (a) and (b) are present in each case in free form or in the form of a pharmaceutically acceptable salt and optionally at least one... Agent: Novartis Corporate Intellectual Property

20080207501 - Amylin family polypeptide-6 (afp-6) analogs and methods of making and using them: The present invention relates to Amylin Family Polypeptide-6 (AFP-6) analogs, which include derivatives and fragments, related nucleic acids, expression constructs, host cells, and processes for recombinant production of the AFP-6 analogs. The AFP-6 analogs of the invention include one or more amino acid sequence modifications. In addition, methods and compositions... Agent: Intellectual Property Department Amylin Pharmaceuticals, Inc.

20080207502 - Anti-angiogenic peptides and methods of use thereof: Anti-angiogenic peptides that inhibit activation or proliferation of endothelial cells are disclosed. Such peptides maybe used to inhibit VEGF binding to the VEGFR2 receptor (also known as the kinase domain receptor or KDR) and bFGF binding to its receptor. Such peptides may also be used to inhibit, VEGF, bFGF, or... Agent: Cooley Godward Kronish LLP Attn: Patent Group

20080207505 - Bna conjugates and methods of use: Modified natriuretic compounds and conjugates thereof are disclosed in the present invention. In particular, conjugated forms of hBNP are provided that include at least one modifying moiety attached thereto. The modified natriuretic compound conjugates retain activity for stimulating cGMP production, binding to NPR-A receptor, decreasing arterial blood pressure and in... Agent: Moore & Van Allen Pllc

20080207516 - Co-administration of a polysaccharide with a chemotherapeutic agent for the treatment of cancer: Disclosed herein are compositions and methods for treating diseases such as cancer. The compositions comprise one or more polysaccharides in an admixture with one or more therapeutic agents. This admixture can be administered to a subject in need thereof using any known method of administration. The therapeutic agent, if administered... Agent: Greenberg Traurig, LLP

20080207503 - Composition and treatment methods for coronary artery disease: The present disclosure demonstrates that cholesterol-free discoidal reconstituted HDL (R-HDL), phosphatidyl-choline (PC) and PC liposomes effectively released cholesterol from ICP. Native HDL and its apolipoproteins were not able to release cholesterol from ICP. The release of ICP cholesterol by R-HDL was dose-dependent and accompanied by the transfer of >8× more... Agent: Bradley Arant Rose & White, LLP Intellectual Property Department-nwj

20080207511 - Compositions and methods for the therapy and diagnosis of breast cancer: Compositions and methods for the therapy and diagnosis of cancer, particularly breast cancer, are disclosed. Illustrative compositions comprise one or more breast tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides.... Agent: Seed Intellectual Property Law Group Pllc

20080207513 - Compositions for buccal delivery of human growth hormone: The present invention provides pharmaceutical compositions for buccal delivery of human growth hormone (hGH) comprising a delivery agent and hGH. The compositions of the present invention provide improved delivery of hGH compared to comparable oral compositions, resulting in increased serum concentrations of hGH. The present invention further provides for methods... Agent: Emisphere Technologies, Inc. C/o Darby & Darby P.c.

20080207497 - Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer: The present invention relates to compositions and methods for the prevention, treatment, and diagnosis of cancer, especially carcinomas, such as ovarian carcinoma. The invention discloses peptides, polypeptides, and polynucleotides that can be used to stimulate a CTL response against cancer.... Agent: Synnestvedt & Lechner, LLP

20080207507 - Extended glp-1 compounds: Protracted GLP-1 compounds and therapeutic uses thereof.... Agent: Novo Nordisk, Inc. Intellectual Property Department

20080207514 - Intraoral dosage forms of glucagon: The present invention provides a composition (e.g., a pharmaceutical composition) comprising at least one delivery agent compound and glucagon. Preferably, the composition includes a therapeutically effective amount of glucagon and the delivery agent compound. The composition of the present invention facilitates the delivery of glucagon and increases its bioavailability compared... Agent: Emisphere Technologies, Inc. C/o Darby & Darby P.c.

20080207500 - Medicament: Analysis of a goat serum product with many therapeutic effects is described. The product is identified as containing proopiomelanocortin (POMC) and Corticotropin releasing factor (CRF) peptides, as well as breakdown products of these peptides. We describe methods of treatment of diseases including cancers, multiple sclerosis, and neural disorders using these... Agent: Carella, Byrne, Bain, Gilfillan, Cecchi, Stewart & Olstein

20080207498 - Methods for treating alzheimer's disease: Polypeptides and other compounds that can bind specifically to the CH2-CH3 cleft of an immunoglobulin molecule, and methods for using such polypeptides and compounds to inhibit Fc-mediated immune complex formation, immune complexed IgG binding to IgG FγR, and immune complexed IgG binding to mC1q (membrane C1q) or soluble C1q. The... Agent: Fish & Richardson P.c.

20080207512 - Methods for treating obesity and obesity related and disorders: Methods for treating obesity or obesity related disorders are disclosed. These methods include the use of anti-obesity agents directed to the forebrain in combination with anti-obesity agents directed to the hindbrain.... Agent: Intellectual Property Department Amylin Pharmaceuticals, Inc.

20080207510 - Modified vitamin k-dependent polypeptides: The invention provides vitamin K-dependent polypeptides with enhanced membrane binding affinity. These polypeptides can be used to modulate clot formation in mammals. Methods of modulating clot formation in mammals are also described.... Agent: Fish & Richardson P.c.

20080207506 - Nucleotide and protein sequence of mammastatin and methods of use: A nucleic acid sequence encoding Mammastatin, a specific mammary cell growth inhibitor. Mammastatin is encoded by a single nucleic acid sequence and has an approximate molecular weight of 44 kDa in its inactive, non-phosphorylated form. Normal mammary cells express functional phosphorylated forms having approximate molecular weights of 53 kDa and... Agent: Casimir Jones, S.c.

20080207515 - Promotion of epithelial regeneration: The invention relates to the use of TGF-β3, or agents having TGF-β3 activity, to promote epithelial regeneration. Methods of manufacturing medicaments, and methods of promoting epithelial regeneration are both provided. In particular, the medicaments and methods of treatment of the invention are applicable to the promotion of epithelial regeneration in... Agent: Darby & Darby P.c.

20080207499 - Rage-related methods for treating and preventing diabetic retinopathy: This invention provides a method for treating diabetic retinopathy in a subject afflicted therewith, comprising administering to the subject's eyes a therapeutically effective amount of soluble RAGE or a derivative thereof, thereby treating diabetic retinopathy in the subject. This invention further provides a method for inhibiting the onset of diabetic... Agent: Cooper & Dunham, LLP

20080207509 - Scaffold: The present invention relates to the use of Stefin A as a scaffold protein for the display of inserted peptides, particularly wherein the Stefin A is a human Stefin A. Several mutations are advantageously made in the wild type stefin A sequence to improve it as a scaffold; preferably the... Agent: Mark Fitzgerald

20080207504 - Secreted frizzled related protein, sfrp, fragments and methods of use thereof: The invention stems from the discovery that sFRP and fragments thereof can bind to members of the Wnt family of proteins and cause an increase in Wnt biological activity. Furthermore, fragments of sFRP that do not contain the CRD domain are shown to bind to Wnt proteins and modulate Wnt... Agent: Klarquist Sparkman, LLP

20080207517 - Selective inhibition of nf-kappab activiation by peptides designed to disrupt nemo oligomerization: The present invention relates to polypeptides that inhibit the NF-κB signaling pathway and polynucleotides encoding the same. The present invention further provides methods for the modulation of and/or treatment of inflammatory responses, oncogenesis, viral infection; the regulation of cell proliferation and apoptosis; and regulation of B or T lymphocytes in... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.c.

20080207508 - Treatment of fungal and/or protist infections: The present invention relates to the use of a polypeptides, comprising repeats of a peptide derived from a Heparan Sulphate Proteoglycan (HSPG) receptor binding region of an apolipoprotein, for treating or preventing a fungal and/or protist infection. The invention further relates to the use of such peptides for treating or... Agent: Davis Wright Tremaine LLP/los Angeles

20080207518 - Adrenocorticotropic hormone analogs and related methods: ACTH analog compounds of the present invention include compounds comprising an ACTH peptide sequence with one or more structural modifications that can have one or more of the following preferred ACTH analog biological functions: (1) reduction of corticosteroid secretion by adrenal membrane in the presence of the ACTH analog compared... Agent: Indianapolis Office 27879 Brinks Hofer Gilson & Lione

20080207519 - Inhibition of hsp27 phosphorylation for the treatment of blistering disorders: A method of treating a blistering disorder, which includes administering to a target tissue in a subject in need thereof an effective amount of a composition that inhibits activation of the HSP27 phosphorylation pathway.... Agent: Jenkins, Wilson, Taylor & Hunt, P. A.

20080207521 - Peptide ligand to impair cancer cell migration: Loss of Wnt-5a protein expression in breast carcinoma patients is associated with a shorter recurrence-free survival as well as increased motility in mammary cell lines. Based on sequence analysis of Wnt-5a 13 peptide fragments were identified and investigated for their ability to mimic effects of the Wnt-5a protein on mammary... Agent: Gauthier & Connors, LLP

20080207520 - Tumor-associated peptides binding promiscuously to human leukocyte antigen (hla) class ii molecules: The present invention relates to immunotherapeutic methods, and molecules and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumour-associated T-helper cell peptide epitopes, alone or in combination with other tumour-associated peptides, that serve as active... Agent: Womble Carlyle Sandridge & Rice, Pllc

20080207522 - Antimicrobial peptides: A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.... Agent: Woodcock Washburn LLP

20080207523 - Compounds as aptamer-dimers and their uses in diagnosis and therapy: n

20080207524 - Medicinal preparations for treating sex hormone-dependent diseases: Medicinal preparations for treating sex hormone-dependent diseases which comprise a combination of a compound having a luteinizing hormone-releasing hormone agonistic effect or its salt with a compound having a luteinizing hormone-releasing hormone antagonistic effect or its salt for administering the compound having a luteinizing hormone-releasing hormone agonistic effect or its... Agent: Foley And Lardner LLP Suite 500

20080207525 - Iap bir domain binding compounds: d

20080207526 - Synthetic peptides and methods of use for autoimmune disease therapies: The invention provides heteropolymer compositions and peptide compositions, and methods of making and using therapeutic compositions comprising amino acid heteropolymers for treatment of a subject for an autoimmune or an inflammatory disease, the heteropolymer compositions made by solid state synthesis. The invention also provides kits for assaying binding of a... Agent: Lawson & Weitzen, LLP

20080207527 - Bicyclic compounds which inhibit beta-secretase activity and methods of use thereof: The present invention provides bicyclic beta-secretase inhibitors and methods for their use, including methods of treating of Alzheimer's disease.... Agent: Morrison & Foerster LLP

20080207528 - Hcv protease inhibitors: This invention relates to the compounds of formula (I) shown below. Each variable in formula (I) is defined in the specification. These compounds can be used to treat hepatitis C virus infection.... Agent: Occhiuti Rohlicek & Tsao, LLP

20080207529 - Isolated dipeptides with ace inhibitor effect: Use of a preparation comprising an isolated peptide selected from the group consisting of: Leu-Val (LV) (SEQ ID NO: 1) and lie-Val (IV) (SEQ ID NO: 2) for the preparation of a composition having angiotensin-converting enzyme (ACE) inhibitor effect. The peptides may e.g. be used to make a functional food... Agent: Foley And Lardner LLP Suite 500

20080207530 - Treatment of copd, gastro-esophageal reflux disease (gerd), food allergies and other gastrointestinal conditions and disorders ameliorated by proper histamine management using a combination of histidine decarboxylase inhibitors, lra drugs, anti-h1 and/or: The invention provides a method for the treatment of COPD and/or gastrointestinal disease conditions ameliorated by histamine management in a subject, comprising administering to the subject an effective amount of a histidine decarboxylase inhibitor.... Agent: Mandel & Adriano

20080207531 - Novel milk protein fractions and use thereof for preventing or treating chronic inflammatory diseases: The invention concerns TGF-β-enriched milk protein fractions, a method for preparing same and use thereof for preparing a medicine and/or a food composition for preventing and/or treating chronic inflammatory diseases, and in particular psoriasis.... Agent: Alston & Bird LLP

20080207534 - 1,4-benzothiazepine 1,1-dioxide derivative, process for its preparation, medicaments comprising this compound, and use thereof as a hypolipidaemic: The invention relates to the compound of the formula (A) and also to its physiologically acceptable salts. The compound is suitable as, for example, a hypolipidemic.... Agent: Andrea Q. Ryan Sanofi-aventis U.s. Llc

20080207535 - Method of attaching drug compounds to non-reactive polymer surfaces: Polymers are disclosed that are chemically modified to retard bacterial growth. Such modified polymers (e.g. ePTFE and polypropylene) are produced by first creating acid groups on the polymer surface through reactions with an anhydride. The acid groups are then linked to polyethylene glycol (PEG) through esterification or other reactions such... Agent: Howrey LLP-hn

20080207533 - Pharmaceutical compositions: A pharmaceutical composition and granulates, prepared by a wet granulation process. The pharmaceutical composition and granulates contain a therapeutic compound, e.g., the 3′-L-valine ester of β-D-2′-C-methyl ribofuranosyl cytidine and its salts, esters, prodrugs or derivatives.... Agent: Novartis Corporate Intellectual Property

20080207532 - Use of nordihydroguaiaretic acid derivatives in the treatment of drug resistant cancer, viral and microbial infection: Compositions and methods for using nordihydroguaiaretic acid (NDGA) derivatives for preventing the expression of MDR-1 gene and the synthesis of PgP protein or reversing multiple drug resistance in cells, and for using NDGA derivatives in combination with additional chemotherapeutic agents to treat drug resistant cancer and infections.... Agent: Venable LLP

20080207536 - Antibacterial agents: The present invention provides acylide derivatives, which can be used as antibacterial agents. Compounds disclosed herein can be used for the treatment or prevention of a condition caused by or contributed to by Gram-positive, Gram-negative or anaerobic bacteria, more particularly against bacterium such as Staphylococci, Streptococci, Enterococci, Haemophilus, Moraxalla spp.,... Agent: Ranbaxy Inc.

20080207537 - Topical ungual formulations: Application of a reducing agent followed by an oxidising agent to a nail substantially increases the permeability thereof, thereby enabling the passage of drugs across the nail.... Agent: Greenlee Winner And Sullivan P C

20080207538 - Enhanced production of functional proteins from defective genes: This invention provides methods for enhancing production in a subject of a functional protein from a gene disrupted by a mutation, for example by the presence of a premature stop codon or by an exon skipping mutation, comprising administering to the subject an amount of an agent effective to suppress... Agent: Amster, Rothstein & Ebenstein LLP

20080207554 - 2-5a analogs and their methods of use: This invention relates to the fields of organic chemistry, pharmaceutical chemistry, biochemistry, molecular biology and medicine. In particular it relates to compounds that activate RNaseL, and to the use of the compounds for treating and/or ameliorating a disease or a condition, such as a viral infection.... Agent: Knobbe Martens Olson & Bear LLP

20080207553 - Biodegradable cationic polymers: Polymers comprising a polyethylenimine, a biodegradable group, and a relatively hydrophobic group are useful for the delivery of bioactive agents to cells.... Agent: Knobbe Martens Olson & Bear LLP

20080207544 - Compositions and methods for delivery of agents into cells: Disclosed herein are novel compositions for delivery of biologically active agents into cells comprising a cationic amphiphile and a complementary lipid composition. Also disclosed are methods of making and using such novel compositions.... Agent: Beusse Wolter Sanks Mora & Maire

20080207541 - Compositions and methods for optimizing cleavage of rna by rnase h: The present invention provides compositions and methods for the optimization of cleavage of RNA species by RNase H. In some embodiments, the invention provides oligonucleotides that possess two or more regions of differing conformation, and at least one transitional nucleobase positioned between the regions that is capable of modulating transfer... Agent: Mcdermott Will & Emery

20080207547 - Compositions and methods for the therapy and diagnosis of breast cancer: Compositions and methods for the therapy and diagnosis of cancer, particularly breast cancer, are disclosed. Illustrative compositions comprise one or more breast tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides.... Agent: Seed Intellectual Property Law Group Pllc

20080207548 - Compositions and methods for the therapy and diagnosis of breast cancer: Compositions and methods for the therapy and diagnosis of cancer, particularly breast cancer, are disclosed. Illustrative compositions comprise one or more breast tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides.... Agent: Seed Intellectual Property Law Group Pllc

20080207552 - Decoy compositions for treating and preventing brain diseases and disorders: The present invention provides introduction of NF-κB decoy oligodeoxynucleotide into rat cranial nerve through a carotid artery during global brain ischemia. Polymerase chain reaction demonstrated that one hour after global brain ischemia, transfected NF-κB decoy oligodeoxynucleotide effectively suppressed expression of tumor necrosis factor α, interleukin 1β and intracellular adhesion molecule... Agent: Ropes & Gray LLP

20080207549 - Genes and polypeptides relating to hepatocellular or colorectal carcinoma: The present application provides novel human genes WDRPUH and KRZFPUH and PPIL1 whose expression is markedly elevated in a great majority of HCC's and colorectal cancers, respectively, compared to corresponding non-cancerous tissues, as well as novel human gene APCDD1 whose expression is elevated in primary colon cancers and down-regulated in... Agent: Townsend And Townsend And Crew, LLP

20080207555 - Hydrolase and methods for its use: This disclosure provides methods for catalyzing the release of ADP-ribose from poly(ADP-ribose) or O-acetyl-ADP-ribose. Also provided are methods for modifying DNA repair or chromatin structure by introducing into the cell an agent that modifies the activity of an ARH3 polypeptide, or variant or fragment thereof. Further provided are methods for... Agent: Klarquist Sparkman, LLP

20080207550 - Immunomodulatory polynucleotides and methods of using the same: The invention provides immunomodulatory polynucleotides and methods for immunomodulation of individuals using the immunomodulatory polynucleotides.... Agent: Morrison & Foerster LLP

20080207540 - Method for the identification of compounds modulating reverse transport of cholesterol: e

20080207545 - Methods and compositions for treating 5alpha-reductase type 1 and type 2 dependent conditions: The invention relates generally to the use of anti-sense oligonucleotides, small interfering RNA, and ribozymes to modulate expression of the human steroid 5α-reductase gene and thereby modulate levels of dihydrotestosterone (DHT). Elevated levels of DHT are associated with various disorders including, but not limited to, skin diseases, hair loss, hirsuitism,... Agent: Morgan Lewis & Bockius LLP

20080207551 - Modified oligonucleotides containing diphosphodiester internucleotide linkages: The synthesis and biochemical utility of modified oligonucleotides containing diphosphodiester internucleotide linkages. The synthesis of these compounds was carried out using diphosphitylating reagents. Oligonucleotides containing diphosphate diester bridges wherein said oligonucleotides are synthesized via a solid-phase synthesis strategy to form modified oligonucleotides. Diphosphitylating, triphosphitylating, tetraphosphitylating, β-triphosphitylating, bifunctional diphosphitylating, bifunctional triphosphitylating,... Agent: Gauthier & Connors, LLP

20080207543 - Modified pituitary gland development in offspring from expectant mother animals treated with growth hormone releasing hormone therapy: The intramuscular electroporated injection of a protease-resistant growth hormone-releasing hormone (“GHRH”) cDNA into rat dams at 16 days of gestation resulted in the enhanced long-term growth of the FI offspring. The offspring were significantly heavier by one week of age and the difference was sustained to 10 weeks of age.... Agent: Pepper Hamilton LLP

20080207556 - Product and process for inhibition of biofilm development: Disclosed are compositions and methods for the inhibition of biofilm formation or reduction of existing or developing biofilms in a patient. These methods also inhibit the aggregation of bacteria that form biofilms in the airways. The methods include administering to a subject that has or is at risk of developing... Agent: Sheridan Ross Pc

20080207546 - Rna aptamers and methods for identifying the same: RNA aptamers and methods for identifying the same are disclosed. The RNA aptamers selectively bind coagulation factors, E2F family members, Ang1 or Ang2, and therapeutic and other uses for the RNA aptamers are also disclosed.... Agent: King & Spalding LLP

20080207542 - Rna inteference mediated inhibition of hepatitis c virus (hvc) gene expression using short interfering nucleic acid (sina): The present invention relates to compounds, compositions, and methods for the study, diagnosis, and treatment of traits, diseases and conditions that respond to the modulation of gene expression and/or activity. The present invention is also directed to compounds, compositions, and methods relating to traits, diseases and conditions that respond to... Agent: Mcdonnell, Boehnen, Hulbert And Berghoff, LLP

20080207539 - Self-processing rna expression cassette: The invention provides a self-processing RNA expression cassette which includes at least one pair of processing units, an RNAi effecter sequence of predetermined length that regulates target gene expression which is flanked by said pair of processing units; and at least one pair of cognate ribozyme cis-cleavage target sites located... Agent: Sutherland Asbill & Brennan LLP

20080207557 - Methods of decreasing or preventing pain using spicamycin derivatives: Methods of providing pain relief by administering a water-soluble derivative of spicamycin. Methods of using pain mediation agents are also provided.... Agent: Myers Bigel Sibley & Sajovec

20080207559 - Carbohydrates mixture: t

20080207558 - Process for the preparation of trivalent iron complexes with mono-, di- and polysaccharide sugars: Process for the preparation of trivalent iron complexes with mono-, di- and polysaccharide sugars, consisting of the activation of the sugar by oxidation with nascent bromine generated in situ by reaction between an alkaline or alkaline earth bromine and an alkaline hypochlorite, the complexation of the activated sugar in solution... Agent: Pearne & Gordon LLP

20080207560 - Composition for external use: The composition for external use is prepared by blending (i) a phospholipid and (ii) a mono- or oligo-glycol ether, together with (iv) at least one bioactive component selected from the group consisting of hyaluronic acid, hyaluronic acid derivatives, vitamin A, vitamin A derivatives, vitamin C, specific vitamin C derivatives, xanthine... Agent: Sughrue Mion, Pllc

20080207561 - Novel biomaterials and a method for making and using same: A novel biomaterial is disclosed having unique properties that make it useful in ocular drug delivery applications, where the drugs selected from the group consisting of a prostaglandin, a prostamide, a non-steroidal anti-inflammatory drug (NSAID), and a corticosteroid, and mixtures, derivatives, salts and esters thereof.... Agent: Allergan, Inc.

20080207562 - Conjugates of hydroxyalkyl starch and active substance, prepared by chemical ligation via thiazolidine: n

20080207563 - Method for inhibiting proliferation of tumor cells: Disclosed are methods for synergistically inhibiting the proliferation of tumor cells by contacting the tumor cells with a MEK inhibitor compound and erlotinib, either sequentially or simultaneously. Also disclosed are methods for inhibiting the proliferation of tumor cells in a human, by administering to the human, sequentially or simultaneously, an... Agent: Hoffmann-la Roche Inc. Patent Law Department

20080207564 - Derivaitves of 4-or 5-aminosalicylic acid: The present invention provides new derivatives of 4- or 5-aminosalicylic acid, and a pharmaceutical composition containing these derivatives of 4- or 5-aminosalicylic acid as active ingredients, useful for the treatment of intestinal diseases such as inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS) and for the prevention/treatment of colon... Agent: Bennett Jones C/o Ms Roseann Caldwell

20080207565 - Use of bisphosphonates for pain treatment: A method for the treatment of pain, in particular antinociceptive or anti-allodynic treatment of pain, in a patient in need of such treatment, e.g. a patient with osteoporosis or osteopenia, a tumour patient or a patient suffering from an inflammatory disease, which comprises administering an effective amount of a bisphosphonate,... Agent: Novartis Corporate Intellectual Property

20080207566 - Methods for the administration of amifostine and related compounds: The present invention provides methods of administering amifostine, WR-1065, or a combination thereof, to patients receiving radiation therapy or chemotherapy in a manner that significantly reduces or decreases the adverse or undesirable side-effects of the compounds as compared with conventional intravenous administration.... Agent: Jones Day

20080207567 - Treatment of hcv disorders: S1P receptor agonists are useful for the treatment of hepatitis C or chronic hepatitis C (HCV).... Agent: Novartis Corporate Intellectual Property

20080207568 - Class of gamma delta t cells activators and use thereof: The present invention relates to a new class of compounds having γδ T cells activating properties referred to herein as angelyl or tiglyl phosphoesters, compositions comprising any of these compounds and methods for regulating an immune response in a subject comprising the step of administering these compounds.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20080207569 - Methods for the treatment of liver diseases: Provided herein are methods for treatment of a liver disease by administering a matrix metalloproteinase inhibitor. Also provided are methods for reducing liver damage associated with a liver disease by administering the matrix metalloproteinase inhibitor described herein. Further provided are methods for lowering an elevated level of liver enzymes by... Agent: Jones Day

20080207570 - Topically applicable oil-in-water emulsions and dermatological applications thereof: Novel topically applicable oil-in-water emulsions, with a high proportion of oily phase in the inner phase, combine the occlusive and emollient properties of an ointment without having the drawbacks of a greasy feel, while at the same time promoting the therapeutic properties of a biologically active agent contained therein; such... Agent: Buchanan, Ingersoll & Rooney Pc

20080207571 - Regimens for oral monophasic contraceptives: The subject invention provides for new regimens for monophasic oral contraceptives.... Agent: Organon Usa, Inc. C/o Schering-plough Corporation

20080207573 - Compounds for treating viral infections: The invention relates to compounds, pharmaceutical compositions and methods useful for treating viral infection.... Agent: Myriad Genetics Inc. Intellecutal Property Department

20080207572 - Use of dual c-kit/fgfr3 inhibitors for treating multiple myeloma: The present invention relates to a method for treating Multiple Myeloma (MM), FGFR3+ myeloma, especially relapsed or refractory multiple myeloma (4/14) expressing FGFR3, comprising administering a dual C-KIT/FGFR3 inhibitor, such as 2-aminoarylthiazoles and 2-aminoaryloxazoles.... Agent: Foley And Lardner LLP Suite 500

20080207574 - Withanolides, probes and binding targets and methods of use thereof: Novel withanolide chemical genetic probes identify the in vivo binding target of withaferin A, which is the intermediate filament type III protein vimentin. In addition, a withanolide-based small molecule screening method screens drug candidates that target intermediate filament type III proteins. The method includes introducing a tagged linker covalently bonded... Agent: Stites & Harbison Pllc

20080207575 - Process for the preparation of drospirenone: A process is described for the preparation of drospirenone, a synthetic steroid with progestogenic, antimineralocorticoid and antiandrogenic activity, useful for preparing pharmaceutical compositions with contraceptive action; comprising the oxidation of 17α-(3-hydroxypropyl)-6β,7β,15β,16β-dimethylene-5β-androstane-3β,5,17β-triol.... Agent: Abelman, Frayne & Schwab

20080207576 - Substituted sapogenins and their use: The invention discloses substituted sapogenins and their use in the treatment of cognitive disfunction and similar conditions. Methods of treatment and pharmaceutical composition are also disclosed... Agent: Hoffmann & Baron, LLP

20080207577 - Combination i: The invention provides a pharmaceutical product, kit or composition comprising a first active ingredient which is a P2X7 receptor antagonist, and a second active ingredient which is a corticosteroid, of use in the treatment of respiratory diseases such as chronic obstructive pulmonary disease and asthma.... Agent: Fish & Richardson P.c.

20080207578 - Method of inducing apoptosis in cancer treatment by using cucurbitacins: This invention relates to the preparation and use of anti-cancer compounds/formulation containing cucurbitacins. Said formulation comprises active ingredients, particularly cucurbitacin B and cucurbitacin D, with the efficacy of anti-proliferation and inducing cellular apoptosis. Said formulation owns the anticancer activity. This invention also provides a method of isolating and purifying the... Agent: Evan Law Group Llc

20080207580 - Method of treating immune pathologies with low dose estrogen: The invention provides a method of ameliorating a Th1-mediated immune pathology in a mammal. The method is practiced by administering a low dose of estrogen to the mammal. Optionally, an immunotherapeutic agent can also be administered to the mammal. Also provided are kits containing a low dose of estrogen and... Agent: Klarquist Sparkman, LLP

20080207579 - Uses of tetrahydrobiopterin and derivatives thereof: The present invention discloses that diabetic rats showed a reduction in nitrergic relaxation of the gastric, impaired nNOS dimerization, decreased BH4 and GTPCH1 levels and thus, are more susceptible to develop diabetic gastroparesis. The use of tetrahydrobiopterin and its derivatives and sex steroid hormones as disclosed herein provides a novel... Agent: Benjamin Adler Adler & Associates

20080207581 - Methods and systems for coating a surface: A coating system and method are described. In some embodiments, a system may include a composition. The composition may include one or more bridged polycyclic compounds. At least one of the bridged polycyclic compounds may include at least two cyclic groups, and at least two of the cyclic groups may... Agent: Meyertons, Hood, Kivlin, Kowert & Goetzel, P.c.

20080207582 - Substituted porphyrins: A series of ortho isomers of meso tetrakis N-alkylpyridylporphyrins (alkyl being methyl, ethyl, n-propyl, n-butyl, n-hexyl, and n-octyl) and their Mn(III) complexes were synthesized and characterized by elemental analysis, uv/vis spectroscopy, electrospray ionization mass spectrometry and electrochemistry. An increase in the number of carbon atoms in the alkyl chains from... Agent: Townsend And Townsend And Crew, LLP

20080207583 - Process for preparing granulates comprising amoxicillin: A novel process for preparing a stable granulate, which comprises a mixture of amoxicillin trihydrate and amoxicillin sodium, by means of extrusion granulation of amoxicillin trihydrate with an aqueous solution of sodium hydroxide, sodium bicarbonate, sodium carbonate and mixture thereof or with an aqueous solution of sodium salt of (C1-8)... Agent: Sandoz Inc

20080207584 - Compound having s1p receptor binding potency and use thereof: (wherein ring A and ring D each represent a cyclic group which may have a substituent(s); E and G each represent a bond or a spacer having 1 to 8 atoms in its main chain; L represents a hydrogen atom or a substituent; X represents amino which may have a... Agent: Sughrue-265550

20080207585 - Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof: h

20080207586 - Novel crystal form of pyrrolidylthiocarbapenem derivative: A novel crystal of a pyrrolidylthiocarbapenem derivative having excellent stability is provided. According to the present invention, a crystal of (+)-(4R,5S,6S)-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-3[[(3S,5S)-5-(sulfamoylaminomethyl)pyrrolidin-3-yl]thio]-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid having a diffraction pattern in powder X-ray diffraction preferably having main peaks at diffraction angles (2θ)=13.04, 14.98, 15.88, 16.62, 20.62, 21.06, 22.18, 23.90, 26.08, 28.22 and 28.98 (degrees)... Agent: Ropes & Gray LLP

20080207587 - Pyridazine derivatives for inhibiting human stearoyl-coa-desaturase: Methods of treating an SCD-mediated disease or condition in a mammal, preferably a human, are disclosed, wherein the methods comprise administering to a mammal in need thereof a compound of formula (I) where x, y, G, J, K, L, M, Q, W, V, R2, R3, R5, R5a, R6, R6a, R7,... Agent: Seed Ip Law Group Pllc

20080207588 - Spiro-heterocyclic chromans, thiochromans and dihydroquinolines: wherein R, R1 to R10 are as described in the specification, and at least one CR5R6, or CR7R8, or CR9R10 is a an optionally substituted azetidine ring or an optionally substituted oxetan ring, which may be useful in the manufacture of pharmaceutical compositions for treating disorders mediated by lipoxygenases. They... Agent: Eli Lilly & Company

20080207589 - Cyclized derivatives as eg-5 inhibitors: The present invention relates to new substituted imidazole compounds have the following Formula (I) and to the pharmaceutically acceptable salts, esters, or prodrugs thereof, to compositions of the compounds together with pharmaceutically acceptable carriers, and to uses of the compounds:... Agent: Novartis Vaccines And Diagnostics Inc.

20080207590 - Inhibitors of histone deacetylase: e

20080207591 - Organic compounds:

20080207592 - Novel 1,4-benzothiazepine-1,1-dioxide derivative having improved properties, method for the production thereof, medicaments containing said compound, and use thereof: The invention relates to the compound of the formula (A) and also to its physiologically acceptable salts. The compound is suitable as, for example, a hypolipidemic.... Agent: Andrea Q. Ryan Sanofi-aventis U.s. Llc

20080207593 - Antihistamine combination: A once daily formulation containing the combination of a non-sedating or selective antihistamine (Loratadine) with a sedating or non-selective antihistamine (Chlorpheniramine) administered at bed-time has demonstrated greater efficacy in relieving allergic symptoms than Loratadine alone.... Agent: Patrea L. Pabst Pabst Patent Group LLP

20080207594 - Use of gsk-3 inhibitors for preventing and treating pancreatic autoimmune disorders: This invention relates to the use of Pax4 stimulating compounds, e.g. Glycogen synthase kinase-3 (GSK-3) inhibitors, particularly in combination with immunomodulating agents, in the prevention, and/or treatment of pancreatic autoimmune disorders, e.g. type I diabetes or LADA. More particularly, this invention relates to the use of compounds selected from paullones,... Agent: Rothwell, Figg, Ernst & Manbeck, P.c.

20080207595 - Aryl-and heteroaryl-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin: i

20080207596 - Novel compounds 329:

20080207597 - Homopiperazine compounds that inhibit ribosomal frameshifting by binding to rna pseudoknot structure of sars coronavirus: Provided is a homopiperazine compound for inhibiting ribosomal frameshifting by binding to an RNA pseudoknot structure of SARS coronavirus. Particularly, the present invention provides a pharmaceutical composition for inhibiting synthesis of protein induced by −1 frameshifting by binding to an RNA pseudoknot structure specifically existing in SARS coronavirus. The composition... Agent: Rabin & Berdo, Pc

20080207598 - Indole derivatives: wherein A represents a 5-membered aromatic heterocyclic ring, wherein X1, X2 and X3 are independently selected from N, O, S and CH; Y represents CH2, O, S or SO2; R1 is H, (C1-4)-alkyl, (C1-4)alkyloxy, CN or halogen; R2, R2′, R3, R3′, R4, R4′, R5 and R5′ are independently hydrogen, (C1-4)alkyl... Agent: Organon Usa, Inc. C/o Schering-plough Corporation

20080207599 - Use of selective chloride channel modulators to treat methamphetamine abuse: The invention relates to methods of and treatments for using pharmaceutical compositions from a class of compounds that directly or indirectly selectively modulates GABAA chloride channel activity to treat alcohol and/or stimulant substance abuse. The present invention also relates to methods of, and protocols for, relieving symptoms associated with alcohol... Agent: John S. Pratt, Esq Kilpatrick Stockton, LLP

20080207601 - Methods of and compositions for the prevention of anxiety, substance abuse, and dependence: Compositions for reducing dependency and addiction to substances of abuse are provided. Chloride channels such as the GABAA receptors are altered under conditions of dependency and withdrawal such that the electrophysiological properties of the GABAA receptor containing neurons are altered thereby providing a pathophysiological condition resulting in symptoms of dependency... Agent: John S. Pratt, Esq Kilpatrick Stockton, LLP

20080207600 - Pharmaceutical combination for the treatment of cns functional disorders: The invention relates to a method and a pharmaceutical combination for the treatment of CNS disorders, which includes at least a first compound having therapeutic effect on the CNS, and a second compound which facilitates penetration through the hematoencephalic barrier of the former. The second compound is administered endonasally, and... Agent: Knobbe Martens Olson & Bear LLP

20080207602 - Succinoylamino benzodiazepines as inhibitors of abeta protein production: to their pharmaceutical compositions and to their methods of use. These novel compounds inhibit the processing of amyloid precursor protein and, more specifically, inhibit the production of Aβ-peptide, thereby acting to prevent the formation of neurological deposits of amyloid protein. More particularly, the present invention relates to the treatment of... Agent: Kelley Drye & Warren LLP

20080207603 - Methods of chemical synthesis and purification of diaminophenothiazinium compounds including methylthioninium chloride (mtc): This invention pertains generally to the field of chemical synthesis and purification, and more specifically to methods of synthesizing and purifying certain 3,7 diamino-phenothiazin-5-ium compounds (referred to herein as “diaminophenothiazinium compounds”) including Methylthioninium Chloride (MTC) (also known as Methylene Blue). In one embodiment, the method comprises the steps of, in... Agent: Foley And Lardner LLP Suite 500

20080207604 - Materials and methods relating to protein aggregation in neurodegenerative disease: The present invention relates to methods for the detection of substances capable of modulating or inhibiting pathological tau-tau protein association. The methods of the present invention are particularly useful in screening substances for the prophylaxis and treatment of Alzheiemer's disease.... Agent: Foley And Lardner LLP Suite 500

20080207605 - Combination therapy for the treatment of liver diseases: Provided herein are methods for treatment of a liver disease by administering a combination of a matrix metalloproteinase inhibitor and a caspase inhibitor. Also provided are methods for reducing liver damage associated with a liver disease by administering the MMP and caspase inhibitors described herein. Further provided are methods for... Agent: Jones Day

20080207606 - Novel heterocycles: Novel heterocyclic compounds of the general formula (I), their derivatives, analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts, pharmaceutical compositions, metabolites and prodrugs thereof are described. These compounds are useful in the treatment of immunological diseases, inflammation, pain disorder, rheumatoid arthritis; osteoporosis; multiple myeloma; uveititis; acute and chronic... Agent: Oliff & Berridge, Plc

20080207607 - Heterotricyclic metalloprotease inhibitors: The present invention relates generally to azatriocyclic containing pharmaceutical agents, and in particular, to azatricyclic metalloprotease inhibiting compounds. More particularly, the present invention provides a new class of azatricyclic MMP-3, MMP-8 and/or MMP-13 inhibiting compounds, that exhibit an increased potency and selectivity in relation to currently known MMP-13, MMP-8 and... Agent: Amgen Inc.

20080207608 - 2-propene-1-ones as hsp 70 inducers: The present invention relates to novel compounds of 2-propene-1-one series, of general formula (I), their derivatives, analogs, tautomeric forms, stereoisomers, polymorphs, pharmaceutically acceptable salts, pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them, wherein R5, R6, Q and Y are as defined in the specification. The present invention also relates... Agent: Jacobson Holman Pllc

20080207609 - Pharmaceutical compounds: wherein R1-R3, A and n have any of the values described in the specification; and pharmaceutically acceptable salts thereof; have activity as inhibitors of PI3K and may thus be used to treat diseases and disorders arising from abnormal cell growth, function or behavior associated with PI3 kinase such as cancer,... Agent: Viksnins Harris & Padys Pllp

20080207610 - Aldh-2 inhibitors in the treatment of addiction: e

20080207611 - Pharmaceutical compounds: wherein R1-R3, A and n have any of the values described in the specification; and pharmaceutically acceptable salts thereof, have activity as inhibitors of PI3K and may thus be used to treat diseases and disorders arising from abnormal cell growth, function or behaviour associated with PI3 kinase such as cancer,... Agent: Viksnins Harris & Padys Pllp

20080207612 - Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof: Compounds of Formula (I) or pharmaceutically acceptable salts thereof; wherein R1, R2, R3, and R4 are as defined in the specification as well as salts and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the management of pain.... Agent: Astra Zeneca Pharmaceuticals Lp Global Intellectual Property

20080207615 - Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatments: The present invention is directed to a method for determining the responsiveness of cancer to an epidermal growth factor receptor (EGFR) treatment. In a preferred embodiment, the presence of at least one variance in the kinase domain of the erbB1 gene confers sensitivity to the tyrosine kinase inhibitor gefitinib. Thus,... Agent: David S. Resnick

20080207614 - Quinazoline derivatives for the treatment and prevention of diabetes and obesity: The present invention relates to novel quinazoline derivatives effective in lowering blood glucose level and body weight, and a medicine for treatment and/or prevention of diabetes and/or obesity, which comprises the compound as an active ingredient.... Agent: Jhk Law

20080207613 - Selective kinase inhibitors: A compound of the general formula (I) or pharmaceutically acceptable prodrugs, salts, hydrates, solvates, crystal forms or diastereomers thereof, wherein A represents a variety of six membered nitrogen containing heterocyclic rings, Q is a bond, halogen, C1-4 alkyl, O, S, SO2, CO or CS and X1, X2, X3 and X4... Agent: Morrison & Foerster LLP

20080207616 - Quinoxalines as b baf inhhibitors: The invention relates to chemical compounds of the formula (I) or pharmaceutically acceptable salts thereof, which possess B Raf inhibitory activity and are accordingly useful for their anti cancer activity and thus in methods of treatment of the human or animal body. The invention also relates to processes for the... Agent: Astrazeneca R&d Boston

20080207618 - 6- (heterocyclyl-substituted benzyl) -4-oxoquinoline compound and use thereof as hiv integrase inhibitor: wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof, or a solvate thereof, and a pharmaceutical composition, an anti-HIV agent and an HIV integrase inhibitor containing such compound. The compound of the present invention has an HIV integrase inhibitory activity, and is useful as... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080207617 - Quinoline derivatives and quinazoline derivatives inhibiting autophosphrylation of flt3 and medicinal compositions containing the same: e

20080207619 - Diaminopyrimidines as p2x3 and p2x2/3 modulators:

20080207620 - Modulators of pharmacokinetic properties of therapeutics:

20080207621 - Soluble epoxide hydrolase inhibitors: Disclosed are sulfonamide compounds and compositions that inhibit soluble epoxide hydrolase (sEH), methods for preparing the compounds and compositions, and methods for treating patients with such compounds and compositions. The compounds, compositions, and methods are useful for treating a variety of sEH mediated diseases, including hypertensive, cardiovascular, inflammatory, pulmonary, and... Agent: Foley & Lardner LLP

20080207622 - Soluble epoxide hydrolase inhibitors: Disclosed are sulfone compounds and compositions that inhibit soluble epoxide hydrolase (sEH), methods for preparing the compounds and compositions, and methods for treating patients with such compounds and compositions. The compounds, compositions, and methods are useful for treating a variety of sEH mediated diseases, including hypertensive, cardiovascular, inflammatory, pulmonary, and... Agent: Foley & Lardner LLP

20080207627 - Methods of preventing and reducing the severity of stress-associated conditions: The present invention provides a method of preventing or reducing the severity of a stress-associated condition in a subject by systemically administering to the subject an effective amount of brimonidine or a pharmaceutically acceptable salt, ester, amide, sterioisomer or racemic mixture thereof. Stress-associated conditions that can be treated according to... Agent: Allergan, Inc.

20080207628 - Methods of preventing and reducing the severity of stress-associated conditions: The present invention provides a method of preventing or reducing the severity of a stress-associated condition in a subject by systemically administering to the subject an effective amount of brimonidine or a pharmaceutically acceptable salt, ester, amide, sterioisomer or racemic mixture thereof. Stress-associated conditions that can be treated according to... Agent: Allergan, Inc.

20080207623 - Peptide-enhanced corneal drug delivery: Improved methods and preparations are provided for ocular administration of therapeutic drugs. The preparations include respective quantities of a drug and a peptide which enhances transport of the drug across ocular tissues. The drug and peptide components may be separately administered or used as a mixture. The preferred peptide is... Agent: Hovey Williams LLP

20080207626 - Stable tablet formulation: The present invention is directed to a stable solid formulations of tetrahydrobiopterin, processes for producing them, and treatment methods using such formulations.... Agent: Marshall, Gerstein & Borun LLP

20080207625 - Synthesis and purification of pteroic acid and conjugates thereof: Methods for purifying pteroic acid, analogs of pteroic acid, and derivatives of pteroic acid are described. Methods for synthesizing and purifying conjugates of vitamins, including FITC conjugates of folic acid, folic acid analogs, and derivatives of folic acid and folic acid analogs are also described. Purified forms of pteroic acid,... Agent: Barnes & Thornburg LLP

20080207624 - Therapeutic agent for bh4-responsive hyperphenylalaninemia: A pharmaceutical preparation containing sapropterin hydrochloride can be used to administer sapropterin hydrochloride, an effective therapeutic agent for the treatment of tetrahydrobiopterin-responsive hyperphenylalaninemia, to patients of a wide range of ages, ranging from infants to adults, in a single preparation. One specific example is a pharmaceutical preparation for the treatment... Agent: Drinker Biddle & Reath (dc)

20080207629 - Liquid preparation comprising pimobendan: The invention relates to novel liquid preparation comprising a substituted benzimidazol, preferably pimobendan as pharmaceutically active compound. In particular, the present invention relates to liquid preparation comprising an etherified cyclodextrin derivative, preferably in a concentration of about 20 to 70% (w/v) and said substituted benzimidazol, preferably in a concentration of... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20080207630 - 2-aminocarbonyl substituted piperazine or diaza-cyclic compounds as apoptosis protein inhibitors (iap) modulators: The present invention relates to compounds of formula (I) or pharmaceutically acceptable salts, solvates, hydrates or pharmaceutically acceptable formulations thereof. These compounds may be used to modulate cellular proliferation and to prevent and/or treat proliferative diseases.... Agent: Novartis Institutes For Biomedical Research, Inc.

20080207631 - Methods for the treatment and prevention of neurodegenerative conditions: Adatanserin is useful for treating neurodegenerative disorders, chronic pain, and other disorders associated with dysfunctional glutamate release. Methods of treating the same comprise administering a therapeutically effective amount of adatanserin or a pharmaceutical salt thereof, to a patient in need of said treatment.... Agent: Pepper Hamilton LLP/wyeth

20080207632 - Protein kinase inhibitors: a

20080207633 - Urea derivatives as calcium channel blockers: Urea derivatives which comprise piperidine or piperazine rings and further substitution are effective in ameliorating conditions characterized by unwanted calcium ion channel activity.... Agent: Morrison & Foerster LLP

20080207634 - Chemical compounds: There is provided novel compounds that demonstrate protective effects on target cells from HIV infection in a manner as to bind to a chemokine receptor, and which affect the binding of the natural ligand or chemokine to a receptor such as CXCR4 of a target cell.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B482

20080207635 - Heterocyclic compounds useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders: The present invention provides compounds capable of modulating tyrosine kinases, compositions comprising the compounds and methods of their use.... Agent: Jones Day

20080207636 - Compounds effecting glucokinase: e

20080207637 - Substituted pyrazoline compounds for reducing triglycerides in blood: The present invention relates to substituted pyrazoline compounds, methods for their preparation, medicaments comprising these compounds as well as their use for the preparation of a medicament for the treatment of humans and animal.... Agent: Banner & Witcoff, Ltd.

20080207638 - Compounds: e

20080207640 - Method of treating cell proliferative disorders using growth hormone secretagogues: The present invention relates to a method of treating cell proliferative disorders by administering to a subject an effective amount of a growth hormone secretagogue compound or a pharmaceutically acceptable salt, hydrate or solvate thereof.... Agent: Edwards Angell Palmer & Dodge LLP

20080207639 - Novel aromatic compounds and their use in medical applications: e

20080207641 - Cyclohexenyl-aryl compounds for inflammation and immune-related uses:

20080207642 - Thienopyrimidinediones and their use in the modulation of autoimmune disease: in which R1 and R2 each independently represent a C1-6alkyl, C3-6alkenyl, C3-6cycloalkylC1-3alkyl or C3-6cycloalkyl; each of which is optionally substituted by 1 to 3 halogen atoms; R3 is isoxazolidin-2-ylcarbonyl or tetrahydroisoxazin-2-ylcarbonyl wherein each ring is optionally substituted by one hydroxy group; Q is —CO— or —C(R4)(R5)— in which R4 is... Agent: Fish & Richardson P.c.

20080207643 - Composition for treating hyperlipaemia: The present invention provides a composition for treating hyperlipemia, which comprises the first active component acipimox, and the second active component atorvastatin, or the pharmaceutically acceptable salt, ester or solvate thereof. Weight ratio of the first to the second active component is (10-80):1. The composition is in the form of... Agent: Foley And Lardner LLP Suite 500

20080207644 - Therapeutic materials and methods: e

20080207645 - Pyridothienopyrimidine derivatives:

20080207646 - Agent for the prevention and treatment of liver diseases containing pyrazolopyrimidine derivative: The present invention relates to the pharmaceutical composition for prevention and treatment of liver diseases containing pyrazolopyrimidine derivative as all active ingredient. According to the present invention, pyrazolopyrimidine derivative has an excellent effect on inhibiting collagen synthesis in hepatic stellate cells and acts directly on the portal vein. Particularly, it... Agent: Lucas & Mercanti, LLP

20080207647 - Pyrazole derivatives having tyrosine kinase activity: Compounds of the formula (I), in which R, X, R1, R2, R3 and R4 have the meanings indicated in Claim (1), are inhibitors of tyrosine kinases, in particular TIE-2, and Raf kinases and can be employed, inter alia, for the treatment of tumours.... Agent: Baker & Daniels LLP

20080207648 - Organic compounds: in free or salt form, wherein R1, R2 and R3 have the meanings as indicated in the specification, are useful for treating conditions mediated by activation of the adenosine A2A receptor, especially inflammatory or obstructive airways diseases. Pharmaceutical compositions that contain the compounds and a process for preparing the compounds... Agent: Novartis Corporate Intellectual Property

20080207649 - Method of treating brain ischemia:

20080207650 - Chemical compounds 636:

20080207651 - Heterocyclic compounds useful in treating diseases and conditions:

20080207652 - Novel inhibitors of folic acid-dependent enzymes: wherein R1═—NH2 or —OH, and C and D are each, independently, a 5- or 6-membered, substituted or unsubstituted, aromatic or non-aromatic ring which may also contain one or more heteroatoms, and C is connected to group B in any available position.... Agent: Wolf Greenfield & Sacks, P.c.

20080207653 - Compositions and method for increasing the efficacy of epidermal growth factor receptor tyrosine kinase inhibitors: Compositions and methods for increasing the efficacy of an epidermal growth factor receptor-tyrosine kinase inhibitor are provided. The drugs are modified stereospecific epidermal growth factor receptor-tyrosine kinase inhibitors that upon modification are able to accumulate at higher levels in tumor cells thereby increasing the efficacy of the inhibitor.... Agent: Licata & Tyrrell P.c.

20080207654 - Heteromonocyclic compound and use thereof: R3 and R4 are each H, or C1-C6 alkyl, C3-C6 cycloalkyl, C1-C6 alkoxy, C1-C6 alkylamino, di(C1-C6)alkylamino or C1-C6 alkylthio, each of which is optionally substituted; and R5 is H, or C1-C6 alkyl, C2-C6 alkenyl, cyclic group, each of which is optionally substituted, —CO—R8 or —O—R8′, or a salt thereof. The... Agent: Foley And Lardner LLP Suite 500

20080207655 - Diaminopyrimidines as p2x3 and p2x2/3 modulators:

20080207656 - Methods, compositions, and kits for organ protection during systemic anticancer therapy: Methods, compositions, and kits are presented for local tissue protection during systemic administration of anticancer therapeutic agents.... Agent: Morgan Lewis & Bockius LLP

20080207659 - Inhibitors of phosphodiesterase type 4: t

20080207658 - Pharmaceutical combination of bcr-abl and raf inhibitors: The invention provides a pharmaceutical combination comprising: a) a pyrimidylaminobenzamide compound, and b) a RAF kinase inhibitor and a method for treating or preventing a proliferative disease using such a combination, wherein compound a) has the following general Formula: (I).... Agent: Novartis Institutes For Biomedical Research, Inc.

20080207660 - Phosphodiesterase 4 inhibitors: Selective PDE4 inhibition is achieved by aryl and heteroaryl pyrazole compounds. The compounds exhibit improved PDE4 inhibition as compared to compounds such as rolipram and show selectivity with regard to inhibition of other classes of PDEs.... Agent: Millen, White, Zelano & Branigan, P.c.

20080207657 - Use of minoxidil sulfate as an anti-tumor drug: The invention relates to compositions, methods and kits for the treatment of cancer. ATP-dependent potassium channel agonists, salts thereof, or chemical analogs thereof, for example, minoxidil sulfate, have been found to possess anti-neoplastic properties. Administering minoxidil sulfate may prolong the life of a cancer patient; for example, a patient with... Agent: Davis Wright Tremaine LLP/los Angeles

20080207665 - Alpha-(aryl-or heteroaryl-methyl)-beta-piperidinopropanoic acid compounds as orl-1-receptor antagonists: This invention provides the compounds of formula (I): or a pharmaceutically acceptable ester or salt thereof, wherein R1 and R2 independently represent hydrogen or the like; R3 represents aryl or the like; —X—Y— represents —CH2O— or the like, and n represents 0, 1 or 2. These compounds have ORL1-receptor antagonist... Agent: Pfizer Inc.

20080207661 - Once daily dosage forms of trospium: A pharmaceutical composition of a pharmaceutically acceptable trospium salt, with upon administration to a human patient generates an average steady state blood levels of trospium with a minimum (Cmin) and maximum (Cmax) blood levels of about 0.5-2.5 ng/ml and about 2.0-6.0 ng/ml, respectively.... Agent: Arent Fox LLP

20080207662 - Once daily dosage forms of trospium: A pharmaceutical composition of a pharmaceutically acceptable trospium salt, with upon administration to a human patient generates an average steady state blood levels of trospium with a minimum (Cmin) and maximum (Cmax) blood levels of about 0.5-2.5 ng/ml and about 2.0-6.0 ng/ml, respectively.... Agent: Arent Fox LLP

20080207663 - Once daily dosage forms of trospium: A pharmaceutical composition of a pharmaceutically acceptable trospium salt, with upon administration to a human patient generates an average steady state blood levels of trospium with a minimum (Cmin) and maximum (Cmax) blood levels of about 0.5-2.5 ng/ml and about 2.0-6.0 ng/ml, respectively.... Agent: Arent Fox LLP

20080207664 - Once daily dosage forms of trospium: A pharmaceutical composition of a pharmaceutically acceptable trospium salt, with upon administration to a human patient generates an average steady state blood levels of trospium with a minimum (Cmin) and maximum (Cmax) blood levels of about 0.5-2.5 ng/ml and about 2.0-6.0 ng/ml, respectively.... Agent: Arent Fox LLP

20080207666 - Substituted pyrano[2,3-b]pyridine derivatives as cannabinoid-1 receptor modulators: Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis,... Agent: Merck And Co., Inc

20080207669 - (s)-n-stereoisomers of 7,8-saturated-4,5-epoxy-morphinanium analogs: Novel (S)-N-stereoisomers of 7,8-saturated-4,5-epoxy-morphinanium analogs are disclosed. Pharmaceutical compositions containing the (S)-N-stereoisomers of 7,8-saturated-4,5-epoxy-morphinanium analogs and methods for their pharmaceutical uses are also disclosed. Such analogs are disclosed as being useful in treating, among varying conditions, hypermotility of the gastrointestinal tract.... Agent: Kelley Drye & Warren LLP

20080207668 - Pharmaceutical compositions of hydromorphone for prevention of overdose or abuse: The invention relates to compounds, compositions and methods comprised of a chemical moiety attached to hydromorphone. The invention provides embodiments that provide a decrease in the potential of hydromorphone to cause overdose or to be abused while still delivering therapeutic activity similar to that of the parent hydromorphone.... Agent: Darby & Darby P.c.

20080207667 - Use of nalbuphine and related compounds to treat symptoms of respiratory problems: The present invention relates to treatment of respiratory diseases. More specifically, the present invention relates to treatment of respiratory diseases in humans and lower animals with nalbuphine.... Agent: Nelson Mullins Riley & Scarborough, LLP

20080207670 - Dermally applicable formulations for treating skin diseases in animals: The invention relates to pharmaceutical formulations comprising a tricyclic compound for the dermal treatment of skin diseases in animals.... Agent: Bayer Healthcare Llc

20080207671 - Diagnosis and treatment of diseases arising from defects in the tuberous sclerosis pathway: The present invention relates to compositions, methods for identifying, and methods for treating abnormalities in TSC signaling pathways. In particular, the present invention relates to methods of diagnosing, treating and preventing disorders caused by defects in the TSC signaling pathway (e.g., TSC-1, TSC-2, TSC-1/TSC-2, Rheb, mTOR, S6K, and 4EBP-1) such... Agent: Medlen & Carroll, LLP

20080207672 - Methods of treating keratin hyperproliferation disorders using mtor inhibitors: A method of treating or preventing keratin hyperproliferation skin disorders is set forth. The method includes the administration of an mTOR inhibitor to a subject afflicted with the hyperproliferation disorder. The mTOR inhibitor can be administered to the subject via any means known in the art including oral, topical, and... Agent: Thorpe North & Western, LLP.

20080207673 - Method for treating cancer, coronary, inflammatory and macular disease, combining the modulation of zinc-and/or copper dependent proteins: A method for treating diseases selected among cancer, coronary disease, inflammatory disease and macular disease by chelation therapy is disclosed.... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20080207675 - Aqueous gel formulations containing 1-(2-methylpropyl)-1h-imidazo[4,5-c][1,5]naphthyridin-4-amine: Pharmaceutical formulations in an aqueous gel formulation including 1-(2-methylpropyl)-1H-imidazo[4,5-c][1,5]naphthyridin-4-amine are provided. Methods of use and kits are also provided.... Agent: Foley And Lardner LLP Suite 500

20080207674 - Immune response modifier formulations and methods: An aqueous parenteral pharmaceutical formulation of the IRM drug compound N-[4-(4-amino-2-ethyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl]methanesulfonamide dissolved in water, buffer selected from citric acid, acetic acid, lactic acid, succinic acid, and tartaric acid, and optionally a tonicity adjuster, preferably selected from sorbitol and mannitol, wherein the pH is no greater than 6 and the formulation... Agent: Wolf Greenfield & Sacks, P.c.

20080207676 - Crystalline forms of an 8-azabicyclo(3.2.1)octane compound: The invention provides a crystalline sulfate salt of 3-endo-(8-{2-[cyclohexylmethyl-((S)-2,3-dihydroxy-propionyl)amino]ethyl}-8-aza-bicyclo[3.2.1]oct-3-yl)benzamide or a solvate thereof. The invention also provides pharmaceutical compositions comprising such crystalline salt forms, methods of using such crystalline salt forms to treat diseases associated with mu opioid receptor activity, and processes useful for preparing such crystalline salt forms.... Agent: Theravance, Inc.

20080207680 - 7-azaindoles, their use as inhibitors of phosphodiesterase 4, and a method for synthesizing them: 7-azaindoles inhibit phosphodiesterase 4 (PDE4). Methods for preparing these compounds and methods of treating arthritis and other conditions with the compounds are also provided.... Agent: Fulbright & Jaworski, LLP

20080207679 - Glutathione peroxidase mimetics for the treatment of dermatoses: This invention relates to compositions and methods for the treatment of dermatological conditions with a glutathione peroxidase mimetic.... Agent: Pearl Cohen Zedek Latzer, LLP

20080207677 - Napthyridine compounds as rock inhibitors: The present invention relates to compounds having a naphthyridine scaffold, and stereoisomeric forms, prodrugs, solvates, hydrates and/or pharmaceutically acceptable salts of these compounds as well as pharmaceutical compositions containing at least one of these naphthyridine derivatives together with pharmaceutically acceptable carrier, excipient and/or diluents. Said naphthyridine compounds have been identified... Agent: Brooks Kushman P.c.

20080207678 - Viral inhibitors: e

20080207681 - Device and methods for identifying and treating aspirin non-responsive patients: The present invention relates to methods and compositions for identifying and treating subjects in need of antithrombotic therapies but who are not responsive to aspirin.... Agent: Townsend And Townsend And Crew, LLP

20080207683 - Biaryl-substituted tetrahydro-pyrazolo-pyridine modulators of cathepsin s: Biaryl-substituted tetrahydro-pyrazolo-pyridine compounds are described, which are useful as cathepsin S modulators. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by cathepsin S activity, such as psoriasis, pain, multiple sclerosis, atherosclerosis, and rheumatoid arthritis.... Agent: Woodcock Washburn LLP

20080207684 - Kinase inhibitors and methods for using the same: a

20080207682 - Phenylurea derivatives as inhibitors of tyrosine kinases for the treatment of tumour diseases: Compounds of the formula (I), in which R1a-R1e, R2a, R2b, R3 and X have the meanings indicated in Claim 1, are inhibitors of tyrosine kinases, in particular TIE-2, and Raf kinases and can be employed, inter alia, for the treatment of tumours.... Agent: Baker & Daniels LLP

20080207685 - Heterocyclic compounds as modulators of peroxisome proliferator activated receptors, useful for the treatment and/or prevention of disorders modulated by a ppar: The present invention is directed to a compound of formula (I), or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof, which is useful in treating or preventing disorders mediated by a peroxisome proliferator activated receptor (PPAR) such as syndrome X, type II diabetes, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hypertension, arteriosclerosis,... Agent: Eli Lilly & Company

20080207686 - Peptide deformylase (pdf) inhibitors 4: e

20080207687 - Quinoline derivatives as antibacterial agents:

20080207688 - Novel piperidine derivatives: The present invention provides a compound of a formula (I): wherein the variables are defined herein; to a process for preparing such a compound; and to the use of such a compound in the treatment of a chemokine (such as CCR3) mediated disease state.... Agent: Fish & Richardson P.c.

20080207689 - Formamide derivatives for the treatment of diseases: e

20080207690 - Benzisoxazole derivatives: This invention relates to compounds of the formula (I): wherein A, B, R1, R4, m, and n are each as described herein or a pharmaceutically acceptable salt thereof, and compositions containing such compounds and the use of such compounds in the treatment of a condition mediated by 5-HT4 receptor activity... Agent: Pfizer Inc.

20080207691 - Cycloalkyl lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1: The present invention provides compounds of formula I that are useful as potent and selective inhibitors of 11-beta hydroxysteroid dehydrogenase 1. The present invention further provides a pharmaceutical composition which comprises a compound of Formula I, or a pharmaceutical salt thereof, and a pharmaceutically acceptable carrier, diluent, or excipient. In... Agent: Eli Lilly & Company

20080207692 - Stabilized and preserved ketoifen ophthalmic compositions: Ophthalmic compositions comprising ketotifen and a source of hydrogen peroxide providing an amount of hydrogen peroxide of from about 0.001 to about 0.1% (w/v) of hydrogen peroxide, and methods for the treatment and prevention of allergic conjunctivitis using these compositions are provided herein.... Agent: Novartis Corporate Intellectual Property

20080207693 - Mitotic kinesin inhibitors: The present invention relates to dihydropyrazole compounds that are useful for treating cellular proliferative diseases, for treating disorders associated with KSP kinesin activity, and for inhibiting KSP kinesin. The invention also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.... Agent: Merck And Co., Inc

20080207694 - Hydroxamates as histone deacetylase inhibitors and pharmaceutical formulations containing them: Compounds of structure (I) having histone deacetylase (HDAC) inhibitor activity are described. The compounds are chemically characterised by the presence of hydroxamic acid, with zinc as chelator, and an aromatic nucleus connected by a linker in which either a bicyclic aromatic system or a piperidino ring are present.... Agent: Jay S Cinamon Abelman, Frayne & Schwab

20080207695 - Thrombin inhibiting 2-oxo-1,2,5,6-tetrahydropyridine derivatives: There is provided a compound of formula (I) wherein R1, R2a, R2b, R3a, R3b, R4, R5a, R5b, R6 to R8, A and G have meanings given in the description, which compounds are useful as, or are useful as prodrugs of, competitive inhibitors of trypsin-like proteases, such as thrombin, and thus,... Agent: Pepper Hamilton LLP

20080207696 - Phenacyl 2-hydroxy-3-diaminoalkanes: useful in treating Alzheimer's disease and other similar diseases. These compounds include inhibitors of the beta-secretase enzyme that are useful in the treatment of Alzheimer's disease and other diseases characterized by deposition of A beta peptide in a mammal. The compounds of the invention are also useful in pharmaceutical compositions... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20080207698 - Novel compounds 569: e

20080207697 - Use of epothilones in the treatment of neuronal connectivity defects such as schizophrenia and autism: The present invention is about the use of at least one epothilone or derivative thereof as an active ingredient for manufacturing a medicament for use in the treatment of disease(s) involving a neuronal connectivity defect, such as schizophrenia or autism.... Agent: Oliff & Berridge, Plc

20080207699 - Pyrazole derivatives: Compounds of the formula (I), in which R1 and R2 have the meanings indicated in claim 1, are inhibitors of tyrosine kinases, in particular TIE-2, and Raf kinases, and can be employed, inter alia, for the treatment of tumours.... Agent: Baker & Daniels LLP

20080207700 - Amino acid salts of rosiglitazone: The invention relates to novel amino acid salts of the racemic or an enantiomeric or tautomeric form of rosiglitazone and to the solvates of said salts.... Agent: Smith Patent Consulting Consulting, Llc

20080207701 - Opioid receptor antagonists: A compound of the formula (I) wherein the variables X1, X2, B, D, R1 to R7 including R3′, p, y, q, and z, are as defined or a pharmaceutically acceptable salt, solvate, enantiomer, racemate, diastereomer or mixtures thereof, useful for the treatment, prevention or amelioration of obesity and Related Diseases... Agent: Francis O. Ginah Eli Lilly And Company

20080207702 - Use of quaternary pyridinium salts as vasoprotective agents: The invention relates to the use of quaternary pyridium salts of formula (1) wherein R is NH2, CH3, or N(H)CH2OH group, and X is pharmaceutically acceptable counterion, for the preparation of vasoprotective agent for the treatment or prevention of conditions or diseases associated with dysfunction of vascular endothelium, oxidative stress,... Agent: Drinker Biddle & Reath Attn: Intellectual Property Group

20080207703 - Antibacterial heterocyclic ureas: The present invention provides novel heterocyclic urea compounds having useful antibacterial activity, pharmaceutical compositions comprising one or more of these compounds, methods of making the same, and methods of using the same.... Agent: Swanson & Bratschun, L.l.c.

20080207704 - Heteroaryl-imidazole derivatives as cannabinoid cb1 receptor antagonists: A heteroaryl-imidazole compound of formula (I) or a pharmaceutically acceptable salt thereof is effective as a cannabinoid CB1 receptor inverse agonist or antagonist, which is useful for preventing or treating obesity and obesity-related metabolic disorders. The present invention also provides a method for preparing a heteroaryl-imidazole compound of formula (I),... Agent: Sughrue Mion, Pllc

20080207705 - Heteroaryl-imidazole derivatives as cannabinoid cb1 receptor antagonists: A novel heteroaryl-imidazole compound of formula (I) or a pharmaceutically acceptable salt thereof is effective as a cannabinoid CB1 receptor inverse agonist or antagonist, which is useful for preventing or treating obesity and obesity-related metabolic disorders. The present invention also provides a method for preparing same, a pharmaceutical composition containing... Agent: Sughrue Mion, Pllc

20080207706 - Thiadiazoline derivative: n

20080207707 - Aryl-substituted heterocycles, process for their preparation and their use as medicaments:

20080207708 - Oxazole and thiazole compounds and their use in the treatment of pge2 mediated disorders:

20080207709 - Thiazole derivatives for treating dyskinesias caused by a chemical treatment: The invention relates to the use of derivatives of thiazoles having general formula (I) for the preparation of a medicament for the treatment or prevention of dyskinesias caused by a chemical treatment. The invention also relates to a combination of thiazole derivatives having general formula (I) and at least one... Agent: Hunton & Williams LLP Intellectual Property Department

20080207710 - Insulin secretagogue drugs: Demanded is an insulin secretagogue that alleviates side effects, such as acceleration of obesity and cells so as not to be detrimental to insulin secretion β capability. The invention provides an insulin secretagogue agent not only dependent on glucose but also responsive to elevated blood sugar levels, comprising an effective... Agent: Wenderoth, Lind & Ponack, L.l.p.

20080207711 - Method for treating an id2-related disorder: Described herein is a method of treating an ID2-related disorder comprising administering to a patient in need thereof an ID2 inhibitor or derivative thereof.... Agent: Kevin C. Hooper, Esq. Bryan Cave LLP

20080207712 - Thiazole-amine compounds for the treatment of neurodegenerative disorders: wherein R1, R3, R4, R5, R6 and R7 are as defined. Compounds of the Formula I have activity inhibiting production of Aβ-peptide. The invention also relates to pharmaceutical compositions and methods of treating disorders and diseases, for example, neurodegenerative and/or neurological disorders, e.g., Alzheimer's disease, in a mammal comprising compounds... Agent: Pfizer Inc

20080207713 - Compositions and methods for enhancing nitric oxide delivery: The present invention is directed to compounds, combinations, compositions and methods for enhancing nitric oxide (NO) delivery to target sites, and in particular to muscle, both normal and dystrophic. Enhanced NO delivery according to the present invention may be achieved by using a combination of a muscle relaxant and an... Agent: Buchalter Nemer

20080207714 - Diagnosis and treatment of breast cancer: The present invention relates to compositions and methods for cancer diagnosis, research and therapy, including but not limited to, cancer markers. In particular, the present invention relates to AGTR1 and LBP markers for breast cancer.... Agent: Casimir Jones, S.c.

20080207715 - Novel inhibitors of glutaminyl cyclase: e

20080207716 - Formulations and dosing regiment for ppar-alpha modulators: The present invention provides dosing regimens for PPAR-alpha agonist and compositions thereof. A further embodiment of the present invention is a solid oral formulation of Propanoic Acid, 2-[4-[3-[2,5-dihy-dro-1-[(4-methylphenyl)methyl]-5-oxo-1H-1,2,4-triazol-3-yl]propyl]phenoxyl-2-methyl- comprising 75 μg or less of Propanoic Acid, 2-[4-[3-[2,5-dihydro-1-[(4-methylphenyl)methyl]-5-oxo-1H-1,2,4-triazol-3-yl]propyl]phenoxy]-2-methyl- per dosage unit.... Agent: Eli Lilly & Company

20080207717 - Composition to provide maintenance and nutritional support in glycemic control deficits: A Composition to provide nutritional support for mammals having glycemic control and deficit concerns, and assist in managing glycemic controls deficits, with a synergistic combination of natural ingredients.... Agent: Nbty, Inc. - Lee Grosskreuz Hechtel, Esq,

20080207718 - Use of fused imidazole derivatives to mediate ccr3 related conditions: The use of compound of formula I in the preparation of a medicament, e.g. for the treatment of condition mediated by CCR3.... Agent: Novartis Institutes For Biomedical Research, Inc.

20080207719 - Treatment of epilepsy: The disclosure relates to a method for the inhibition of the development of epilepsy with an alpha2-adrenoceptor antagonist or a pharmaceutically acceptable salt or ester thereof.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080207720 - Novel imidazolecarboxamide derivatives as fructose-1,6-bisphosphatase inhibitors, and pharmaceutical compositions comprising same: e

20080207721 - Chemical compounds:

20080207722 - Glepp-1 inhibitors in the treatment of autoimmune and/or inflammatory disorders: The present invention is related to the use of a Glepp-1 inhibitor for the manufacture of a medicament for the treatment of an autoimmune and/or an inflammatory disorder.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20080207723 - Methods for detecting and monitoring cox-2 rna in plasma and serum: This invention provides methods for detecting or inferring the presence of malignant or premalignant cells in a human wherein the malignant or premalignant cells express COX-2. The methods of the invention detect extracellular COX-2 RNA in blood, plasma, serum, and other bodily fluids. The inventive methods are useful for aiding... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20080207724 - Use of inhibitors of histone deacteylases in combination with compounds acting as nsaid for the therapy of human diseases: The present invention relates to the medical use of compounds acting as inhibitors of enzymes having histone deacetylase activity in conditions where their combination with compounds known as NSAID's, Non Steroidal Anti Inflammatory Drugs, causes an enhanced beneficial therapeutic effect. These conditions comprise cancer, cancer predisposing conditions, inflammatory and metabolic... Agent: Cermak Kenealy & Vaidya LLP

20080207725 - Phenyl-pyrazole derivatives as non-steroidal glucocorticoid receptor ligands: e

20080207727 - 3-aminocarbazole compounds, pharmaceutical composition containing the same and method for the preparation thereof: A compound of formula (I), in which R1, R2, R3, R4, R5, R6, X and Y have the meanings indicated in the description, and the pharmaceutically acceptable salts thereof. A pharmaceutical composition containing a compound of formula (I) or a pharmaceutically acceptable salt thereof. A method for preparing the abovementioned... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.c.

20080207726 - Process for the purification of carvedilol or its salts thereof: The present invention provides processes for reducing bis impurities ((1,1′-[2-(2-methoxyphenoxy)ethyl]iminobis-[3-(9H-carbazol-4-yloxy)]-propan-2-ol)), in particular Bis 1 and Bis 2, in carvedilol preparations. The process may comprise (a) combining carvedilol base with phosphoric acid in ethanol to obtain a reaction mixture; and (b) precipitating carvedilol phosphate from the reaction mixture, where the carvedilol... Agent: Kenyon & Kenyon LLP

20080207728 - Bicyclic acyltryptophanols: e

20080207729 - Indole derivatives having antitumor activity: Indole derivatives of Formula (I+A) having antitumour and chemosensitizing activity are described. Also described are pharmaceutical compositions containing the above-mentioned compounds, for the treatment of tumours.... Agent: Lucas & Mercanti, LLP

20080207730 - Methods of using (+)-2-[1-(3-ethoxy-4 methoxyphenyl)-2-methylsulfonylethyl]-4 acetylaminoisoindoline 1,3-dione: Stereomerically pure (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, substantially free of its (−) isomer, and prodrugs, metabolites, polymorphs, salts, solvates, hydrates, and clathrates thereof are discussed. Also discussed are methods of using and pharmaceutical compositions comprising the (+) enantiomer of 2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione are disclosed. The methods include methods of treating and/or preventing disorders ameliorated by the... Agent: Jones Day

20080207731 - 3-(3-indolyl) propionic acid calcium salt and method of making 3-(3-indolyl) propionic acid free acid therefrom: Substantially pure 3-(3-indolyl)propionic acid free acid is synthesized by converting the free acid to 3-(3-indolyl)propionic acid calcium salt (3-IPA calcium), precipitating and washing, and then reconverting the 3-IPA calcium to the free acid. 3-IPA calcium is suitable for use in pharmaceutical compositions in tablet and sustained-release dosage forms. 3-IPA calcium... Agent: Darby & Darby P.c.

20080207732 - Pyrrolidine derivatives as histamine h3 receptor antagonists: The present invention discloses novel compounds of Formula (I) or pharmaceutically acceptable salts thereof which have histamine-H3 receptor antagonist or inverse agonist activity, as well as methods and intermediates for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula (I) as well as methods... Agent: Eli Lilly & Company

20080207733 - Composition for the treatment of vitiligo: The present invention is related with the field of dermatology and in particular with a solution that may be used in those of cosmetics and medicine, useful for the treatment of lesions caused by vitiligo. The amino acid L-Proline is the active principle of the subject composition of the present... Agent: Lackenbach Siegel, LLP

20080207734 - Novel alkoxylactones, alkoxylactams and alkoxythiolactams for controlling processes based on microbial interaction: wherein A1 is O or NH; A2 is O or S; each of R1 and R2 is independently hydrogen, a methyl or C2-C8-saturated or mono- or doubly unsaturated, branched or linear hydrocarbon group; and R3 is a C1-C18-saturated or mono- or doubly unsaturated, branched or linear hydrocarbon group wherein, each... Agent: Paul & Paul

20080207735 - 1-amino linked compounds: The present invention is directed to compounds of formula (I): or a pharmaceutically acceptable salt thereof; wherein A is (II); X is selected from CH, CF and N, R8 is selected from H, C1-C6 alkyl, aryl, heteroaryl, C1-C6 alkylaryl, C1-C6 alkylheteroaryl, C2-C6 alkyl-O—C1-C6 alkyl, C1-C6 haloalkyl, hydroxy C2-C6 alkyl, —C(O)R9... Agent: Eli Lilly & Company

20080207737 - Methods for the treatment of hyperhidrosis: The present invention relates in general to methods of treating sweating disorders and in particular to topical compositions for the treatment of hyperhidrosis. The methods of the present invention relate to the topical application of a composition comprising a therapeutically effective amount of oxybutynin, tolterodine or a substituted benzamide such... Agent: Fennemore Craig

20080207736 - Quaternary ammonium diphenylmethyl compounds useful as muscarinic receptor antagonists: in salt or zwitterionic form or a pharmaceutically acceptable salt thereof, wherein R1-6, a-e and Q are as defined in the specification. These compounds are muscarinic receptor antagonists. The invention also provides pharmaceutical compositions containing such compounds, processes for preparing such compounds and methods of using such compounds to, for... Agent: Theravance, Inc.

20080207738 - Drug combinations to treat drug resistant tumors: Embodiments of the invention provide a method and composition for treating or reducing multiple drug resistance in cancers. Embodiments of the invention also provide for a xanthene compound to inhibit multidrug resistance protein 1.... Agent: Faegre & Benson LLP Patent Docketing

20080207739 - Ophthalmic uses of s1p receptor modulators: The present invention pertains to the use of a S1P receptor agonist in the manufacture of a medicament in the treatment of an ocular disorder.... Agent: Novartis Corporate Intellectual Property

20080207740 - Small organic molecule regulators of cell proliferation: The present invention makes available methods and reagents for modulating proliferation or differentiation in a cell or tissue comprising contacting the cell with a hedgehog agonist, such as the compounds depicted in FIGS. 32 and 33. In certain embodiments, the methods and reagents may be employed to correct or inhibit... Agent: Ropes & Gray LLP

20080207741 - Novel hydroxylated aromatic compounds: e

20080207742 - Therapeutic effects of bryostatins, bryologs, and other related substances on head trauma-induced memory impairment and brain injury: The invention provides for the use of protein kinase activators or boosters of nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF) or other neurotrophic factors to treat head trauma. Specifically, the present invention provides methods of treating head trauma comprising the steps of identifying a subject having suffered a head... Agent: Milbank, Tweed, Hadley & Mccloy LLP

20080207743 - Biologically active taxane analogs and methods of treatment: wherein R1 and R2 are each selected from H, alkyl, alkenyl or aryl; R3 is hydroxyl or OP1; R4 is OH or R7COO; R7 is alkyl, alkenyl or aryl, R8 and R9 are each independently selected from H, alkyl or alkenyl. The compounds of the present application may particularly be... Agent: Morgan, Lewis & Bockius LLP

20080207744 - Biologically active taxane analogs and methods of treatment: wherein R1 and R2 are each selected from H, alkyl, alkenyl or aryl; R3 is hydroxyl or OP1; R4 is OH or R7COO; R7 is alkyl, alkenyl or aryl, R8 and R9 are each independently selected from H, alkyl or alkenyl. The compounds of the present application may particularly be... Agent: Morgan, Lewis & Bockius LLP

20080207745 - Orally-absorbed formulation for paromomycin: A composition for oral treatment of visceral leishmaniasis comprises paromomycin and a permeation enhancer that increases oral bioavailability of the paromomycin to at least 20%.... Agent: Richard Aron Osman

20080207746 - Intracorporeal medicaments for photodynamic treatment of disease: New intracorporeal photodynamic medicaments and certain medical uses and methods for use of such photodynamic medicaments for treatment of disease in human or animal tissue are described, wherein a primary active component of such medicaments is a halogenated xanthene or halogenated xanthene derivative. In preferred embodiments, such medicaments are used... Agent: Cook, Alex, Mcfarron, Manzo, Cummings & Mehler Ltd

20080207747 - Lipase inhibitors: w

20080207748 - Vitamin c preparation: The present invention relates to vitamin C preparations which enhance absorption of vitamin C into cells, and prolong the retention of vitamin C within the blood plasma and tissue of mammals, such as humans. The vitamin C preparations of the present invention include lipophilic molecules which improve the absorption of... Agent: Darby & Darby P.c.

20080207749 - Use of mglur5 (esp. afq056) in gi (esp.gerd): The invention relates to the use of a compound acting as mGluR5 antagonist in the treatment, preventions and/or delay of progression of disorders of the gastrointestinal tract, disorders of the urinary tract and/or post-operative disorders and to the treatment, prevention and/or delay of progression of pain associated with these indications.... Agent: Montgomery, Mccracken, Walker & Rhoads, LLP

20080207750 - Use of n-chlorotaurine for treatment of oozing tissue deficiencies: A pharmaceutical composition containing N-chlorotaurine is administered to a mammal to treat oozing tissue deficiencies.... Agent: Proskauer Rose LLP Patent Department

20080207751 - Sulindac derivatives for treatment of cancer: The present invention relates to novel non steroidal anti-inflammatory compounds (NSAIDs) derivatives of sulindac, for the treatment/prevention, alone or in combination, of cancer.... Agent: Schneck & Schneck

20080207752 - Poly (epsilon-caprolactone-co-methylmethacrylate), method for preparing the same using super critical fluid, and method for preparing therapeutic agent for skin diseases such as acne, atopy and athlete's foot comprising the same: A biodegradable polymer comprising a spherical poly (ε-caprolactone-co-methylmethacrylate) used in a therapeutic agent for skin diseases and a method for preparing the same, and a method for preparing the therapeutic agent for skin diseases having the particle size of 50 to 100 nm and a spherical shape comprising the poly... Agent: Greer, Burns & Crain, Ltd.

20080207753 - Analogues of lipid mediators derived from omega-3 pufas and methods of use: The present invention is directed to compounds that are analogues of lipid mediators derived from a fish oil-derived fatty acid, eicosapentaenoic acid [C20:5 ω-3; EPA], but with a longer tissue half-life and enhanced bioactivity. These analogues may be used to treat inflammatory, angioproliferative, cardiovascular, thrombophlebotic, vascular, ocular, dermatologic, neurodegenerative, pulmonary,... Agent: Ropes & Gray LLP

20080207754 - Method and apparatus for palatable prevention of acid reflux: A method and applicators for preventing or reducing acid reflux (or “GERD”) by delivering a proper dose of vinegar directly to the back of the throat without exposing the taste buds, and immediately followed by a shot of water or other pleasant tasting chaser to wash it down. One applicator... Agent: Ober, Kaler, Grimes & Shriver Attorneys At Law

20080207755 - Alpha 2 delta ligands for fibromyalgia and other disorders: R2 is straight or branched alkyl of from 4 to 8 carbon atoms, straight or branched alkenyl of from 2 to 8 carbon atoms, cycloalkyl of from 3 to 7 carbon atoms, alkoxy of from 1 to 6 carbon atoms, -alkylcycloalkyl, -alkylalkoxy, -alkyl OH, -alkylphenyl, -alkylphenoxy, or -substituted phenyl. The... Agent: Pfizer Inc.

20080207756 - Bio-absorbable oil suspension: Exemplary embodiments of the invention provide a dispersing liquid for coating internal body tissues with a bio-absorbable oil, a method of making the dispersing liquid, methods of using the dispersing liquid and a kit for coating internal body tissues using the dispersing liquid. The dispersing liquid includes a suspension of... Agent: Lahive & Cockfield, LLP

20080207757 - Polar hydrophilic prodrugs of amphetamine and other stimulants and processes for making and using the same: Disclosed are polar, hydrophilic stimulant prodrug compositions comprising at least one stimulant chemically attached to a polar hydrophilic ligand, a salt thereof, a derivative thereof, or a combination thereof. Methods of making and using the same are also disclosed.... Agent: Mcandrews Held & Malloy, Ltd

20080207758 - Rhein conjugates, preparation method thereof and their uses in producing medicines for treating diabetic nephrosis, intestinal adhesion and osteoarthritis: The conjugates of present invention are formed by the combination of rhein or their analogues with the organic bases or amino acids in molecular force between them. The methods for preparing the conjugates and their uses for manufacturing medicines in the treatment of diabetic nephrosis, recovery of gastrointestinal function and... Agent: Schmeiser, Olsen & Watts

20080207759 - Method for protecting mitochondria: The present invention relates to a method for protecting mitochondria from damage in a mammalian subject, which comprises administering an effective amount of a prostaglandin compound to a subject in need thereof. Also provided is a method for treating mitochondrial dysfunction as well as a condition associated with mitochondrial dysfunction... Agent: Sughrue Mion, Pllc

20080207760 - Pharmaceutical compositions for and methods of inhibiting hcv: The present invention relates generally to replicase complex defect inducers and pharmaceutical compositions containing such inducers. Methods of developing mutants that are resistant to replicase complex defect inducers are also provided. Further included are mutants that can be used in screening for replicase complex defect inducers. Methods of screening test... Agent: Cantor Colburn, LLP

20080207761 - Pharmaceutical formulations of modafinil: Compositions of modafinil and methods of treating neurologically related conditions with the administration of modafinil. Also compositions that include modafinil and one or more excipients such as diluents, disintegrants, binders and lubricants.... Agent: Cephalon, Inc.

20080207762 - Method of treating inflammatory acne vulgaris with carbamide peroxide: A method of treating inflammatory acne vulgaris comprises the topical application of a formulation incorporating carbamide peroxide in a pharmaceutically acceptable vehicle. Inflammatory acneform lesions that can be successfully treated with the inventive method include erythematous papules, pustules, nodules, and cysts. Suitable pharmaceutical vehicles for the topical application of carbamide... Agent: Barnes & Thornburg LLP

20080207763 - Method and composition for potentiating the antipyretic action of a nonopiod analgesic: A composition and method of treating fever, and optionally treating pain, is disclosed. The composition and method utilize a nonopioid analgesic and an endothelin antagonist as active agents to treat fever in mammals, including humans. The composition also is useful in the prevention and treatment of stroke and other cardiovascular... Agent: Marshall, Gerstein & Borun LLP

20080207764 - Novel benzamidine derivatives having anti-inflammatory and immunosuppressive activity: c

20080207765 - Method for inhibiting neuronal cell death induced by oxidative glutamate toxicity: A neuronal cell death induced by an oxidative glutamate toxicity is substantially inhibited by administrating to an mammal an effective amount of a phenylenediamine derivative compound of formula (I), wherein R is phenyl or butyl.... Agent: Ditthavong Mori & Steiner, P.c.

20080207766 - Methods and compositions for treating at least one upper gastrointestinal symptom: The present disclosure is directed to methods and formulations for treating, modifying, and/or managing at least one upper gastrointestinal symptom. Methods of using at least one α3 β4 nAChR antagonist and formulations comprising at least one α3 β4 nAChR antagonist, or pharmaceutically acceptable salt thereof are included.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080207767 - Foamable alcoholic composition: A foamable composition includes greater than about 40 weight percent of an alcohol, based upon the total weight of the alcoholic composition, and a foaming surfactant selected from gemini surfactants, sulfuric acid esters, di-esters, C10-34 fatty alcohols, polyquaternium polymers, and combinations thereof.... Agent: Renner Kenner Greive Bobak Taylor & Weber

20080207768 - Medicament for preventive and/or therapeutic treatment of lower urinary tract symptom: A medicament for preventive and/or therapeutic treatment of a lower urinary tract symptom caused by a lower urinary tract disorder, which comprises as an active ingredient a retinoid such as, for example, 4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)carbamoyl]benzoic acid... Agent: Greenblum & Bernstein, P.L.C

20080207769 - Method for treating benign prostatic hyperplasia: The use of 1-alpha-fluoro-25-hydroxy-16,23E-diene-26,27-bishomo-20-epi-cholecalciferol, or a pharmaceutically acceptable salt or ester thereof, for the manufacture of a medicament for the prevention and/or treatment of benign prostatic hyperplasia (BPH) and associated symptoms.... Agent: Edwards Angell Palmer & Dodge LLP

20080207770 - Compositions enriched in phenolic compounds and methods for producing the same: Provided are processes for the preparation of compositions enriched in phenolic compounds from a crude plant extract. One process includes a novel column purification step using a polymer resin that releasably adsorbs the phenolic compounds but does not retain polar non-phenolic compounds, wherein the resin comprises aromatic rings substituted with... Agent: Hogan & Hartson LLP

20080207771 - Topical compositions: The present invention provides new topical pharmaceutical or cosmetic compositions for the prevention and treatment of irritation of mucous cells, or skin cells, comprising a combination of: xylitol, myoinositol or mannitol or any combination of these; glycerol and/or urea; water; in the absence of any oil in water or wax... Agent: Fleit Gibbons Gutman Bongini & Bianco Pl

20080207772 - Mixture of interference pigments: The present invention relates to a mixture of interference pigments, where the mixture comprises at least one interference pigment A comprising a substrate and a coating comprising metallic iron, and an interference pigment B comprising a substrate and a coating comprising metallic tin and in addition at least one metal... Agent: Millen, White, Zelano & Branigan, P.c.

20080207773 - Cosmetic, pharmaceutical and dermatological products: e

20080207774 - Anionic latex as a carrier for active ingredients and methods for making and using the same: This invention relates to the field of polymeric materials that can be used in combination with a wide variety of substrates, such as personal care products, textiles, metal, cellulosic materials, plastics, and the like, and to the field of active agents including, for example, antimicrobial, antibacterial and antifungal materials. This... Agent: Amy H. Fix Womble Carlyle Sandridge & Rice Pllc

20080207775 - Method for producing an aqueous suspension and a powdered preparation of one or more carotinoids: Aqueous suspensions comprising: (a) at least one carotenoid, (b) at least one modified starch, and (c) sucrose; wherein the at least one carotenoid is present in the suspension in an amount of 1 to 25% by weight, based on the dry matter of the aqueous suspension; and wherein the at... Agent: Connolly Bove Lodge & Hutz, LLP

20080207777 - Emulsifier system, emulsion and the use thereof: The present invention relates to an emulsifier system comprising a) an ascorbic ester with long-chain fatty acids, b) an ethoxylated sorbitan fatty acid ester and c) a sugar fatty acid ester and emulsions prepared therewith.... Agent: Connolly Bove Lodge & Hutz, LLP

20080207776 - Highly packed polycationic ammonium, sulfonium and phosphonium lipids: The present invention discloses highly packed polycationic ammonium, sulfonium and phosphonium lipid compounds useful for making lipid aggregates for delivery of macromolecules and other compounds into cells. They are especially useful for the DNA-dependent transformation of cells. Methods for their preparation and use as intracellular delivery agents are also disclosed.... Agent: Invitrogen Corporation C/o Intellevate

20080207778 - Support comprising a wax derivative for making topical cosmetic formulations: Disclosed is a support, in particular for making topical cosmetic formulations comprising a mixture containing polyol esters with saturated linear acids and unsaturated linear and/or saturated branched acids, monounsaturated linear or saturated branched acid esters with saturated linear alcohols, saturated linear acid esters with monounsaturated linear or saturated branched alcohols,... Agent: Cantor Colburn, LLP

20080200367 - Compositions and methods for treating sleep disorders: The present invention relates to a method for preventing or ameliorating a sleep-related breathing disorder. The method involves the use of one or a combination of cholecystokinin (CCK) receptor antagonists.... Agent: Licata & Tyrrell P.C.

20080200370 - Method of treating drug addiction using dextro-morphine: The present invention relates a method of treating drug addiction in an individual by administering to the addicted individual a therapeutically effective amount of dextro-morphine capable of activating an opioid receptor. It is disclosed here that dextro-morphine is suitable for treating addiction to natural opiates, semi-synthetic opiates, fully synthetic opioids,... Agent: Quarles & Brady LLP

20080200368 - Peptide composition: There is provided a method for selecting a tolerogenic peptide by selecting a peptide which is capable of binding to an MHC class I or II molecule without further processing. There is also provided a peptide selected by such a method and its use in a pharmaceutical composition and a... Agent: Wilmerhale/dc

20080200366 - Trimeric peptides for use in treating obesity: The present invention relates to novel peptide compounds which are effective in modulating one or more melanocortin receptor types, to the use of the compounds in therapy, to methods of treatment comprising administration of the compounds to patients in need thereof, and to the use of the compounds in the... Agent: Novo Nordisk, Inc. Intellectual Property Department

20080200369 - Trophinin-binding peptides and uses thereof: Disclosed herein are compositions and methods useful for promoting sperm motility, promoting embryonic stem cell formation, promoting trophoblast formation, or promoting neuronal growth. The compositions and methods are based on peptide sequences that bind trophinin, inhibit bystin-mediated arrest of epidermal growth factor (EGF) receptor, and promotes EGF receptor autophosphorylation.... Agent: Needle & Rosenberg, P.C.

20080200371 - Thiazole and thiadiazole inhibitors of tyrosine phosphatases: Compounds and compositions are provided for modulating the activity of protein tyrosine phosphatases. In one embodiment, the compounds and compositions are thiazoles and thiadiazoles that inhibit the activity of protein tyrosine phosphatase 1B.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20080200372 - Glycosaminoglycan peptides derived from connective tissues and use thereof in the prevention of arthritis and other degenerative medical conditions: The inventors sought to provide compositions and methods of prophylaxis to prevent these harmful immune responses in patients and to prevent the related undesirable symptoms biological tissue such as for example inflammation, cell injury, tissue injury, tissue degradation, tenderness, redness, joint stiffness, joint swelling, restricted mobility and reduced strength. The... Agent: Nixon & Vanderhye, PC

20080200375 - Angiogenesis using hepatocyte growth factor: Methods for enhancing angiogenesis in a mammal using hepatocyte growth factor (“HGF”) are provided. In the methods, HGF can be administered to mammals suffering from, for instance, vascular insufficiency or arterial occlusive disease. Articles of manufacture and kits containing HGF are also provided.... Agent: Genentech, Inc.

20080200385 - Annexin for cancer risk assessment: A method treats urogenital and/or intestinal tract cancer and includes administering a therapeutically effective amount of at least one annexion protein, annexin of A3, to a mammal.... Agent: Ip Group Of Dla Piper US LLP

20080200387 - Anti-angiogenic protein, composition and use thereof: The present invention relates to an anti-angiogenic protein comprising a mutant kringle 1-5 (K1-5) fragment of plasminogen, wherein a set of mutation position is selected from the group consisting of positions 227, 284 and 470 of SEQ ID NO. 6, and wherein the position 227 is replaced with an amino... Agent: Wpat, PC Intellectual Property Attorneys

20080200386 - Compositions and methods for the therapy and diagnosis of breast cancer: Compositions and methods for the therapy and diagnosis of cancer, particularly breast cancer, are disclosed. Illustrative compositions comprise one or more breast tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides.... Agent: Seed Intellectual Property Law Group PLLC

20080200376 - Compositions and methods for the treatment of obesity and sexual dysfunction: The present invention relates to methods of treating and preventing obesity and obesity-related disorders in a subject comprising administering a neurokinin-1 antagonist and an anti-obesity agent, such as a melanocortin 4 receptor agonist, to said subject. The present invention further related to methods of treating or preventing sexual dysfunction, including... Agent: Merck And Co., Inc

20080200380 - Compositions for buccal delivery of parathyroid hormone: Compositions and pharmaceutical formulations for buccally delivering parathyroid hormone comprising a) a delivery agent, b) a PTH component and, optionally, c) an antiresorptive agent are provided.... Agent: Emisphere Technologies, Inc

20080200379 - Diagnostic markers of human female infertility: The subject invention pertains to methods and reagents for the diagnosis of female infertility, prognostic indicators for female infertility, compounds for the treatment of female infertility, compounds and methods for contraception. Methods and compounds are based on the levels of ebaf in endometrial tissue. Methods for diagnosing endometrial receptivity and... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20080200390 - Exendins and exendin agonists modified with polyamino acids: Novel modified exendins and exendin agonists having an exendin or exendin agonist linked to one or more molecular weight increasing compounds, for example, polyamino acids, polyethylene glycol polymers, and related formulations and dosages and methods of administration thereof are provided. These modified exendins and exendin agonists, compositions and methods are... Agent: Intellectual Property Department Amylin Pharmaceuticals, Inc.

20080200391 - Human extracellular matrix-1: A human ECM-1 polypeptide and DNA (RNA) encoding such polypeptide and a procedure for producing such polypeptide by recombinant techniques is disclosed. Also disclosed are methods for utilizing such polypeptide for stimulating the differentiation in growth of osteoblasts and osteoclasts, which may be used to promote the healing of bone... Agent: Human Genome Sciences Inc. Intellectual Property Dept.

20080200378 - Kgf polypeptide compositions: Compositions comprising keratinocyte growth factor (KGF) polypeptides and methods of using the same are described. The KGF polypeptides of the present invention display enhanced bioactivity relative to full-length KGF163. Accordingly, the KGF polypeptides of the present invention may be used in compositions in lesser amounts than would be necessary using... Agent: Novartis Vaccines And Diagnostics Inc.

20080200384 - Method for the diagnosis and prognosis of demyelinating diseases and for the development of medicaments against demyelinating diseases: The present invention refers to the use of glutamate transporters, glutamate and EGF to detect the presence of demyelinating diseases in a subject, to determine the status or severity of the same or to monitor the effects of a therapy administered to a subject who suffers from such diseases; to... Agent: Intellectual Property / Technology Law

20080200381 - Methods and compositions for regulating bone and cartilage formation: The invention provides methods and compositions for diagnostic assays for detecting bone and cartilage formation and therapeutic methods and compositions for treating disease and disorders related to bone and cartilage formation or resorption, such as osteoporosis and bone fractions. The invention also provides therapeutic methods for diseases related to bone... Agent: Fitzpatrick Cella (wyeth)

20080200373 - Multi-component biological transport systems: Compositions and methods are provided that are useful for the delivery, including transdermal delivery, of biologically active agents, such as non-protein non-nucleotide therapeutics and protein-based therapeutics excluding insulin, botulinum toxins, antibody fragments, and VEGF. The compositions and methods are particularly useful for topical delivery of antifungal agents and antigenic agents... Agent: King & Spalding

20080200374 - Mutational derivatives of microcin j25: Analogs of bacteriocidal peptide microcin J25 (MccJ25) are provided that have an amino acid sequence that differs from that of MccJ25 by having at least one amino acid substitution; and that inhibit bacterial cell growth with a potency at least equal to that of MccJ25.... Agent: Hoffmann & Baron, LLP

20080200382 - Novel use of aim3 acting as a tumor suppressor: The present invention relates to novel uses of AIM3 acting as a tumor suppressor, and more particularly to methods for using an AIM3 protein or a nucleic acid encoding the protein to activate ATM or ATR and to treat ATM- or ATR-mediated diseases. The AIM3 protein according to the present... Agent: Buchanan, Ingersoll & Rooney PC

20080200383 - Pharmaceutical formulations comprising incretin peptide and aprotic polar solvent: The present disclosure is directed to stable pharmaceutical formulations and uses thereof.... Agent: Intellectual Property Department Amylin Pharmaceuticals, Inc.

20080200377 - Polymer particles: A composition including a solution suitable for introduction into a blood vessel comprising particles comprising a treatment agent and a polymeric product of at least one activated diamine and at least one activated dicarboxylic acid. A method including introducing a delivery device into a blood vessel; and introducing a solution... Agent: Blakely Sokoloff Taylor & Zafman LLP

20080200389 - Rank-ligand-induced sodium/proton antiporter polypeptides: This invention relates to RIPPA, a new member of the human Na+/H+ antiporter polypeptide family, methods of making such polypeptides, and to methods of using RIPPA and RIPPA-Like polypeptides and agonists or antagonists.... Agent: Immunex Corporation Law Department

20080200388 - Stem cell factor-like proteins and uses thereof: The invention relates to pharmaceutical compositions comprising gastrointestinal proliferative factor SCFA2, SCFA4 or SCFA4v polynucleotides and polypeptides. The invention further relates to the therapeutic use of SCFA2, SCFA4 or SCFA4v to prevent or treat conditions or disorders associated with the degeneration of the epithelial mucosa.... Agent: Robins & Pasternak

20080200392 - Methods for treating parkinson's disease: Polypeptides and other compounds that can bind specifically to the CH2-CH3 cleft of an immunoglobulin molecule, and methods for using such polypeptides and compounds to inhibit Fc-mediated immune complex formation, immune complexed IgG binding to IgG FγR, and immune complexed IgG binding to mC1q (membrane C1q) or soluble C1q. The... Agent: Fish & Richardson P.C.

20080200393 - Method and composition for treating angiogenesis and for preventing cancer progression and metastasis comprising a prostate secretory protein (psp94) family member: Angiogenesis, the formation of new blood vessels, is an integral part of normal physiological and developmental processes as well as several pathologies, ranging from tumor growth and metastasis to inflammation and ocular disease. Methods and compositions are provided for controlling normal angiogenesis and for treating angiogenesis associated or mediated diseases... Agent: Kirkpatrick & Lockhart Preston Gates Ellis LLP (formerly Kirkpatrick & Lockhart Nicholson Graham)

20080200395 - Treatment of cancer by a combination of non-ionizing radiation and androgen deprivation: A combined androgen deprivation and thermotherapy cancer treatment. For example, the combination can be used to treat prostate cancer. Chemical compounds, including a non-steroidal anti-androgen and/or an LH-RH agonist, such as androgen deprivation therapy (“ADT”), can be used in combination with application of non-ionizing radiation to treat cancer. The chemical... Agent: King & Spalding LLP

20080200394 - Treatment of inflammatory airway disease: This invention relates to methods of treatment of inflammatory airway disease, and in particular to methods of treatment of asthma and chronic obstructive pulmonary disease. The invention is applicable to both allergic (atopic) and non-allergic (intrinsic) asthma. In one form the method comprises the step of administering an effective amount... Agent: Proskauer Rose LLP

20080200396 - Peptides or peptidic conjugate derivatives of msh and the use thereof for cosmetically fighting against canities: The invention relates to a peptide of formula W-DPhe-Arg-Z (I) and to a conjugate thereof of a formula A-W-DPhe-Arg-Z (II), wherein A is a radical corresponding to a nionocarboxylic acid of general formula HOOC—R (III), wherein R is an linear or branched possibly substituted by a hydroxy group aliphatic C1-C24... Agent: Foley And Lardner LLP Suite 500

20080200397 - Peptidomimetic agents from dextrorotatory amino acids as well as pharmaceutical agents that contain the latter for treatment of neurodegenerative diseases: A peptidomimetic agent from dextrorotatory amino acids includes vGek with Dval-gly-Dglu-Dlys as a central D-amino acid sequence, whereby gly is equal to D-glycine, which is equal to L-glycine. Pharmaceutical agents for use in the treatment of neurodegenerative diseases, in particular Alzheimer's disease, Parkinson's disease, Lewy Body dementia, Creutzfeldt-Jakob disease, as... Agent: Young & Thompson

20080200398 - Compounds for enzyme inhibition: Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases. The activities of those Ntn having multiple activities can be differentially inhibited by the compounds described. For example, the chymotrypsin-like activity of the 20S proteasome may be selectively inhibited with the inventive compounds.... Agent: Ropes & Gray LLP

20080200399 - Compounds for treating neurologic diseases, otologic diseases, or ophthalmologic diseases and methods of use thereof: Described herein are compounds and methods for treating or preventing a neurologie, otologic, or ophthalmologic disease in a subject. Also described herein are compounds that can be used as therapeutics.... Agent: Needle & Rosenberg, P.C.

20080200400 - Dermatological compositions including oligopeptides for increasing skin sensitivity and neuronal perception: The invention relates to dermatological compositions including at least one oligopeptide with a sequence of 4, 5 or 6 amino acids and/or a derivative thereof as means for increasing the sensitivity of skin, wherein the amino acid sequence comprises the dipeptide sequence Ile-Pro and/or Pro-Ile.... Agent: Scully Scott Murphy & Presser, PC

20080200401 - Scf extract containing cardiac glycoside: A supercritical fluid (SCF) extract of a cardiac glycoside-containing plant mass is provided. The extract can be included in a pharmaceutical composition containing an extract-solubilizing amount of solubilizer. Oleandrin is included within the extract when a cardiac glycoside-containing plant, such as Nerium oleander, is extracted by SCF extraction. The extract... Agent: Innovar, LLC

20080200402 - Use of fumagillin and the derivatives thereof to increase the bioavilability of the macrocyclic lactones: The invention relates to the use of fumagillin and the analog derivatives thereof, as inhibitors of cellular transporters, such as ABC transporters, and especially of P-glycoprotein, in order to increase the bioavailability of active ingredients that can be used in the treatment of pathologies such as cancers or parasitic diseases,... Agent: Young & Thompson

20080200403 - 9a-carbamoyl and thiocarbamoyl azalides with anti-inflammatory activity: The use of semi-synthetic 9a-carbamoyl or thiocarbamoyl azalides for the treatment and prevention of inflammatory diseases and conditions in humans and animals. More particularly, the invention relates to the use of 15-membered azalides having at the 9a-position carbamoyl or thiocarbamoyl group, and their pharmaceutically acceptable derivatives for the treatment and... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B482

20080200404 - Novel antimalarial 9a-carbamoyl-aminoalkyl and 9a-thiocarbamoyl-aminoalkyl azalides: Novel 9a-N′-substituted-carbamoyl- and thiocarbamoyl-aminoalkyl-9a-aza-9-deoxo-9-dihydro-9a-homoerythromycin A and 3-O-decladinosyl-9a-aza-9-deoxo-9-dihydro-9a-homoerythromycin A compounds having antimalarial activity are claimed. More particularly, the invention relates to 9a-N′-substituted-carbamoyl- and thiocarbamoyl-β-aminoethyl- or -γ-aminopropyl-9a-aza-9-deoxo-9-dihydro-9a-homoerythromycin A and 3-O-decladinosyl-9a-aza-9-deoxo-9-dihydro-9a-homoerythromycin A compounds and to pharmaceutically acceptable derivatives thereof having antimalarial activity.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B482

20080200405 - Drug resistance reversal in neoplastic disease: The present invention is directed to compounds, compositions, and methods for halting or reversing the effects of chemoresistance in neoplastic diseases. In particular the use of hydroxylamines is described.... Agent: Woodcock Washburn LLP

20080200406 - Methods of use of glycomimetics with replacements for hexoses and n-acetyl hexosamines: Methods are provided for using a compound to treat, for example, endothelial dysfunction including vascular abnormalities. More specifically, methods are described for using an oligosaccharide compound or glycomimetic compound wherein a cyclohexane derivative is incorporated in either.... Agent: Seed Intellectual Property Law Group PLLC

20080200409 - Antisense oligonucleotides for inducing exon skipping and methods of use thereof: Antisense molecules capable of binding to a selected target site in the dystrophin gene to induce exon skipping are described.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B482

20080200412 - Astrocyte elevated gene-1 and its promoter in treatments for neurotoxicity and malignancy: The present invention is based, at least in part, on the discovery that Astrocyte Elevated Gene-1 (‘AEG-1’) expression (i) suppresses the Excitatory Amino Acid Transporter-2 (‘EAAT-2’) promoter, thereby inhibiting glutamate transport; (ii) supports anchorage independent colony formation of cells, in which it is synergistic with the RAS oncogene; and (iii)... Agent: Baker Botts L.L.P.

20080200418 - Compositions for drug administration: A composition having at least one alkyl glycoside and at least one therapeutic agent, wherein the alkylglycoside has an alkyl chain length from about 10 to about 16 carbon atoms and wherein the therapeutic agent is an oligonucleotide.... Agent: Dla Piper US LLP

20080200408 - Deletion mutants of tetrodotoxin-resistant sodium channel alpha subunit: The present invention is directed to deletion mutants of a human sodium channel alpha subunit and methods and compositions for making and using the same.... Agent: Vertex Pharmaceuticals Inc.

20080200414 - Hcarg, a novel calcium-regulated gene: Novel nucleic acids and corresponding encoded proteins are described. Also described are corresponding recombinant vectors and host cells, as well as methods of producing the proteins. Also described are mimetics and antibodies to the proteins as well as compositions comprising the nucleic acid or proteins or a portion thereof. Methods... Agent: Banner & Witcoff, Ltd.

20080200417 - High efficiency encapsulation of charged therapeutic agents in lipid vesicles: Methods for the preparation of a lipid-nucleic acid composition are provided. According to the methods, a mixture of lipids containing a protonatable or deprotonatable lipid, for example an amino lipid and a lipid such as a PEG- or Polyamide oligomer-modified lipid is combined with a buffered aqueous solution of a... Agent: Seed Intellectual Property Law Group PLLC

20080200420 - In vivo production of small interfering rnas that mediate gene silencing: The invention provides engineered RNA precursors that when expressed in a cell are processed by the cell to produce targeted small interfering RNAs (siRNAs) that selectively silence targeted genes (by cleaving specific mRNAs) using the cell's own RNA interference (RNAi) pathway. By introducing nucleic acid molecules that encode these engineered... Agent: Lahive & Cockfield, LLP

20080200411 - Means and methods for diagnosing and treating affective disorders: Nucleic acid molecules encoding an ATP-gated ion channel P2X7R which contains a mutation or a deletion are disclosed. Polypeptides encoded by the nucleic acid molecules and antibodies that specifically are directed to these polypeptides are disclosed. Aptamers that specifically bind the nucleic acid molecules, and primers for selectively amplifying the... Agent: Foley And Lardner LLP Suite 500

20080200410 - Method for detection of 5t4 rna in plasma or serum: This invention relates to methods of detecting or inferring the presence of malignant or premalignant cells in a human that express 5T4. Provided are methods for detecting 5T4 RNA in blood, plasma, serum, other bodily fluids, cells, and tissues. The invention thereby provides an aid for the detection, diagnosis, monitoring,... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20080200407 - Methylated cpg polynucleotide: It is an object of the present invention to provide a polynucleotide, which can effectively suppress the immunoreactivity caused by DNA having a CpG motif and which can be used for preventing and/or treating immune-mediated diseases such as arthritis. The present invention provides a polynucleotide comprising a CpG motif wherein... Agent: Greenblum & Bernstein, P.L.C

20080200416 - Modulation of t cell signaling threshold and t cell sensitivity to antigens: MicroRNAs (miRNAs) are a diverse and abundant class of ˜22-nucleotide (nt) endogenous regulatory RNAs that play a variety of roles in animal cells by controlling gene expression at the posttranscriptional level. Increased miR-181a expression in mature T cells is shown to cause a marked increase in T cell activation and... Agent: Bozicevic, Field & Francis LLP

20080200415 - Plant activation of insect toxin: Compositions and methods for protecting a plant from an insect pest are provided. In particular, nucleic acid sequences encoding insect protoxins modified to comprise at least one proteolytic activation site that is sensitive to a plant protease or an insect gut protease are provided. Cleavage of the modified protoxin at... Agent: Alston & Bird LLP Pioneer Hi-bred International, Inc.

20080200413 - Rna aptamers and methods for identifying the same: RNA aptamers and methods for identifying the same are disclosed. The RNA aptamers selectively bind coagulation factors, E2F family members, Ang1 or Ang2, and therapeutic and other uses for the RNA aptamers are also disclosed.... Agent: King & Spalding LLP

20080200419 - Splicing variant of tgf-beta2 and uses thereof: An alternatively spliced form of transforming growth factor-beta2 (TGF-β2), herein denoted Δ6-TGF-β2 is disclosed. Δ6-TGF-β2 differs from TGF-β2 in the sequence of the three C-terminal exons. This novel protein is secreted, induced by cytotoxic stress in hematopoietic stem cells, and specifically blocks the enhancing effects of TGF-β2 on adult stem... Agent: Crowell & Moring LLP Intellectual Property Group

20080200421 - Coating for a medical device having an anti-thrombotic conjugate: A conjugate between an anti-thrombotic agent and a bioabsorbable polymer is provided. In addition, a method is provided for applying a coating comprising an anti-thrombotic agent and a bioabsorbable polymer conjugate to at least a portion of an implantable device to prevent or reduce the formation of thrombosis on the... Agent: Philip S. Johnson Johnson & Johnson

20080200422 - Methods for reduction of adipose tissue mass: The present disclosure relates to diets, compounds, e.g., GCN2 agonists and methods that selectively reduce adipose tissue mass relative to the mass of other tissue types and increase insulin sensitivity. Another aspect of the disclosure relates to methods for identifying GCN2 agonists that will decrease the activity and/or expression of... Agent: Mcdermott Will & Emery LLP

20080200425 - Methods and compositions for regulating bone mineral density: A method for treating or preventing osteoporosis or a medical condition associated with a reduced or loss of bone mineral density and its related complications, in a mammalian subject is accomplished by intravenously administering to the mammalian subject, a therapeutically effective amount of a sterile aqueous liposomal suspension of lipoprotein... Agent: Winston & Strawn LLP Patent Department

20080200423 - Novel tricyclic nucleosides or nucleotides as therapeutic agents: Nucelosides and nucleotides containing a tricyclic base portion thereof are useful for treating infectious diseases and proliferative disorders, such as viral infections or cancer respectively.... Agent: Seed Intellectual Property Law Group PLLC

20080200424 - Preparation for treating cancer: an effective quantity of a cytostatic anti-cancer drug, such as a compound from the class of oxysterols or polyphenols, or a mixture containing selenium and L-cystcine and/or L-glutathione, or a mixture containing vitamins of the B-complex, in particular with the vitamins B1 and/or B6 and/or B12, with the exception of... Agent: Morriss Obryant Compagni, P.C.

20080200428 - Antiproliferative drug: Object of the present invention are esterified conjugates of hyaluronic acid having anti-proliferative activity.... Agent: Cooley Godward Kronish LLP Attn: Patent Group

20080200429 - Purified beta glucan composition: The invention provides methods of using beta glucans to treat conditions associated with bone loss or low bone density as well as methods for promoting bone growth in situations where enhanced bone growth is desirable. In the invention methods beta glucans are administered so as to enhance the development of... Agent: Lisa A. Haile, J.d., Ph.d. Dla Piper US LLP

20080200427 - Topical compositions and the use thereof: The invention relates to a composition for topical application as well as the use of such a composition. The invention is characterised in that it comprises at least one first and one second mono- or oligosaccharide, each of said first and second mono- or oligosaccharides being capable of limiting the... Agent: Westerman, Hattori, Daniels & Adrian, LLP

20080200426 - Use of chondroitin sulphate e (cs-e) for the treatment of diseases or conditions related to collagen fibril formation: The present invention comprises the use of chondroitin sulphate (CS-E) or an active fragment thereof for the treatment of diseases or conditions related to collagen fibril formation. Said compounds can be administrated either by oral, topical, injectable or by any other suitable route.... Agent: Wolf Greenfield & Sacks, P.C.

20080200430 - Methods of use of biomaterial and injectable implant containing biomaterial: This invention relates to the use of a biomaterial for the treatment, repair and/or enhancement of bodily tissue insufficiencies of the vocal chords, muscles, ligaments, cartilage, post-operative regions, sexual organs and/or weight supporting areas of the feet as well as other conditions of the bones and joints. The biomaterial for... Agent: King & Spalding

20080200431 - Heterocyclic sulfonamide derivatives as inhibitors of factor xa: The invention relates to compounds of formula (I), Chemical formula should be inserted here. Please see paper copy wherein R1, R2, R3 and R4 are independently selected from carbon and nitrogen, and where is nitrogen; A1 is a single bond or a double bond; n is 0, 1, 2 or... Agent: Pepper Hamilton LLP

20080200432 - Fiber-treating agent: The present invention relates to a fiber-treating agent having a pH value of 2 to 5 at 20° C. and containing an alkoxysilane (a), an organic acid (b) and water (c), wherein 50% or more by weight of the component (a) is an alkoxysilane represented by the following formula (1):... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080200434 - Chemical target-binding compositions: Herein is described compositions and methods for modulating and regulating the concentration of a chemical target in an organism or in an ecosystem. In one embodiment, the concentration is regulated such that it is maintained below or above a certain threshold, thus avoiding toxic or harmful effects of the chemical... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20080200433 - Molecular chaperone function regulator: r

20080200435 - Combinations of a pyrimidine containing nnrti with rt inhibitors: The present invention concerns combinations of a pyrimidine containing NNRTI with nucleoside reverse transcriptase inhibitors and/or nucleotide reverse transcriptase inhibitors useful for the treatment of HIV infected patients or for the prevention of HIV transmission or infection.... Agent: Philip S. Johnson Johnson & Johnson

20080200436 - Combination comprising zd6474 and an antiandrogen: The present invention relates to a method for the production of an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal such as a human which is optionally being treated with ionising radiation, particularly a method for the treatment of a cancer, particularly a cancer involving a solid tumour,... Agent: Morgan Lewis & Bockius LLP

20080200437 - Cyclitols and their derivatives and their therapeutic applications: The present invention is directed to polyphosphorylated and pyrophosphate derivatives of cyclitols. More particularly, the invention relates to polyphosphorylated and pyrophosphate derivatives of inositols. The invention also relates to compositions of the polyphosphorylated and pyrophosphate derivatives of inositol and other similar, more lipophilic derivatives, and their use as allosteric effectors,... Agent: King & Spalding LLP

20080200438 - Treatment of autoimmune diseases: Methods of treating various autoimmune diseases, such as multiple sclerosis, peripheral neuritis, optical neuritis, amylotrophic lateral sclerosis, and uveitis utilizing specific amino alcohol derivatives are provided herein.... Agent: Novartis Corporate Intellectual Property

20080200439 - Methods and compositions for modulating bk channel activity and vasodilation: Methods and compositions are provided for modulating myocyte BK channel activity and for screening for modulators of BK channel activity. The methods and compositions are useful in the treatment of disorders where increasing myocyte BK channel activity can attenuate, revert or prevent the disorder. For example, the methods and compositions... Agent: Jenkins, Wilson, Taylor & Hunt, P. A.

20080200440 - Progesterone receptor antagonists: t

20080200441 - Estrogen receptor modulators associated pharmaceutical compositions and methods of use: Selective estrogen receptor modulators, as well their related pharmaceutical compositions and methods of use, are provided herein. These estrogen receptor modulators include compounds that primarily exhibit estrogen receptor antagonist activity or primarily exhibit selective estrogen receptor antagonist and agonist activity, i.e., SERM activity, in specific tissue types. Particular embodiments provide... Agent: Patrea L. Pabst Pabst Patent Group LLP

20080200442 - Compositions and methods for treating, reducing, ameliorating, or preventing infections of the ear or upper respiratory tract: Compositions for treating, reducing, ameliorating, or preventing infection of an ear or upper respiratory tract comprise a fluroquinolone having Formula I, II, or III. Methods for treating, reducing, ameliorating, or preventing such infection use such compositions. Such compositions and methods can be effective against certain antibiotic-resistant microbial pathogens found in... Agent: Bausch & Lomb Incorporated

20080200443 - Zinc complexes of natural amino acids for treating elevated copper caused toxicities: The present invention relates to the use of zinc complexes of natural amino acids, especially L-arginine, L-lysine, L-ornithine, and other natural amino acids, in a molar ratio of about 1:2 (metal:amino acid), and formulations thereof. These pharmaceutical compositions offer better tolerated and faster acting regimens than common zinc salts (i.e.,... Agent: Technology Law, PLLC

20080200444 - Soluble epoxide hydrolase inhibitors: Disclosed are urea compounds of formula I, stereoisomer, or pharmaceutical acceptable salts thereof, and compositions that inhibit soluble epoxide hydrolase (sEH), methods for preparing the compounds and compositions, and methods for treating patients with such compounds and compositions. The compounds, compositions, and methods are useful for treating a variety of... Agent: Foley & Lardner LLP

20080200446 - Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof: s

20080200445 - Heterocyclic aspartyl protease inhibitors:

20080200447 - Neurotherapeutic compositions and method: Administration of β-Lactam compounds, including β-lactam antibiotics and β-lactamase inhibitors provides significant neurotropic effects in warm-blooded vertebrates evidence inter alia by anxiolytic and anti-aggressive behavior modification and enhanced cognition. Therapeutic methods for using such compounds and their pharmaceutical formulations are described.... Agent: Barnes & Thornburg LLP

20080200448 - New pyridine analogues viii 518: m

20080200449 - Treprostinil administration using a metered dose inhaler: Treprostinil can be administered using a metered dose inhaler. Such administration provides a greater degree of autonomy to patients. Also disclosed are kits that include a metered dose inhaler containing a pharmaceutical formulation containing treprostinil.... Agent: Foley And Lardner LLP Suite 500

20080200450 - Use of ivabradine for obtaining medicaments intended for the treatment of endothelial dysfunction: Use of ivabradine, or 3-{3-[{[(7S)-3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-trien-7-yl]-methyl}-(methyl)-amino]-propyl}-7,8-dimethoxy-1,3,4,5-tetrahydro-2H-3-benzazepin-2-one, its addition salts with a pharmaceutically acceptable acid and their hydrates, for obtaining a medicament intended for the treatment of endothelial dysfunction.... Agent: The Firm Of Hueschen And Sage

20080200451 - Tetrahydroquinolines for use as modulators of the mitotic motor protein eg5: Compounds of the formula (I), in which W, R, R1, R2, R3, R4, R5, R6 and R7 have the meanings indicated in claim 1, can be employed, inter alia, for the treatment of tumours.... Agent: Millen, White, Zelano & Branigan, P.C.

20080200453 - Methods of treating metabolic syndrome using dopamine receptor agonists: The present invention is directed to a method of simultaneously treating hypertension, hypertriglyceridemia, a pro-inflammatory state, a pro-coagulative state, and insulin resistance (with or without treating obesity or endothelial dysfunction), associated with or independent from Metabolic Syndrome, as well as vascular disease such as cardiovascular, cerebrovascular, or peripheral vascular disease... Agent: Wiggin And Dana LLP Attention: Patent Docketing

20080200452 - Oral, rapidly disintegrating film, which cannot be spat out, for a neuroleptic: Film-form, single-layered, cavity-free preparation free of surfactants, effervescent additive and taste masker and comprising one or more film former(s), one or more gel former(s) and one or more active ingredient(s) from the group of neuroleptics.... Agent: Licata & Tyrrell P.C.

20080200454 - Carbon-linked tetrahydro-pyrazolo-pyridine modulators of cathepsin s: Carbon-linked tetrahydro-pyrazolo-pyridine compounds are described, which are useful as cathepsin S modulators. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by cathepsin S activity, such as psoriasis, pain, multiple sclerosis, atherosclerosis, and rheumatoid arthritis.... Agent: Woodcock Washburn LLP

20080200455 - 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands: The present invention provides a compound of formula I and the use thereof in the therapeutic treatment of disorders related to or affected by the 5-HT6 receptor.... Agent: Wyeth Patent Law Group

20080200456 - Substituted 8-heteroaryl xanthines: The present invention provides compounds and pharmaceutical compositions that are selective antagonists of A2B adenosine receptors (ARs). These compounds and compositions are useful as pharmaceutical agents.... Agent: Williams Mullen

20080200457 - 4-cyclopropyl-1,2,3,-thiadiazole compound, agrohorticultural plant disease controlling agent and method of using the same: wherein R1, R2, R3, R4 and R5 each represents H, halogen, CN, alkyl, alkoxyalkyl, aryl, arylalkyl, alkylcarbonyl or the like; R6 represents —C═(W1)YR7 in which R7 reresents H, alkyl, alkenyl, phenylcarbonyl, heterocyclic ring-carbonyl, arylsulfonyl or the like; Y represents O, S, —N(R11), —N(R11)O— in which R11 represents H, alkyl, cycloalkyl,... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080200458 - Methods and compositions for the treatment of body composition disorders: This invention relates to methods of treating, managing and preventing body composition disorders, and to compounds and pharmaceutical compositions useful in such methods.... Agent: Lexicon Pharmaceuticals, Inc.

20080200459 - Tetrahydroquinoline cannabinoid receptor modulators: i

20080200460 - Chemical compounds:

20080200461 - Modulators of acetyl-coenzyme a carboxylase and methods of use thereof: along with methods of use thereof for the control of agricultural pests, particularly fungal pests, weedy pests and insect pests, as well as use as pharmaceuticals, particularly the treatment of obesity, metabolic syndrome, atherosclerosis, cardiovascular disease and insulin resistance, e.g., type II or adult-onset diabetes as well as fungal pathogens... Agent: Myers Bigel Sibley & Sajovec

20080200462 - Substituted pyrazole and triazole compounds as ksp inhibitors: Disclosed are new substituted pyrazole and triazole compounds of Formula (I) and pharmaceutically acceptable salts, esters or prodrugs thereof, compositions of the derivatives together with pharmaceutically acceptable carriers, and uses thereof:... Agent: Novartis Vaccines And Diagnostics Inc.

20080200463 - Thiazole derivatives and use thereof: The present invention is related to thiazole derivatives of Formula (I) in particular for the treatment and/or prophylaxis of autoimmune disorders and/or inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, bacterial or viral infections, kidney diseases, platelet aggregation, cancer, transplantation, graft rejection or lung injuries.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20080200465 - Antipathogenic benzamide compounds: e

20080200464 - Substituted heterocycles and methods of use: Selected compounds are effective for prophylaxis and treatment of diseases, such as HGF mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention... Agent: Amgen Inc.

20080200466 - Organic compounds for the treatment of inflammatory or allergic conditions: Compounds of formula (I) in free or pharmaceutically acceptable salt form, where R1, R2, R3, R4, R5, R6, R7, m, n, w, X, and Y have the meanings as indicated in the specification, are useful for treating conditions mediated by the CRTh2 receptor, especially inflammatory or obstructive airways diseases.... Agent: Novartis Corporate Intellectual Property

20080200467 - Soluble epoxide hydrolase inhibitors: Disclosed are alpha keto amide and alpha hydroxy amide compounds and compositions that inhibit soluble epoxide hydrolase (sEH), methods for preparing the compounds and compositions, and methods for treating patients with such compounds and compositions. The compounds, compositions, and methods are useful for treating a variety of sEH mediated diseases,... Agent: Foley & Lardner LLP

20080200468 - 2-substituted 5-membered heteroaryl carboxylates as hm74a receptor agonists: Therapeutically active heteroaryl carboxylic acid derivatives of Formula (I) wherein R1, R2, W, X, Y and Z are as defined in the specification, processes for the preparation of said derivatives, pharmaceutical formulations containing the active compounds and the use of the compounds in therapy, particularly in the treatment of diseases... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20080200469 - Phthalazinone derivatives: wherein A and B together represent an optionally substituted, fused aromatic ring; X can be NRX or CRXRY; if X=NRX then n is 1 or 2 and if X=CRXRY then n is 1; RX is selected from the group consisting of H, optionally substituted C1-20 alkyl, C5-20 aryl, C3-20 heterocyclyl,... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080200471 - 6' substituted compounds having 5-ht6 receptor affinity: e

20080200470 - Diaza- or thiazadione derivatives with neuroprotective activity: The present invention relates to certain derivatives of cycloalkanediones invariably substituted with a chroman-2-yl, 2-quinolyl or —O-phenyl residue which are serotonin (5-hydroxytryptamine, 5-HT) 5-HT1A receptor subtype agonists modulators, to their stereochemical isomers and to their use in the preparation of a medicament for the treatment of pathological states for which... Agent: Harness, Dickey, & Pierce, P.l.c

20080200472 - Therapeutic agents useful for treating pain: wherein X is S or O and A, R1, R2, R3, R4, n, and m are disclosed herein, or a pharmaceutically acceptable salt thereof (a “Pyridazinylpiperazine Compound”), compositions comprising a Pyridazinylpiperazine Compound, and methods for treating or preventing pain, UI, an ulcer, IBD and IBS in an animal comprising administering... Agent: Dechert LLP

20080200473 - Imidazo [1,2-a]pyridine compounds, compositions, uses and methods thereto: e

20080200474 - Novel flunarizine salt forms and methods of making and using the same: Disclosed herein are novel salts of flunarizine with improved properties. Also described herein are novel pharmaceutical compositions comprising such flunarizine salts, methods of making, and related methods of treatment.... Agent: Philip S. Johnson Johnson & Johnson

20080200475 - 4-piperazinothieno[2,3-d] pyrimidine compounds as platelet aggregation inhibitors: Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I: (I) wherein A1, A2, A3, A4, A5, A6, A7, A8, X4, X6, R2a, Rx, R4, R5, and R6 are as defined in the detailed description of the invention. Corresponding pharmaceutical compositions,... Agent: Pfizer Inc.

20080200476 - Alaphatic pyrazinoylguanidine sodium channel blockers: The present invention relates to sodium channel blockers. The present invention also includes a variety of methods of treatment using these inventive sodium channel blockers.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080200478 - Antineoplastic and curcumin derivatives and methods of preparation and use: e

20080200477 - Retinoid-containing compositions having reduced irritation effect: The present invention features a composition including (i) a retinoid, and (ii) an interleukin-8 inhibitor. The composition provides reduced irritation to human skin.... Agent: Philip S. Johnson Johnson & Johnson

20080200480 - Fungicidal 6-phenyltriazolopyrimidinylamines: e

20080200479 - Ocaperidone salts and pharmaceutical compositions containing the same: The invention relates to new salts of ocaperidone and uses thereof, particularly in the pharmaceutical industry. The invention discloses specific salts of ocaperidone having increased water solubilities, as well as therapeutic methods by administering said salts, in particular for treating various diseases of the central or peripheral nervous system, especially... Agent: Philip S. Johnson Johnson & Johnson

20080200481 - Method of treatment of myocardial infarction: Myocardial infarction in a mammal is treated by administering to the mammal a therapeutically effective amount of a chemical Src family tyrosine kinase protein inhibitor and the use of such inhibitor compounds for the preparation of a medicament for treating myocardial infarction. Myocardial infarction can be prevented by administering to... Agent: Olson & Cepuritis, Ltd.

20080200482 - Use of a partially neutralized, anionic (meth)acrylate copolymer as a coating for the production of a medicament releasing active substance at reduced ph values: (EN) The invention relates to the use of a partially neutralized, anionic (meth)acrylate copolymer comprising radically polymerized units of 25 to 95 percent by weight of C1 to C4 alkyl esters of acrylic or methacrylic acid and 5 to 75 percent by weight of (meth)acrylate monomers with an anionic group,... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080200484 - Pharmaceutical compositions comprising a multifunctional phosphodiesterase inhibitor and an adenosine uptake inhibitor: The present invention relates to pharmaceutical compositions comprising at least one multifunctional phosphodiesterase inhibitor (MPDEI) and at least one adenosine uptake inhibitor. The present invention also relates to compositions comprising cilostazol and dipyridamole and their use.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080200483 - Purine derivatives for use as adenosin a-2a receptor agonists: in free or salt form, wherein R1, R2 and R3 have the meanings as indicated in the specification, are useful for treating conditions mediated by activation of the adenosine A2A receptor, especially inflammatory or obstructive airways diseases. Pharmaceutical compositions that contain the compounds and a process for preparing the compounds... Agent: Novartis Corporate Intellectual Property

20080200485 - Kinase inhibitors: Disclosed are protein kinase inhibitors, compositions comprising such inhibitors, and methods of use, thereof. More particularly, disclosed are inhibitors of Aurora-2 (Aurora-A) protein kinase. Also disclosed are methods of treating diseases associated with protein kinases, especially diseases associated with Aurora-2, such as cancer.... Agent: King & Spalding

20080200489 - Combination of organic compounds: s

20080200486 - Combination of organic compounds:

20080200488 - Combinations comprising a protein kinase inhibitor being a pyrimidylaminobenzamide compound and a hsp90 inhibitor such as 17-aag:

20080200487 - Salts of 4-methyl-n-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide: Salts of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide are prepared by various processes.... Agent: Novartis Corporate Intellectual Property

20080200491 - 1,2-dihydro-spiro[3h-indole-3,4'-piperidine] compounds, as modulators of the mas receptor novel: The present invention relates to certain 1,2-dihydro-spiro[3H-indole-3,4′-piperidine]compounds of Formula (Ia): and pharmaceutically acceptable salts, solvates and hydrates thereof, wherein G, R1, R2, R3, R4, R5, and Ar are as disclosed herein (“Compound(s) of the Invention”), which are useful, for example, as cardio-protective and/or neuro-protective agents. The invention also provides pharmaceutical... Agent: Bozicevic, Field & Francis LLP

20080200490 - Alpha-(aryl-or heteroaryl-methyl)-beta-piperidino propanamide compounds as orl-1-receptor antagonists: This invention provides the compounds of formula (I), or a pharmaceutically acceptable salt thereof, wherein R1 and R2 independently represent hydrogen or the like; R3 and R4 independently represents hydrogen or the like; R5 represents aryl or the like; —X—Y— represents —CH2O— or the like; and n represents 0, 1... Agent: Pfizer Inc.

20080200492 - Methods for the treatment of alcohol abuse, addiction and dependency: The present invention is directed to methods for the treatment of alcohol abuse, addiction and/or dependency, alone and in combination with one or more anti-addiction agents.... Agent: Philip S. Johnson Johnson & Johnson

20080200493 - Use of oxycodone for treating visceral pain: It is possible to effectively treat moderate to severe visceral pain by administering analgesic medications comprising the opioid oxycodone or pharmaceutically acceptable salts thereof. Visceral pain and especially acute (i.e. non-chronic) visceral pain can be effectively treated by administering oxycodone at a dosage which is lower than the corresponding dosage... Agent: Darby & Darby P.C.

20080200494 - Imidazopyridine derivatives: The invention provides imidazopyridine derivatives represented by the general formula [I] [in which R1 and R2 may be the same or different and stand for C1-6 alkyl or the like, R3 and R4 stand for hydrogen atom, methyl group or the like, W stands for mono- or bi-cyclic 3- to... Agent: Merck And Co., Inc

20080200495 - Pyrrolopyridine compounds, method of making them and uses thereof: e

20080200496 - Substituted 1h-pyrrolo[3,2-b, 3,2-c, and 2,3-c]pyridine-2-carboxamides and related analogs as inhibitors of casein kinase ie: wherein M is N, and K and L are each C with the remaining substituents further defined herein. These compounds are effective as inhibitors of human casein kinase Iε, and as such are useful in the treatment of central nervous system diseases and disorders including mood disorders and sleep disorders.... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20080200497 - Hepatitis c inhibitor peptide analogs: The compounds of formula I wherein R1, R2, R3, R4 and R5 are defined herein, are useful as inhibitors of the hepatitis C virus NS3 protease The invention further relates to azalactone compounds of the formula (II) which can be reacted with an amide anion to produce the HCV NS3... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20080200498 - Pharmaceutical composition for the treatment of disorders of sexual desire: The invention relates to the use of a monoamine neurotransmitter re-uptake inhibitor comprising a 2,3-disubstituted tropane moiety, or a tautomer, a pharmaceutically acceptable salt, solvate, or physiologically functional derivative thereof for the manufacture of a medicament for the for the treatment of sexual desire disorders.... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20080200501 - Novel cannabinoid receptor ligands, pharmaceutical compositions containing them, and processes for their preparation: The present invention relates to novel cannabinoid receptor modulators, in particular cannabinoid 1 (CB1) or cannabinoid 2 (CB2) receptor modulators, and uses thereof for treating diseases, conditions and/or disorders modulated by a cannabinoid receptor (such as pain, neurodegenative disorders, eating disorders, weight loss or control, and obesity).... Agent: Darby & Darby P.C.

20080200500 - Quinoline derivatives as nk3 antagonists: e

20080200499 - Selective insecticides and/or acaricides based on substituted cyclic dicarbonyl compounds and safeners:

20080200502 - Methods of lowering lipid levels in a mammal: This invention relates to methods for lowering lipid levels in mammals using compounds that inhibit advanced glycation endproducts (AGEs), LR-9, LR-74 and LR-90. These compounds, which inhibit non-enzymatic protein glycation, also inhibit the formation of advanced lipoxidation endproducts (ALES) on target proteins by trapping intermediates in glycoxidation and lopoxidation and... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20080200503 - Macrocylic inhibitors of hepatitis c virus: i

20080200504 - Amide alkyl pyridiyl quinolines as nk3 receptor modulators: Compounds of Formula (I) wherein R1, A, R2, R3, R4, R5,n, m and q are as described in the specification, pharmaceutically-acceptable salts, methods of making, pharmaceutical compositions containing and methods for using the same.... Agent: Astra Zeneca Pharmaceuticals Lp Global Intellectual Property

20080200505 - Piperidines for the treatment of chemokine mediated diseases: The present invention provides a compound of a formula (I): wherein the variables are defined herein; to a process for preparing such a compound; and to the use of such a compound in the treatment of a chemokine (such as CCR3) or H1 mediated disease state.... Agent: Fish & Richardson P.C.

20080200506 - Oral preparation of dyclonine hydrochloride: The present invention discloses an oral preparation of dyclonine hydrochloride for the endoscope examination in upper gastrointestinal tract, which has the effects of anaesthetization and lubrication, and especially an oral preparation comprising dyclonine hydrochloride that has the advantages of avoiding the foam in the body cavity, preventing vomit, and offering... Agent: Crowell & Moring LLP Intellectual Property Group

20080200507 - Crystalline non-solvated methanesulfonic acid salt of 1-(4-(2-piperidinylethoxy)phenoxy)-2-(3-hydroxyphenyl)-6-hydroxynaphthalene: The present invention relates to the mesylate salt of 1-(4-(2-piperidinylethoxy)phenoxy)-2-(3-hydroxyphenyl)-6-hydroxynaphthalene.... Agent: Eli Lilly & Company

20080200508 - Pharmaceutical compositions for sleep disorders: Pharmaceutical compositions are provided for the pharmacological treatment of breathing disorders and, more specifically, to compositions containing agents having serotonin receptor modulating activity for the alleviation of sleep apnea (central and obstructive) and other sleep-related breathing disorders wherein the active ingredients are released such as to extend effective blood plasma... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080200509 - 3,4-disubstituted 1h-pyrazole compounds and their use as cyclin dependent kinase and glycogen synthase kinase-3 modulators: a

20080200510 - Combination of organic compounds:

20080200512 - Hepatitis c virus polymerase inhibitors: and methods for making and using the same, where R1 and R2 are independently hydrogen, C1-6 alkyl or C1-6 haloalkyl; R3 is hydrogen, halogen, C1-6 alkyl or C1-6 alkoxy; R4 is hydrogen or halogen; and R5 is a mono- or di-amino acid moiety, a succinic acid moiety, a urea moiety,... Agent: Roche Palo Alto LLC Patent Law Dept. M/s A2-250

20080200511 - Novel compounds and methods of using the same: The present invention relates to novel compounds of Formula (I) wherein ‘X’ represents an amino acid group, ‘n’ is an integer between 1 and 4, ‘R1’ represents benzyl, t-butyl or 9-fluorenylmethyl and ‘R2’ represents a tetramethylmercaptoimidazole derivative or —S+R3R4, wherein R3 and R4 each independently represent lower alkyl, or a... Agent: Fish & Richardson PC

20080200513 - Pyridine n-oxides as antiviral agents: e

20080200517 - Crystalline forms of solvated ilaprazole: The invention relates to crystalline forms of various solvates of ilaprazole, 2[[(4-methoxy-3-methyl-2-pyridinyl)-methyl]sulfinyl]-5-(1H-pyrrol-1-yl) 1H-Benzimidazole. The invention also relates to a pharmaceutical composition for inhibiting gastric acid secretion comprising crystalline ilaprazole hydrate according to the invention in an amount effective to inhibit gastric acid secretion and a pharmaceutically acceptable carrier. The invention... Agent: Nixon Peabody, LLP

20080200514 - Indications for direct thrombin inhibitors: The invention relates to new indications for direct thrombin inhibitors such as dabigatran etexilate in the CNS and other fields.... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20080200515 - Solid state forms of enantiopure ilaprazole: The invention relates to solid state forms of enantiopure ilaprazole, 2[[(4-methoxy-3-methyl-2-pyridinyl)-methyl]sulfnyl]-5-(1H-pyrrol-1-yl) 1H-Benzimidazole. The invention also relates to a pharmaceutical composition for inhibiting gastric acid secretion comprising a solid form of ilaprazole according to the invention in an amount effective to inhibit gastric acid secretion and a pharmaceutically acceptable carrier. The... Agent: Nixon Peabody, LLP

20080200516 - Solid state forms of racemic ilaprazole: The invention relates to crystalline forms of racemic ilaprazole, 2[[(4-methoxy-3-methyl-2-pyridinyl)-methyl]sulfinyl]-5-(1H-pyrrol-1-yl) 1H-Benzimidazole. The invention also relates to a pharmaceutical composition for inhibiting gastric acid secretion comprising a crystalline Form of ilaprazole according to the invention in an amount effective to inhibit gastric acid secretion and a pharmaceutically acceptable carrier. The invention... Agent: Nixon Peabody, LLP

20080200518 - Substituted cyclic urea derivatives: Certain novel phenyl substituted cyclic urea derivatives have unexpected insecticidal activity. These compounds are represented by formula I: where A, B a, D, b, E, G, c, d, J, X and R through R10, inclusively, are fully described herein. In addition, compositions comprising an insecticidally effective amount of at least... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20080200519 - Tetrahydronaphthalenylamides, a process for their production and their use as anti-inflammatory agents: r

20080200520 - Iron modulators: Iron modulator compounds of formula (I) are provided for treating amyloidoses wherein R1 is selected from H, C1-6 alkyl, C1-6 alkenyl, C1-6 hydroxyalkyl, C1-6 hydroxyalkenyl, R2 is selected from H, C1-6 alkyl, C1-6 alkenyl, C1-6 hydroxyalkyl, C1-6 hydroxyalkenyl and C6-10 aralykyl in which the aryl group of the aralkyl group... Agent: Nixon & Vanderhye, PC

20080200521 - Novel hydroxamic acid containing amino acid derivatives: Novel hydroxamic acid containing amino acid derivatives are provided that are useful for treatment of inflammation, inflammatory and immunological diseases; lowering blood glucose, serum insulin, free fatty acids, cholesterol and triglyceride levels; and for treatment or prophylaxis of metabolic disorders.... Agent: Beyer Weaver LLP

20080200522 - Composition and method for controlling house insect pest: The present invention provides a composition for controlling a house insect pest, such as termites, ants or cockroaches, which comprises, as active ingredients, at least two compounds selected from the group consisting of (a) a certain pyridine compound, (b) a benzoylurea compound, (c) a pyrethroid compound and (d) a certain... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080200523 - Derivatives of squaric acid with anti-proliferative activity: The present invention provides derivatives of squaric acid, in particular derivatives of 3,4-diamino-cyclobut-3-ene-1,2-dione and tautomers and isomers thereof, as a single stereoisomer or a mixture of stereoisomers, or as a pharmaceutically acceptable salt thereof. These compounds show anti-proliferative activity, including against tumor cells, and are useful in the treatment of... Agent: Leon R. Yankwich

20080200524 - Amide compounds as ion channel ligands and uses thereof: e

20080200525 - Pesticidally active ketone and oxime derivatives: and, where applicable, their possible E/Z isomers, E/Z isomeric mixtures and/or tautomers, in each case in free form or in salt form, a process for the preparation of those compounds and their use, pesticidal compositions in which the active ingredient has been selected from those compounds and agrochemically acceptable salts... Agent: Syngenta Crop Protection , Inc. Patent And Trademark Department

20080200526 - Composition for the prevention and treatment of allergic inflammatory disease: Disclosed herein is a composition for the treatment and prevention of allergic inflammatory diseases comprising N-hydroxy-4-{5-[4-(5-isopropyl-2-methyl-1,3-thiazol-4-yl)phenoxy]pentoxy}-benzamidine, 4-{5-[4-(5-isopropyl-2-methyl-1,3-thiazol-4-yl)phenoxy]pentoxy}-benzamidine or pharmaceutically acceptable salts. The composition exhibits excellent medicinal effects on allergic inflammatory diseases, with a great reduction in typical chronic inflammation symptoms, such as an increase of eosinophil level in bronchoalveolar lavage... Agent: Casimir Jones, S.c.

20080200527 - Cannabinoid receptor modulators: wherein A1 is hydrogen, —COOH, or tetrazolyl, and A2 is hydrogen, —COOH, tetrazolyl, —CN, —CF3, —COR6, —SO2R6, —OR7, —NR7R8, —NHCOR6, and —NR7SO2R8 provided that one of A1 and A2 is either —COOH or tetrazolyl; p is 0 or 1 and A3 is phenyl or cycloalkyl, either of which is optionally... Agent: Banner & Witcoff, Ltd.

20080200528 - Derivatives of a 1-phenyltriazole: e

20080200529 - Novel 2-amino benzimidazole derivatives and their use as modulators of small-conductance calcium-activated potassium channels:

20080200530 - Diaryl and arylheteroaryl urea derivatives as modulators of 5-ht2a serotonin receptor useful for the prophylaxis or treatment of progressive multifocal leukoencephalopathy: The present invention relates to certain pyrazole derivatives of Formula (I) and pharmaceutical compositions thereof that modulate the activity of the 5-HT2A serotonin receptor. Compounds and pharmaceutical compositions thereof are directed to methods useful in the prophylaxis or treatment of progressive multifocal leukoencephalopathy.... Agent: Fish & Richardson P.C.

20080200531 - Cdki pathway inhibitors as inhibitors of tumor cell growth: The invention provides new methods for inhibiting the CDKI pathway and specifically inhibiting tumor cell growth. The invention further provides new and specific inhibitors of tumor cell growth, as well as means for discovery of additional such inhibitors. The present inventors have surprisingly discovered that Cyclin-Dependent Kinase 3 (CDK3) is... Agent: Keown & Zucchero, LLP

20080200532 - Fluvastatin sodium crystal forms xiv, lxxiii, lxxix, lxxx and lxxxvii, processes for preparing them, compositions containing them and methods of using them: Provided are polymorphic forms of fluvastatin sodium and processes for their preparation.... Agent: Kenyon & Kenyon LLP

20080200534 - Cosmetic and pharmaceutical compositions comprising lauroyl proline and an ester of anhydrohexitol and of an aliphatic carboxylic acid: Composition (A) containing, for 100% of its mass: from 10 mass % to 90 mass % of N-lauroyl proline (I) and from 10 mass % to 90 mass % of an ester (II) of anhydrohexitol and of a saturated or unsaturated, linear or branched aliphatic carboxylic acid containing from 12... Agent: Young & Thompson

20080200533 - Drug or pharmaceutical compounds and a preparation thereof: The administration of pharmaceuticals of drugs which are having less solubility, lower bioavailability, lower bioabsorbability, less rate of absorption has become a big challenge in day to day life. Therefore an attempt has been made to prepare a complex modified form of the said pharmaceutical or drug such that the... Agent: Brooks Kushman P.C.

20080200535 - Amine compounds: Novel amine compounds having an S1P1/Edg1 receptor agonist effect, possible stereoisomers or racemic bodies of the compounds, or pharmacologically acceptable salts, hydrates or solvates of the compound, the stereoisomers or the racemic bodies, or prodrugs of the compounds, the stereoisomers, the racemic bodies, the salts, the hydrates or the solvates,... Agent: Birch Stewart Kolasch & Birch

20080200536 - Pharmaceutical formulation with high stability and dissolution and manufacturing process: Disclosed herein are a pharmaceutical formulation with high stability and dissolution, and a method for preparing the pharmaceutical formulation. The pharmaceutical formulation comprises a pharmacologically active substance, a solvent, a solubilizer, a surfactant, an antioxidant, and an adsorbent. According to the pharmaceutical formulation and the method, the pharmacologically active substance... Agent: Hughes Law Firm, PLLC

20080200537 - Antiestrogenic glyceollins suppress human breast and ovarian carcinoma proliferation and tumorigenesis: The flavonoid family of phytochemicals, particularly those derived from soy, has received attention regarding their hormonal activity and their effects on human health and disease. The types and amounts of these compounds in soy and other plants are controlled by both constitutive expression and stress-induced biosynthesis. The health benefits of... Agent: Usda, Ars, Ott

20080200538 - Inhibition of monocyte survival, differentiation, or proliferation: Methods comprising administering to the subject apigenin, an apigenin derivative, apigenin and at least one apigenin derivative, or a combination of apigenin derivatives are provided for treating inflammation in a subject in need of the same.... Agent: Calfee Halter & Griswold, LLP

20080200539 - Topical antifungal treatment: The present invention is a topical skin preparation for treatment of fungal infections of the skin and nails. The preparation comprises triacetin in combination with one or more antifungal agents. In a preferred form, the preparation comprises a combination of the antifungal agents tolnaftate and grisiofulvin are used in combination... Agent: Alexander D. Bommarito

20080200540 - Antiparasitic agents: e

20080200541 - Benzofuranyl alkanamine derivatives and uses thereof: wherein each of R1, R1′, R2, R3, R4, n, and Ar are as defined, and described in classes and subclasses herein, which are agonists or partial agonists of the 2C subtype of brain serotonin receptors. The compounds, and compositions containing the compounds, can be used to treat a variety of... Agent: Choate, Hall & Stewart LLP/wyeth

20080200542 - Benzoyl-substituted serineamides: e

20080200543 - Immunomodulating agent, anti-cancer agent and health food containing monoacetyldiacylglycerol derivatives: The uses of mono acetyl diacyl glycerol derivatives extracted from deer antler for immunomodulating agent disclosed. Medical supplies and health foods containing the same as an effective ingredient also disclosed. Mono acetyl diacyl glycerol derivatives shows significantly effect for immuno modulation including immune enhancing. In the case of inducing cancer... Agent: Elmore Patent Law Group, PC

20080200544 - Oil agent and lubricant agent, moisturizer and external preparation composition containing the same: wherein R1 is an alkylene group having a carbon number of 2-4, which may be mono- or poly substituted, R2 and R3 are, independently of each other, an alkyl group having a carbon number of 1-4, which may be mono- or poly substituted, n and m are, independently of each... Agent: Wolf Greenfield & Sacks, P.C.

20080200545 - Peeling process with surfactants: Process for the treatment of, e.g., visible and/or tactile irregularities of human skin, by applying topically, to the skin, a composition containing, in a physiologically acceptable medium, at least 5% by weight of one or more surfactants comprising at least one alkyl chain having from 6 to 16 carbon atoms.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080200547 - Highly purified ethyl epa and other epa derivatives: A pharmaceutical preparation comprising EPA in an appropriately assimilable form where of all the fatty acids present in the preparation at least 90%, and preferably at least 95%, is in the form of EPA and where less than 5%, and preferably less than 3%, is in the form of DHA... Agent: Howrey LLP

20080200546 - Oral composition for enhancing skin properties: A stable consumable emulsion, comprising at least 50% water, 0.2 to 3 wt % of an oil comprising at least 12 wt % of docosahexaenoic acid and eicosapentaenoic acid, an antioxidant, a flavouring and at least 0.01 wt % food-grade phospholipid emulsifier is provided which provides noticeable improvements in skin... Agent: Unilever Patent Group

20080200548 - N-acetylcysteine amide (nac amide) for treatment of oxidative stress associated with infertility: An in vitro culture and/or fertilization medium containing N-acetylcysteine amide (NAC amide) reduces or prevents oxidative stress and free radical formation that contribute to the cellular damage and eventual demise of sperm, oocytes and embryos that are cultured, fertilized and maintained in vitro. The NAC amide-containing medium composition for in... Agent: Mintz Levin Cohn Ferris Glovsky & Popeo Attn: Patent Intake Customer No. 35437

20080200549 - Pharmaceutical composition of ibuprofen and paracetamol and methods of using the same: A combination pharmaceutical composition for the treatment of pain comprising between about 125 mg and about 150 mg ibuprofen and between about 475 mg and about 500 mg paracetamol, and a method for alleviating pain in a patient comprising administering to the patient a pharmaceutical composition comprising between about 125... Agent: Matthias Scholl

20080200550 - Inhibition of hiv-1 replication by disruption of the processing of the viral capsid-spacer peptide 1 protein: Inhibition of HIV-1 replication by disrupting the processing of the viral Gag capsid (CA) protein (p24) from the CA-spacer peptide 1 (SP1) protein precursor (p25) is disclosed. Amino acid sequences containing a mutation in the Gag p25 protein, with the mutation resulting in a decrease in the inhibition of processing... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20080200551 - Flourene derivative: The compound of the invention has an advantage in that it has high affinity for serotonin receptor subtypes, particularly for 5-HT2B receptor and 5-HT7 receptor, and shows excellent pharmacological effects in comparison with the conventional compounds which have only one of the antagonistic activities of 5-HT2B receptor and 5-HT7 receptor,... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080200552 - Vitamin d receptor modulators: The present invention relates to novel, non-secosteroidal, hydroxyl substituted, carbon-linked diaryl compounds with vitamin D receptor (VDR) modulating activity that are less hypercalcemic than 1?,25 dihydroxy vitamin D3. These compounds are useful for treating bone disease and psoriasis.... Agent: Eli Lilly & Company

20080200553 - Pentafluorosulfanylbenzoylguanidines, processes for their preparation, their use as medicaments or diagnostic aids, and medicaments comprising them: in which R1 to R4 have the meanings stated in the claims, are suitable as antiarrhythmic medicaments with a cardioprotective component for the prophylaxis of infarction and treatment of infarction and for the treatment of angina pectoris. They also inhibit preventively the pathophysiological processes associated with the development of ischemia-induced... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20080200554 - Cycloaklyldiene-(ortho substituted phenyl)-acetonitriles and their use as odorants:

20080200555 - Use of norepinephrine reuptake inhibitors for the treatment of tic disorders: Selective norepinephrine reuptake inhibitors are used to treat tic disorders.... Agent: Eli Lilly & Company

20080200556 - Amine compounds and inhibiting neurotrasmitter reuptake: The invention relates to amine compounds as well as methods and materials involved in modulating neurotransmitter reuptake. For example, the invention provides amine compounds, methods for synthesizing amine compounds, and methods for inhibiting neurotransmitter reuptake.... Agent: Fish & Richardson P.C.

20080200557 - Method for inhibiting lipid peroxidation: The invention relates generally to the use of N-substituted dopamine derivatives for the treatment of diseases and disorders that involve abnormal lipid peroxidation. This method comprises the administration of a pharmaceutically effective amount of N-acetyldopamine derivatives or N-alkyldopamine derivatives and a pharmaceutically acceptable carrier for treating an animal or human... Agent: Nixon Peabody, LLP

20080200558 - Inhibitory or blocking agents of molecular generating and/or/ inducing functions: e

20080200559 - Substances having body mass redistribution properties: There is provided a method for altering the distribution of body mass by altering the distribution of body mass by decreasing overall percentage fat and/or increasing the proportion of lean mass to fat mass comprising administering to a subject one or more compounds having the ability to alter body mass... Agent: Reed Smith LLP

20080200560 - Pigments: The present invention relates to pigments comprising a substrate and, applied thereto, an iron-containing coating comprising metallic iron, process for the preparation of the pigments according to the invention, and the use thereof.... Agent: Millen, White, Zelano & Branigan, P.C.

20080200561 - Emulsifiable granules formulations with boron containing fertilisers: The invention relates to formulations of agrochemical compounds formulated as water emulsifiable granules and combined with boron containing fertilisers in the spray tank, to a process for the production of such formulations and to their use as novel, advantageous formulations of crop protection agents.... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20080200562 - Polymer conjugate enhanced bioassays: Modified branched polymers are combined with bioactive agents which are one member of a binding pair for use in an assay.... Agent: Mdip LLC

20080200564 - Copolymers based on n-vinylpyrrolidone and branched aliphatic carbonxylic acids, and their use as solubilizers: Copolymers comprising: (a) 60 to 99% by weight of at least one monomer selected from the group consisting of N-vinyllactams, N-vinylamides, and mixtures thereof; (1) 1 to 40% by weight of at least one monomer selected from the group consisting of vinyl esters of aliphatic branched C8-C30-carboxylic acids; (c) 0... Agent: Connolly Bove Lodge & Hutz, LLP

20080200563 - Use of compounds containing thiol groups as efflux pump inhibitors: The non-invasive administration of many active ingredients fails with efflux pumps which sharply reduce the active ingredient absorption on mucous membranes. According to the invention, the active ingredient absorption on mucous membranes can be drastically improved by using dosages containing glutathione and/or compounds comprising numerous thiol groups, in addition to... Agent: Lowrie, Lando & Anastasi, LLP

20080200565 - Surfactant-only microemulsions for cleaning system design and product delivery: Surfactant systems are provided that, upon contact with an oil, can produce a Windsor Type III middle phase microemulsion at a total surfactant concentration of 1.5% to 1.0% or less based on the weight of water in the surfactant system, without the need for a cosolvent or linking molecule. The... Agent: Dunlap Codding & Rogers, P.C.

20080200566 - Dephosphorylation of hdac7 by myosin phosphatase: The present invention relates to screening methods that make use of a histone deacetylase interacting with a myosin phosphatase for the identification of novel therapeutics useful for inhibiting or inducing apoptosis and for the treatment of pathological conditions, such as smooth muscle cell disorder, cardiac hypertrophy or asthma. Also disclosed... Agent: Townsend And Townsend And Crew, LLP

20080200568 - Genes associated with type ll diabetes mellitus: Genes associated with Type II Diabetes Mellitus (T2DM) are identified and screening methods to identify chemical compounds that act on those targets for the treatment of T2DM or its associated pathologies are discussed. The use of EP3 antagonist was found to affect blood glucose levels in mice fed a high-fat... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B482

20080200567 - In vivo screening models for treatment of alzheimer's disease and other qpct-related disorders: A transgenic non-human animal, in particular a transgenic mouse, encoding Qpct proteins which have been implicated in Qpct-related diseases. Also disclosed are cells and cell lines comprising transgenes encoding for Qpct. Further disclosed are methods and compositions for evaluating agents that affect Qpct, for use in compositions for the treatment... Agent: Sonnenschein Nath & Rosenthal LLP

20080194458 - Artificial pulmonary surfactant compositions and use of the same: The artificial pulmonary surfactant composition according to the present invention comprises a lipid mixture system containing no protein or peptide or a protein/peptide-lipid mixture prepared by adding a protein or a peptide to the above lipid mixture system. The artificial pulmonary surfactant composition of this invention is useful for RDS... Agent: Birch Stewart Kolasch & Birch

20080194456 - Compositions and methods related to an intestinal inflammation and uses therefor: Described herein are screening methods to identify therapeutic compositions for the treatment of an intestinal inflammation, inflammatory bowel disease or pathogen infection, as well as therapeutic methods and compositions useful for ameliorating an intestinal inflammation, inflammatory bowel disease or pathogen infection.... Agent: Ewards Angell Palmer & Dodge LLP (client: Mgh, Partners)

20080194459 - Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides: Disclosed herein are non-natural amino acids and polypeptides that include at least one non-natural amino acid, and methods for making such non-natural amino acids and polypeptides. The non-natural amino acids, by themselves or as a part of a polypeptide, can include a wide range of possible functionalities, but typical have... Agent: Wilson Sonsini Goodrich & Rosati

20080194457 - Frizzled proteins and detection and treatment of cancer: The present specification provides, inter alia, methods of using Wnt and FZD proteins, genes, FZD and Wnt-specific antibodies and probes in diagnosis and treatment of cancer and for screening test compounds for an ability to treat cancer. Also disclosed are compounds useful for treating cancer such as liver cancer.... Agent: Fish & Richardson Pc

20080194460 - Modified chimeric polypeptides with improved pharmacokinetic properties and methods of using thereof: Modified chimeric polypeptides with improved pharmacokinetics are disclosed. Specifically, modified chimeric Flt1 receptor polypeptides that have been modified in such a way as to improve their pharmacokinetic profile are disclosed. Also disclosed are methods of making and using the modified polypeptides including but not limited to using the modified polypeptides... Agent: Regeneron Pharmaceuticals, Inc

20080194461 - Stabilizing alkylglycoside compositions and methods thereof: The present invention relates to alkylglycoside-containing compositions and methods for increasing the stability, reducing the aggregation and immunogenicity, increasing the biological activity, and reducing or preventing fibrillar formation of a peptide, polypeptide, or variant thereof, for example amylin, a monoclonal antibody, insulin, Peptide T or analog thereof.... Agent: Dla Piper Us LLP

20080194462 - Methods and compositions for treatment of autoimmune diseases: The present invention provides methods and compositions for treating autoimmune diseases and other unwanted immune reactions comprising administering a copolymer that binds to one or more HLA-DQ molecules and modulates DQ-restricted T cell responses. The copolymers are random copolymers of amino acids and copolymers comprising anchor residues to facilitate binding... Agent: Ropes & Gray LLP

20080194463 - Antibacterial antisense oligonucleotide and method: A method for enhancing, by at least 10 fold, the antibacterial activity of an antisense oligonucleotide composed of morpholino subunits linked by phosphorus-containing intersubunit linkages. The method includes one or both of: conjugating an arginine-rich carrier to a 3′ or 5′ end of the oligonucleotide and modifying the oligonucleotide to... Agent: Perkins Coie LLP

20080194466 - (5z)-5-(6-quinoxalinylmethylidene)-2-[(2,4,6-trichlorophenyl)amino]-1,3-thiazol-4(5h)-one: Invented is the compound (5Z)-5-(6-quinoxalinylmethylidene)-2-[(2,4,6-trichlorophenyl)amino]-1,3-thiazol-4(5H)-one, and pharmaceutically acceptable salts, hydrates, solvates and pro-drugs thereof. Also invented are pharmaceutical compositions containing this compound, methods of preparing this compound and pharmaceutically acceptable salts, hydrates, solvates and pro-drugs thereof. Also invented are methods of using this compound as an inhibitor of hYAK3 proteins.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20080194464 - Cross-linked glycopeptide-cephalosporin antibiotics: This invention provides cross-linked glycopeptide-cephalosporin compounds and pharmaceutically acceptable salts thereof which are useful as antibiotics. This invention also provides pharmaceutical compositions containing such compounds; methods for treating bacterial infections in a mammal using such compounds; and processes and intermediates useful for preparing such compounds.... Agent: Theravance, Inc.

20080194465 - Cross-linked glycopeptide-cephalosporin antibiotics: This invention provides cross-linked glycopeptide-cephalosporin compounds and pharmaceutically acceptable salts thereof which are useful as antibiotics. This invention also provides pharmaceutical compositions containing such compounds; methods for treating bacterial infections in a mammal using such compounds; and processes and intermediates useful for preparing such compounds.... Agent: Theravance, Inc.

20080194467 - Cancer treatment methods using cadherin antagonists in combination with anticancer agents: Improved methods for treating cancer which employ combinations comprising cadherin antagonists with certain anticancer agents or treatments are provided. The methods of the invention involve the administration of cadherin antagonist before, concurrent with, or after, administration of an anticancer agent or treatment and provide unexpectedly improved therapeutic benefit in the... Agent: Seed Intellectual Property Law Group Pllc

20080194469 - Pharmaceutical formulation composed of a polymer blend and an active compound for time-controlled release: A formulation containing a biologically active compound having a chemical structure with hydrogen bonding sites, a first biocompatible, hydrolytically degrading polycarbonate with hydrogen bonding sites and tyrosine-derived diphenol monomer units, and a second biocompatible hydrolytically degrading polymer that is less hydrophobic than the polycarbonate, wherein the second polymer degrades hydrolytically... Agent: Fox Rothschild LLP Princeton Pike Corporate Center

20080194468 - Transporter-enhanced corticosteroid activity and methods and compositions for treating dry eye: wherein Z1 is carbonyl, β-hydroxymethylene or methylene; R2 is H, —OH or —OCOR3 wherein R3 is C1-5 alkyl; Y is —OH, —SH or —OCOR4 wherein R4 is C1-5 alkyl, cyclopentylethyl or diethylaminoethyl; and the dotted line in ring A indicates that the 1,2-linkage is saturated or unsaturated. Ophthalmic administration in... Agent: Buchanan, Ingersoll & Rooney Pc

20080194471 - Compositions and methods for treating wounds: Disclosed are compositions for the treatment of anorectal disorders comprising at least one analgesic, at least one anti-inflammatory agent, antibiotic, and optionally but preferably hyaluronic acid, in amounts and under conditions effective to treat said anorectal disorder.... Agent: Synnestvedt & Lechner, LLP

20080194470 - Nim811 in cerebral ischemia and brain and spinal cord injury: Non-immunosuppressive, cyclophilin-binding cyclosporins, in particular, [Melle]4-Ciclosporin, are useful as neuroprotective agents, e.g., in the prevention or treatment of cerebral ischemia or traumatic brain or spinal cord injury.... Agent: Novartis Corporate Intellectual Property

20080194481 - Albumin fusion proteins: The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080194475 - Erythropoietin protein variants: Erythropoietin (EPO) variants, in particular variants that have improved stability, their manufacture and use, for example in therapy.... Agent: Klarquist Sparkman, LLP

20080194483 - Glp-1 (9-36) methods and compositions: Methods of inhibiting hyperglycemia-induced or free fatty acid-induced reactive oxygen formation in mammalian cells and mammals using the degradation product of glucagon-like peptide 1, GLP-1 (9-36) are provided. Various GLP-1 (9-36) compositions are also provided.... Agent: Amster, Rothstein & Ebenstein LLP

20080194473 - Hydrocephalus treatment: A method and compound for treatment of hydrocephalus is presented. Hepatocyte growth factor (HGF) is administered intraventricularly.... Agent: Oliff & Berridge, Plc

20080194476 - Medicament comprising a peptide extract of avocado, which is intended for the treatment and prevention of illnesses that are linked to an immune system deficiency: The invention relates to a medicament which comprises a peptide extract of avocado and which can also comprise a composition containing D-mannoheptulose and/or perseitol, such as a water-soluble extract of avocado sugars, and/or a peptide extract of lupine. The inventive medicament is intended for the treatment and/or prevention of illnesses... Agent: Foley And Lardner LLP Suite 500

20080194479 - Methods and compositions to treat mucositis: Methods and compositions of AMP-18 derived peptides enablingly demonstrate that AMP-18 derived peptide compositions surprisingly reduce mucositis in mammals. Methods and peptide compositions treat mucositis, delays the onset or duration of mucositis, including cancer therapy-induced mucositis are disclosed. AMP 77-97 peptide derived from human AMP-18 protein alleviates cancer therapy-induced mucositis.... Agent: Barnes & Thornburg LLP

20080194474 - Methods for the treatment of autoimmune diseases: The invention provides for methods for causing myeloid precursor cells in bone marrow to differentiate into dendritic cells, methods of screening for compounds that relieve a block in the development of mature myeloid progeny and/or that increase the population of HSA+/Ly6C+ cells in bone marrow, and methods of preventing or... Agent: Fish & Richardson P.c.

20080194480 - Pancreatic cancer genes: The present invention provides the art with the DNA coding sequences of polynucleotides that are up-or-down-regulated in cancer and dysplasia. These polynucleotides and encoded proteins or polypeptides can be used in the diagnosis or identification of cancer and dysplasia. Inhibitors of the up-regulated polynucleotides and proteins can decrease the abnormality... Agent: Novartis Vaccines And Diagnostics, Inc. Corporate Intellectual Property-r338

20080194477 - Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules: Compositions of modified cytokines and uses thereof generated using processes and systems for the high throughput directed evolution of peptides and proteins, particularly cytokines that act in complex biological settings, are provided. Also provided are modified cytokines formulated for oral delivery and uses thereof to treat diseases and conditions mediated... Agent: Fish & Richardson, Pc

20080194482 - Selective apac2 receptor peptide agonists: The present invention encompasses peptides that selectively activate the VPAC2 receptor and are useful in the treatment of diabetes.... Agent: Eli Lilly & Company

20080194472 - Use of fgf-18 protein, target proteins and their respective encoding nucleotide sequences to induce cartilage formation: The use of fibroblast growth factor (FGF)-18 protein, certain of its downstream target genes and respective expressed proteins, in particular sonic hedgehog (Shh), Shh protein, β-catenin, β-catenin protein, and the Wnt family of proteins that stimulate β-catenin, and the respective nucleotide sequences encoding this protein, particularly for inducing cartilage formation,... Agent: Hasse & Nesbitt Llc

20080194478 - Wound healing agent and composition: The present invention relates to a wound-treating agent and to a composition for the treatment of wounds comprising a polypeptide having the amino acid sequence of SEQ ID NO:2, or of a polypeptide having at least 50%, preferably 70%, more preferably 90% identity with the amino acid sequence of SEQ... Agent: Young & Thompson

20080194484 - Tml polynucleotides: The present invention is directed to polynucleotides, peptides, variants, and uses thereof for a novel peptide fragment designated TML peptides. Binding of the peptide fragment has been shown in kidney and small intestine. The present invention further includes agonists, antagonists, variants, antibodies, host cells expressing the cDNA encoding the novel... Agent: Amgen Inc. Law Department

20080194485 - Detection and use of prolylcarboxypeptidase: The present invention relates to weight control, control of body fat and food intake, and provides useful methods for treating, inter alia, obesity, diabetes, and conditions, diseases, and disorders relating thereto.... Agent: Morgan Lewis & Bockius LLP

20080194486 - Novel anti-obesity agents: The present invention relates to a compound comprising a PYY peptide or a functional derivative thereof, which is coupled to a reactive group. Such a reactive group is capable of reacting on a blood component so as to form a stable covalent bond therewith. The present invention also relates to... Agent: Lowrie, Lando & Anastasi, LLP

20080194488 - Orally active peptides that prevent cell damage and death: This invention provides an ADNF polypeptide comprising an active core site, the active core site comprising at least one D-amino acid. The invention also provides a pharmaceutical composition comprising an ADNF polypeptide comprising an active core site, the active core site comprising at least one D-amino acid. In particular, the... Agent: Townsend And Townsend And Crew, LLP

20080194487 - Treatment of skin diseases: Substance P or its analogs are useful for treating certain skin diseases. The active agents can be administered topically. Disease severity is reduced by substance P treatment.... Agent: Jones Day

20080194489 - Treatment of iatrogenic disease: The invention relates to the field of human or veterinary medicine and to the treatment of subjects (be it man or animal) that suffer from iatrogenic disease, i.e., experience problems or complications resulting from a medical treatment. Provided is a method for modulating an iatrogenic event in a subject, the... Agent: Trask Britt

20080194490 - At4 receptor ligands as angiogenic, anti-angiogenic, and anti-tumor agents: AT4 receptor agonists are potent activators of angiogenesis and can be used to treat diseases that are characterized by vascular insufficiency. AT4 receptor antagonists, which are potent inhibitors of angiogenesis, and can be used as anti-angiogenic agents for the treatment of cancer, diabetic retinopathy, rheumatoid arthritis, psoriasis, atherosclerotic plaque formation,... Agent: Seed Intellectual Property Law Group Pllc

20080194491 - Methods of diagnosing, preventing, and treating early onset of pulmonary hypertension: Early onset of pulmonary disorders such as pulmonary hypertension are treated or prevented by administration of an apoptosis inhibitor or a survival factor. Early onset of such disorders may be diagnosed by assessing apoptosis in lung tissue.... Agent: The Webb Law Firm, P.c.

20080194493 - Compositions containing d-carnosine: Disclosed are compositions containing D-carnosine as active ingredient, mixed with suitable vehicles or excipients.... Agent: Ladas & Parry LLP

20080194492 - Plant extracts for the treatment of incresed bone resorption: The present invention concerns the use of γ-glutamyl-peptide, for example γ-L-glutamyltrans-S-1-propenyl-L-cysteine sulfoxide, in the treatment or prevention of diseases or conditions which are characterized by increased bone resorption, such as Paget's disease, tumor-induced bone disease or osteoporosis, inhibits dose-dependently the resorption activity of osteoclasts, the minimal effective dose being about... Agent: Novartis Corporate Intellectual Property

20080194494 - 4-biarylyl-1-phenylazetidin-2-one glucuronide derivatives for hypercholesterolemia: e

20080194495 - Oligosaccharide derivative: wherein A represents a group such as a cyclic group, R1 and R2 represent groups such as alkyl groups or hydroxymethyl groups, and n represents 1 or 2, or pharmacologically acceptable salts thereof or pharmacologically acceptable esters thereof have superior activity and stability, and are useful for the treatment and/or... Agent: Morgan & Finnegan, L.l.p.

20080194496 - Skin aging treatment comprising paeoniflorin: The present invention relates to a skin aging treatment comprising paeoniflorin as an active ingredient. Since paeoniflorin is effective in significantly inhibiting and improving intrinsic skin aging, significantly inhibiting and improving DNA impairment and skin wrinkling caused by UV and improving existing wrinkles, a cosmetic composition and a pharmaceutical composition... Agent: Sheridan Ross Pc

20080194497 - Macrolide polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof: The invention relates to novel forms of compounds displaying broad spectrum antibiotic activity, especially crystalline polymorphic forms and amorphous forms of such compounds, compositions comprising such crystalline polymorphic forms and amorphous forms of such compounds, processes for manufacture and use thereof. The compounds and compositions of the invention are useful... Agent: Morgan Lewis & Bockius LLP

20080194498 - Avermectins and avermectin monosacharides substituted in the 4'-and 4\" position having pesticidal properties: Described is a compound of the formula (1) wherein the bond between carbon atoms 22 and 23 is a single or double bond; m is 0 or 1; R1, is C1-C12alkyl, C3-C8cycloalkyl or C2-C12alkenyl; and either (A) R2 is —N(R3)R4, and (1) X is 0, wherein R3 is, for instance,... Agent: Syngenta Crop Protection , Inc. Patent And Trademark Department

20080194499 - Composition for selective serotonin reuptake inhibition and process thereof: The present invention relates to a novel pharmaceutical composition for serotonin reuptake inhibition, wherein the composition comprises pentacyclic terpenoid glycosides, preferably asiaticoside and madecassoside optionally along with excipients. Also the present invention relates to a process of preparation of novel pharmaceutical composition for serotonin reuptake inhibition, wherein the process comprising... Agent: Duane Morris, LLP Ip Department

20080194500 - Semi-fluorinated block copolymers for delivery of therapeutic agents: The present invention provides semi-fluorinated block copolymers and related methods of synthesizing and using semi-fluorinated block copolymers for drug delivery and drug formulation applications. Semi-fluorinated block copolymers of this aspect of the invention include block copolymers having discrete hydrophilic, fluorophilic and hydrophobic structural domains that are capable of forming supramolecular... Agent: Greenlee Winner And Sullivan P C

20080194501 - Cyclic bioisosters of derivatives of a purine system and pharmaceutical composition based thereon: and their pharmacologically acceptable salts having a normalizing effect on endocellular processes, in particular, it is capable eliminating endocellular metabolic acidosis and capable of binding excessively formed free radicals, in particular, free-radical forms of oxygen, capable of normalizing the nitrergic mechanisms of the cells, and also capable of interreacting with... Agent: Morgan & Finnegan, L.l.p.

20080194502 - Protecting groups for rna synthesis: Aspects of the invention include 2′ protected nucleoside monomers that are protected at the 2′ site with orthoester-type protecting groups. The 2′ protected monomers also include a second, aryl carbonate-type, protecting group. Aspects of the invention further include nucleic acids that include the protecting groups of the invention, as well... Agent: Agilent Technologies Inc.

20080194503 - Antisense modulation of p38 mitogen activated protein kinase expression: Compositions and methods for the treatment and diagnosis of diseases or conditions amenable to treatment through modulation of expression of a gene encoding a p38 mitogen-activated protein kinase (p38 MAPK) are provided. Methods for decreasing airway hyperresponsiveness or airway inflammation in an animal are also provided.... Agent: Swanson & Bratschun, L.l.c.

20080194515 - Bone morphogenic proteins (bmp), bmp receptors and bmp binding proteins and their use in the diagnosis and treatment of glaucoma: The present invention provides methods and kits for diagnosing and treating glaucoma.... Agent: Alcon

20080194508 - Cell counting: The inventions relates to compositions and method for determining the absolute counts of cells per unit volume of a sample. Such a method comprises: (a) providing a container containing: (i) a predetermined quantity of microparticles; and (ii) a cell-binding agent; in which the microparticles are disposed in or on a... Agent: Dako/finnegan, Henderson, LLP

20080194511 - Codon optimized synthetic plasmids: One aspect of the current invention is an optimized synthetic mammalian expression plasmid (e.g. pAV0201). This new plasmid comprise a therapeutic element, and a replication element. The therapeutic element of the new plasmid comprises a eukaryotic promoter; a 5′ untranslated region (“UTR”); a codon-optimized-eukaryotic therapeutic gene sequence; and a poly... Agent: Pepper Hamilton LLP

20080194512 - Compositions and methods for inhibiting viral replication: The present invention relates to a double-stranded ribonucleic acid (dsRNA) having a nucleotide sequence which is less that 30 nucleotides in length and which is substantially identical to at least a part of a 3′-untranslated region (3′-UTR) of a (+) strand RNA virus, such as HCV, as well as pharmaceutical... Agent: Lowrie, Lando & Anastasi, LLP A2038

20080194507 - Defibrotide an/or oligodeoxyribonucleotides for treating angiogenesis-dependent tumors: The use of defibrotide and/or oligodeoxyribonucleotides having a molecular weight of 4000-10000 Dalton as an anti-tumour agent, alone or in combination with other active ingredients with anti-tumour action, is described. The oligotide may be produced by extraction from animal and/or vegetable tissues, in particular, from mammalian organs, or may be... Agent: Intellectual Property Group Fredrikson & Byron, P.a.

20080194514 - Methods and compositions for inhibiting the function of polynucleotide sequences: A therapeutic composition for inhibiting the function of a target polynucleotide sequence in a mammalian cell includes an agent that provides to a mammalian cell an at least partially double-stranded RNA molecule comprising a polynucleotide sequence of at least about 200 nucleotides in length, said polynucleotide sequence being substantially homologous... Agent: Cooley Godward Kronish LLP Attn: Patent Group

20080194509 - Novel adenyl dinucleotides with antitumour activity and a method of preparing thereof: The invention relates to novel adenyl dinucleotides which are isomers of the dinucleotide Ap2A, having formulae (I) and (II). The dinucleotides of the invention have antitumour activity, particularly against tumours of haematological origin, such as for example leukaemias and lymphomas. The invention further relates to the use of such dinucleotides... Agent: Roylance, Abrams, Berdo & Goodman, L.l.p.

20080194505 - Nucleic acid and amino acid sequences relating to streptococcus pneumoniae for diagnostics and therapeutics: The invention provides isolated polypeptide and nucleic acid sequences derived from Streptococcus pneumoniae that are useful in diagnosis and therapy of pathological conditions; antibodies against the polypeptides; and methods for the production of the polypeptides. The invention also provides methods for the detection, prevention and treatment of pathological conditions resulting... Agent: Hamilton, Brook, Smith & Reynolds, P.c.

20080194506 - Oligodeoxyribonuleotides of 4000-10000 dalton for treating: The use of oligodeoxyribonucleotides having a molecular weight of 4000-10000 Dalton as an anti-tumour agent, alone or in combination with other active ingredients with anti-tumour action, is described. The oligotide may be produced by extraction from animal and/or vegetable tissues, in particular, from mammalian organs, or may be produced synthetically.... Agent: Intellectual Property Group Fredrikson & Byron, P.a.

20080194504 - Rna-mediated interference to control disease in terrestrial and aquaculture animals: The invention is directed to compositions (e.g., feeds, feed supplements, and therapeutic products) and methods for inhibiting an animal pathogen using RNA-interference technology.... Agent: Duane Morris, LLP Ip Department

20080194513 - Rnai-mediated inhibition of aquaporin 4 for treatment of ocular neovascularization: RNA interference is provided for inhibition of aquaporin 4 (AQP4) to treat conditions associated with neovascularization.... Agent: Alcon

20080194510 - Substances, compositions and methods for preventing and treating immune-mediated inflammatory disorders: A substance or a composition for preventing, delaying the onset of or treating one or more than one immune-mediated inflammatory disorder in an organism who is susceptible to developing the immune-mediated inflammatory disorder, who is developing the immune-mediated inflammatory disorder or who has the immune-mediated inflammatory disorder. A method of... Agent: Sheldon Mak Rose & Anderson Pc

20080194517 - Equine or canine immunomodulating composition and treatment method: An equine or canine immunomodulating composition comprises a pre-packaged, feed supplement comprising effective amounts of a beta-glucan mixture which is at least 60 percent purified. The feed supplement may be a dry feed supplement further including (b) an effective amount of at least one flavoring, and (c) an effective amount... Agent: Blynn L. Shideler The Blk Law Group

20080194516 - System for managing anti-coagulant infusions in patients: An anti-coagulant maintenance system for use in the treatment of patients with deep-vein thrombosis (DVT), pulmonary embolism (PE), Acute Coronary Syndrome, need for prophylactic anticoagulation or another related condition. The system establishes and adjusts the dosing of an anti-coagulant based upon periodic blood testing of a system specified frequency. Warning... Agent: Woodard, Emhardt, Moriarty, Mcnett & Henry LLP

20080194518 - Antimicrobial compositions: An antimicrobial composition, including a synergistic combination of three or more agents as an active ingredient. Each of the three or more potentiating agents can be selected from the following types of compounds: sequestering agents, carbohydrates and carbohydrate derivatives, terpenes/terpenoids, amines and amine derivatives, plant-derived oils, sulfonates, phenols, fatty acids,... Agent: Miles & Stockbridge Pc

20080194519 - Topiramate compositions and methods for their use: The invention provides compositions that include topiramate and a cyclodextrin and methods for their use.... Agent: Viksnins Harris & Padys Pllp

20080194521 - Diacylhydrazine ligands for modulating the expression of exogenous genes in mammalian systems via an ecdysone receptor complex: The present invention relates to non-steroidal ligands for use in nuclear receptor-based inducible gene expression system, and a method to modulate exogenous gene expression in which an ecdysone receptor complex comprising: a DNA binding domain; a ligand binding domain; a transactivation domain; and a ligand is contacted with a DNA... Agent: Sughrue Mion, Pllc

20080194520 - Sulfonyl amino cyclic derivatives and use thereof: The present invention is related to derivatives of Formula (I) and use thereof in particular for the treatment and/or prophylaxis of autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, cancer, respiratory diseases and fibrosis, including multiple sclerosis, arthritis, emphysema, chronic obstructive pulmonary disease, liver and pulmonary fibrosis.... Agent: Hamilton, Brook, Smith & Reynolds, P.c.

20080194522 - Development of fluorogenic substrates for monoamine oxidases (mao-a and mao-b): The present invention relates to compounds useful for detecting the activity of monoamine oxidases, compounds useful for competitively inhibiting monoamine oxidases, for determining inhibitors of monoamine oxidases and compounds useful for treating monoamine oxidase-related nervous system pathologies, as well as pharmaceutical compositions and methods of manufacture thereof.... Agent: Cooper & Dunham, LLP

20080194523 - Hiv integrase inhibitors: The present invention features compounds that are HIV integrase inhibitors and may be useful in the inhibition of HIV replication, the prevention and/or treatment of infection by HIV, and in the treatment of AIDS and/or ARC.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B482

20080194524 - Compounds for the inhibition of undesired cell proliferation and use thereof: wherein the dashed line indicates a single or double bond or is absent and wherein A1-A9, Q, R1-R11, T, U, V, W1-W3, X1, X2, Y and Z are as defined in the claims and description, pharmaceutical compositions comprising the compounds and the use of the compounds for the manufacture of... Agent: Rothwell, Figg, Ernst & Manbeck, P.c.

20080194525 - Process of making geminal bisphosphonic acids and pharmaceutically acceptable salts and/or hydrates thereof: This invention relates to the process of making geminal bisphosphonic acids and pharmaceutically acceptable salts and/or hydrates thereof which have the formula (I): wherein X1, X2, X3, X1R1 and R2 are described herein.... Agent: Frommer Lawrence & Haug

20080194526 - Liquid formulations: Disclosed is a concentrate for dilution comprising a S1P receptor agonist or a pharmaceutically acceptable salt thereof, propylene glycol and optionally glycerin. This formulation is adapted for patients in a difficult condition to swallow.... Agent: Novartis Corporate Intellectual Property

20080194527 - Compositions and combinations 2: Compositions and methods for preventing, inhibiting or treating a disorder associated with the loss of normal adult tissue architecture are provided.... Agent: Schwegman, Lundberg & Woessner, P.a.

20080194528 - Pharmaceutical compositions comprising organopolysiloxane elastomers and solubilized bioactive compounds: Stable, anhydrous pharmaceutical compositions contain an organopolysiloxane elastomer and, as bioactive ingredient, at least one vitamin D compound in a solubilized form, and are useful for the topical treatment of psoriasis and other skin disorders/afflictions.... Agent: Buchanan, Ingersoll & Rooney Pc

20080194529 - Highly selective and long-acting pde5 modulators: Disclosed herein are substituted phosphodiesterase type 5 enzyme modulators of Formula I, processes of preparation thereof, pharmaceutical compositions thereof, and methods of use thereof.... Agent: Global Patent Group - Apx Ms. Lavern Hall

20080194530 - Chemical compounds: The invention provides sarsasapogenin in novel amorphous, crystalline, solvated and hydrated forms, and the use thereof in manufacturing pharmaceutical or edible grade sarsasapogenin and its derivatives.... Agent: Ronald I. Eisenstein Nixon Peabody LLP

20080194532 - Compositions containing quaternary ammonium compounds: Compositions containing quaternary ammonium compounds in which the nitrogen atom is substituted by at least one alkyl group having at least 12 carbon atoms, where composition includes at least 20% in weight by weight of the total composition, of ammonium halides in which the nitrogen atom is substituted by at... Agent: Young & Thompson

20080194531 - Methods for treating visual disorders: The present invention provides methods for treating visual disorders. Exemplary visual disorders include macular degeneration, retinitis pigmentosa, glaucoma, and/or retinal degeneration.... Agent: Mueting, Raasch & Gebhardt, P.a.

20080194534 - Modified retinoid compounds and their uses: A method of minimizing or reducing the toxicity of a retinoid having a free carboxyl group and the resulting modified retinoids are described. The method comprises the step of esterifying the carboxyl group of the retinoid with a highly sterically hindered compound, which is preferably a secondary or tertiary alcohol.... Agent: Andrus, Sceales, Starke & Sawall, LLP

20080194533 - Process for selective sulfation of aromatic hydroxyl groups: The present invention relates to processes for selective sulfation of an aromatic hydroxyl group over an aliphatic hydroxyl group where both are present in the same molecule. This invention also relates to processes for selective sulfation of the aromatic hydroxyl group of equilin, equilenin, estradiol, estra(1,3,5-triene)-3,16,17-triol, dihydroequilenin or dihydroequilin. This... Agent: Pepper Hamilton LLP/wyeth

20080194535 - Diaminopropane derived macrocycles as inhibitors of beta amyloid production: wherein R1, R2, R3, m, n, W, X, Y, Z and L as defined herein, their pharmaceutical compositions and methods of use. These novel compounds inhibit the processing of amyloid precursor protein (APP) by β-secretase and, more specifically, inhibit the production of Aβ-peptide. The present disclosure is directed to compounds... Agent: Louis J. Wille Bristol-myers Squibb Company

20080194536 - Cyanoarylamines: e

20080194537 - Compounds modifying apoptosis: The present invention relates to compounds capable of inhibiting binding of the Smac protein to Inhibitors of apoptosis (IAPs). Such compounds are preferably capable of inhibiting IAP and thus may promote apoptosis or sensitize cells for apoptosis. The compounds may be used in the treatment of proliferative diseases, such as... Agent: Gifford, Krass, Sprinkle,anderson & Citkowski, P.c

20080194538 - Method for pain treatment: This invention discloses a method of treating pain by administering histamine H4 receptor ligands and compositions comprising the same.... Agent: Paul D. Yasger Abbott Laboratories

20080194539 - Phenyl diazepane carboxamides and annelated phenyl piperazine carboxamides containing oxygen and used as dopamine d3 antagonists: i

20080194540 - Use of a tricyclic antidepressant drug for promoting endocytosis: The invention teaches the use of a tricyclic compound for promoting the endocytotic uptake of macromolecular active ingredients.... Agent: Mayer & Williams Pc

20080194541 - Anti-inflammatory agents: The invention provides compounds, compositions and uses of compounds of general formula (I) or pharmaceutically acceptable salts thereof, which are 3-aminocaprolactam derivatives, for the preparation of a medicament intended to treat an inflammatory disorder wherein X is —CO—Y—(R1)n or SO2—Y—(R1)n; and Y is 0 cycloalkyl or polycyloalkyl group (such as... Agent: Schwegman, Lundberg & Woessner, P.a.

20080194542 - Pharmaceutical compositions of amlodipine and benazepril: A stable pharmaceutical composition consisting of (a) benazepril, in free or pharmaceutically acceptable salt form; and (b) amlodipine, in free or pharmaceutically acceptable salt form. The composition is free of alkali and alkaline earth metal carbonates and phosphates. The composition is also free of excipients which increase the pH of... Agent: Frommer Lawrence & Haug

20080194543 - Immunosuppressive ningalin compounds: The present invention provides compositions and methods comprising ningalins for use in modulating immune responses to infection, injury, allergy and/or transplantation.... Agent: Edwards Angell Palmer & Dodge, LLP Client: Sloan Memorial

20080194544 - Aqueous formulations of epinastine for treating allergic rhinitis: There is provided homogeneous pharmaceutical compositions for the treatment of, for example, rhinitis, asthma and/or chronic obstructive pulmonary disease comprising a corticosteroid and an antihistamine, a polar lipid liposome and a pharmaceutical-acceptable aqueous carrier.... Agent: Howery LLP

20080194545 - Antimicrobial compositions and methods of use: The present invention is directed to compounds of formula I, pharmaceutical compositions comprising the compounds, and methods for making and using the inventive compounds.... Agent: Dla Piper Us LLP

20080194546 - Pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mtor inhibitors: wherein: one or two of X5, X6 and X8 is N, and the others are CH; R7 is selected from halo, ORO1, SRS1, NRN1RN2, NRN7aC(═O)RC1, NRN7bSO2RS2a, an optionally substituted C5-20 heteroaryl group, or an optionally substituted C5-20 aryl group, where RO1 and RS1 are selected from H, an optionally substituted... Agent: Morgan Lewis & Bockius LLP

20080194547 - Antibacterial agents: Naphthalene, quinoline, quinoaline and naphthyridine derivatives useful in the treatment of bacterial infections in mammals, particularly humans, are disclosed herein.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20080194548 - Drug combination therapy and pharmaceutical compositions for treating inflammatory disorders: A combination of a CCR2 antagonist and a statin is useful in the treatment and or prevention of inflammatory and other disorders, and methods of treating inflammatory and other disorders using a combination of a CCR2 antagonist and a statin.... Agent: Merck And Co., Inc

20080194550 - Long acting beta-2-agonists and their use as medicaments: c

20080194549 - Organic compounds: The invention relates to the use of (3,4-di-, 3,3,4-tri, 3,4,4-tri- or 3,3,4,4-tetra-)substituted pyrrolidine compounds for the preparation of a pharmaceutical formulation for the treatment of a disease that depends on activity of renin; the use of a compound of that class in the treatment of a disease that depends on... Agent: Novartis Institutes For Biomedical Research, Inc.

20080194551 - Acetylene derivatives: The invention provides compounds of formula (I), wherein the substituents are as defined in the specification, to processes for their preparation and their use as pharmaceuticals.... Agent: Novartis Corporate Intellectual Property

20080194552 - Aminopyrimidine derivatives with tie2 inhibiting activity: The invention relates to a compound of the Formula I or salt thereof wherein Rx, Ry, Rx, R5, R6, A, B, L, n and m are as defined in the description. The invention also relates to pharmaceutical compositions of said compounds, the use of said compounds as medicaments and in... Agent: Astrazeneca R&d Boston

20080194554 - Hiv protease inhibitors: The present invention features compounds that are HIV protease inhibitors and therefore are useful in the inhibition of HIV replication, the prevention and/or treatment of infection by HIV, and in the treatment of AIDS and/or ARC.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B482

20080194555 - Novel benzimidazole and benzothiazole derivatives, method for preparing same, use thereof as drugs, pharmaceutical compositions and novel use especially as c-met inhibitors: e

20080194553 - Use of compounds that are able to increase the serum igf-1 level for the preparation of a therapeutical composition for treatment of various disease states associated with a reduced igf-1 serum level in humans and animals: The present invention relates to the use of one or more compounds that are capable of increasing the serum level of insulin-like growth factor 1 (IGF-1) for the preparation of a therapeutical composition, in particular in the form of a food supplement, for the treatment of subjects suffering from serious... Agent: Harness, Dickey & Pierce, P.L.C

20080194557 - Methods and compositions for the treatment of pain, inflammation and cancer: This invention relates to methods of treating, managing and preventing pain, inflammation, cancer, and ocular diseases and disorders, and to compounds and pharmaceutical compositions useful in such methods.... Agent: Lexicon Pharmaceuticals, Inc.

20080194558 - Quinazoline analogs as receptor tyrosine kinase inhibitors: where an A group is bonded to at least one of the carbons at the 5, 6, 7 or 8 position of the bicyclic ring, and the ring is substituted by up to three independent R3 groups. The invention also includes methods of using these compounds as type I receptor... Agent: Mcdermott Will & Emery LLP

20080194556 - Quinazolines and their use as aurora kinase inhibitors: The invention provided a compound of formula (I) for use in the treatment of disease, in particular proliferative diseases such as cancer and for use in the preparation of medicaments for use in the treatment of proliferative diseases; the invention also processes for the preparation of such compounds, as well... Agent: Astrazeneca R&d Boston

20080194560 - Disintegration promoters in solid dose wet granulation formulations: e

20080194559 - Remedy for angiospasm accompanying subarachnoid hemorrhage containing thrombin receptor antagonist as the active ingredient: A therapeutic agent for subarachnoid hemorrhage or a drug for improving prognosis of subarachnoid hemorrhage, comprising a compound having a PAR1 inhibitory effect, its pharmaceutically acceptable salt or a hydrate thereof.... Agent: Dickstein Shapiro LLP

20080194561 - Compounds: t

20080194562 - Pyrazole derivatives for the inhibition of cdk's and gsk's: The invention provides compounds of the formula (I) or a salt, tautomer, solvate or N-oxides thereof; wherein: R1 is selected from (a) 2,6-dichlorophenyl; (b) 2,6-difluorophenyl; (c) a 2,3,6-trisubstituted phenyl group wherein the substituents are fluorine, chlorine, methyl or methoxy; and (d) a group R0 wherein R0 is a 3-12 membered... Agent: Heslin Rothenberg Farley & Mesiti Pc

20080194563 - Shp-2 inhibitors, pharmaceutical compositons comprising them and their use for treating phosphatase-mediated diseases: The present invention relates to small molecule protein tyrosine phosphatase inhibitors, especially Shp-2 inhibitors, of formula (I) and/or (II), and to pharmaceutical compositions comprising them. The invention is also directed to the use of said compounds for the treatment of phosphatase-mediated diseases, especially cancer and metastasis. The invention further concerns... Agent: Millen, White, Zelano & Branigan, P.c.

20080194564 - Hexenoic acid derivatives, processes for the preparation thereof, pharmaceutical compositions comprising them, and therapeutic applications thereof: Compounds of the formula (I): in which R, R1, R2 and R3 are as defined in the description, the use thereof for the treatment of dyslipidaemia, atherosclerosis and diabetes, pharmaceutical compositions comprising them, and processes for the preparation of these compounds.... Agent: Millen, White, Zelano & Branigan, P.c.

20080194565 - 5-phenyl-pentanoic acid derivatives as matrix metalloproteinase inhibitors for the treatment of asthma and other diseases: The present invention relates to C ompounds having the structure of Formula I: wherein n is an integer from 1 to 5; R1 is optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, aralkyl, alkoxy, aryloxy, alkenyloxy or alkynyloxy; R2 is alkenyl, allcynyl, aryl, heterocyclyl, heteroaryl, cycloalkyl, NR4R5, —NHC(═Y)R4, —NHC(═Y)NR5Rx,... Agent: Ranbaxy Inc.

20080194567 - Combination treatment for enhancing diuresis: A combination therapy for promoting diuresis in a patient comprises administering levosimendan or its active metabolite or any of their pharmaceutically acceptable salts in conjunction with a diuretic to a patient. The combination therapy provides diuretic effect also in patients who are refractory to standard diuretic therapy.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080194566 - Pyridazine compound and use thereof: c

20080194569 - Phthalazinones: Compounds of the formula I, in which R, R1, R2, R3, R4, R5, R6, R7, R8, Z1, Z2, Z3 and Y1 have the meanings indicated in claim 1, can be employed, inter alia, for the treatment of tumours... Agent: Baker & Daniels LLP

20080194568 - Pyridomorphinans, pyridazinomorphinans and use thereof: Compounds represented by formula (I) wherein R is C1-6cycloalkylalkyl; or C3-6 alkenyl; R′ is H or C1-6 alkyl; X is H or OH; Y is alkyl, cycloalkyl, aryl, heteroaryl or aroyl; and Z is CH or N; provided that X is H, when Z is CH and R is C4... Agent: Connolly Bove Lodge & Hutz LLP

20080194570 - Solid pharmaceutical formulations of a homogeneous dispersion of active principles having ph-dependent solubility: The present invention relates to solid pharmaceutical formulations of a homogeneous dispersion of at least one active principle which possesses pH-dependent solubility, e.g. 1-[4-chloroanilino]-4-[4-pyridylmethyl]phthalazine, or a pharmaceutically acceptable salt thereof, to solid dosage forms comprising said solid pharmaceutical formulations, to methods of preparing said solid pharmaceutical formulations and said solid... Agent: Millen, White, Zelano & Branigan, P.c.

20080194572 - 5,6,7,8-tetrahydropteridine derivatives as hsp90 inhibitors: The present invention relates to compounds that inhibit HSP90 function, processes for their preparation, pharmaceutical compositions containing them as the active ingredient, to their use as medicaments and to their use in the manufacture of medicaments for use in the treatment in warm-blooded animals such as humans of diseases such... Agent: Morgan Lewis & Bockius LLP

20080194571 - Acetylenic piperazines as metabotropic glutamate receptor antagonists: e

20080194573 - 3-(heteroaryl-oxy)-2-alkyl-1-aza-bicycloalkyl derivatives as alpha. 7-nachrligands for thetreatment of cns diseases: The present invention relates to 1-aza-bicycloalkyl derivatives of formula (I) wherein the substituents are as defined in the specification, to processes for their production, their use as pharmaceuticals in the prevention and treatment of psychotic and neurodegenerative disorders. The claimed compounds act as nicotinic acelylcholine receptors (NACHR) ligands.... Agent: Novartis Institutes For Biomedical Research, Inc.

20080194574 - Pyrazine derivatives as effective compounds against infectious diseases: The present invention relates to pyrazine derivatives according to the general formula (I) and pharmaceutically acceptable salts thereof and their use as pharmaceutical compounds as well as the use of these compounds for the preparation of a pharmaceutical composition for the prophylaxis and/or treatment of infectious diseases, including opportunistic diseases,... Agent: Brooks Kushman P.c.

20080194577 - 2-aminopyrimidine modulators of the histamine h4 receptor: 2-Aminopyrimidine compounds are described, which are useful as H4 receptor modulators. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by H4 receptor activity, such as allergy, asthma, autoimmune diseases, and pruritis.... Agent: Philip S. Johnson Johnson & Johnson

20080194576 - Pyrimidine derivatives and their use as p2y12 receptor antagonists: The invention relates to 4-aminocarbonyl-pyrimidine derivatives and their use as P2Y12 receptor antagonists in the treatment and/or prevention and/or treatment of peripheral vascular, of visceral-, hepatic- and renal-vascular, of cardiovascular and of cerebrovascular diseases or conditions associated with platelet aggregation, including thrombosis in humans and other mammals.... Agent: Dickstein Shapiro LLP

20080194575 - Treatment for non-alcoholic-steatohepatitis: e

20080194578 - Quinazoline based egfr inhibitors containing a zinc binding moiety: The present invention relates to quinazoline containing zinc-binding moiety based derivatives that have enhanced and unexpected properties as inhibitors of epidermal growth factor receptor tyrosine kinase (EGFR-TK) and their use in the treatment of EGFR-TK related diseases and disorders such as cancer. The said derivatives may further act as HDAC... Agent: Elmore Patent Law Group, Pc

20080194579 - 1,3-dihydro-imidazo [4,5-c] quinolin-2-ones as lipid kinase inhibitors: processes for the preparation thereof, the application thereof in a process for the treatment of the human or animal body, the use thereof—alone or in combination with one or more other pharmaceutically active compounds—for the treatment of an inflammatory or obstructive airway disease, such as asthma, disorders commonly occurring in... Agent: Novartis Corporate Intellectual Property

20080194580 - Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas: This invention relates to a group of quinolyl, isoquinolyl and pyridyl ureas, their the use in treating raf mediated diseases, and pharmaceutical compositions which contain these ureas for use in such therapy.... Agent: Millen, White, Zelano, & Branigan, P.c. Arlington Courthouse Plaza I

20080194581 - Pyrrole derivatives, intermediates therefor, preparation and therapeutic use thereof: i

20080194582 - Mitotic kinesin inhibitors: The present invention relates to dihydropyrazole compounds that are useful for treating cellular proliferative diseases, for treating disorders associated with KSP kinesin activity, and for inhibiting KSP kinesin. The invention also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.... Agent: Merck And Co., Inc

20080194585 - Fungicidal pyrazine derivatives: Compounds of Formula 1, and their N-oxides and agriculturally suitable salts, are disclosed as useful as fungicides (INSERT FORMULA I HERE) wherein R1 is NR4R5, N═CR19R21, OR6, G1 or G2; or C1-C8 alkyl, C2-C8 alkenyl, each optionally substituted; A is O, S or NR7; R2 is cyano, NR8 N═CR9R10, NC(═O)R30;... Agent: Heiser, David E. E.i. Du Pont De Nemours And Company

20080194584 - Nitrogen heteroaromatic compounds which bind to the active site of protein kinase enzymes: or pharmaceutically acceptable salts, hydrates, solvates, geometrical isomers, tautomers, optical isomers, or prodrug forms thereof, wherein X, Y, Z, R1, R2, R3 and R4 are as defined herein are capable of binding to the active site of protein kinase enzymes. In particular, they are inhibitors of a serine/threonine kinase more... Agent: Klauber & Jackson

20080194583 - Tubulin inhibitors: Compounds of general formula (I), (II) (III) and (V) are described for use in modulating microtubule polymerisation and in the treatment of associated disease states. Use of compounds (I), (III) and (V) in the treatment of kinase-associated disease states is also described. Further described are novel compounds of formula (II),... Agent: Morrison & Foerster LLP

20080194586 - Fused-aromatic compounds having anti-diabetic activity: Fused aromatic compounds of Formula (I) are PPAR gamma agonists or partial agonists and are useful in the treatment or control of type II diabetes, including hyperglycemia, dylipidermia, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, and obesity that are often associated with type 2 diabetes.... Agent: Merck And Co., Inc

20080194588 - Modulation of pathogcnicity: s

20080194587 - Novel salts of 6-heterocycle substituted hexahydrophenanthridine derivatives: The invention relates to salts of 6-heteroaryl substituted hexahydrophenanthridine PDE4-inhibiting compounds, which can be used in the pharmaceutical industry for the production of pharmaceutical compositions for use, e.g., in treatment of airway disorders.... Agent: Nath & Associates Pllc

20080194589 - Pyrazolo[1,5-alpha]pyrimidinyl derivatives useful as corticotropin-releasing factor (crf) receptor antagonists: and pharmaceutically acceptable salts, esters, solvates, stereoisomers and prodrugs thereof, wherein R1, R2a, R2b, Y, Het, n, o, R6, Ar and R7 are as defined herein. Compositions containing a CRF receptor antagonist in combination with a pharmaceutically acceptable carrier are also disclosed, as well as methods for use of the... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20080194590 - 4-piperazinylthieno [2,3-d] pyrimidine compounds as platelet aggregation inhibitors: Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula (I) wherein A1, A2, A3, A4, A5, A6, A7, A8, X4, X6, X2k, R2l, R4, R5, and R6 are as defined in the detailed description of the invention. Corresponding pharmaceutical compositions, methods... Agent: Pfizer Inc.

20080194591 - Anhydrous crystalline forms of n-[1-(2-ethoxyethyl)-5-(n-ethyl-n-methylamino)-7-(4-methylpyridin-2-yl-amino)-1h-pyrazolo[4,3-d]pyrimidine-3-carbonyl]methanesulfonamide: The invention comprises (1) anhydrous crystalline forms of N-[1-(2-ethoxyethyl)-5-(N-ethyl-N-methylamino)-7-(4-methylpyridin-2-yl-amino)-1H-pyrazolo[4,3-d]pyrimidine-3-carbonyl]methanesulfonamide, (2) pharmaceutical compositions comprising at least one such form, (3) methods for the treatment of a phosphodiesterase-5-mediated condition using at least one such form, and (4) methods for preparing such forms. The compound N-[1-(2-ethoxyethyl)-5-(N-ethyl-N-methylamino)-7-(4-methylpyridin-2-yl-amino)-1H-pyrazolo[4,3-d]pyrimidine-3-carbonyl]methanesulfonamide has the following structure (I).... Agent: Pfizer Inc.

20080194592 - Organic compounds: The invention provides a new method of treating diseases or conditions characterized by reduced dopamine D1 receptor signaling activity, such as Parkinson's disease, depression, and cognitive impairment of schizophrenia, comprising administering an effective amount of a 1,3,5,-substituted, 6,7-dihydro-1H-pyrazolo[4,3-d]pyrimidin-7-one to a patient in need thereof.... Agent: Hoxie & Associates Llc

20080194593 - A2b adenosine receptor antagonists: Disclosed are methods for treating asthma, inflammatory gastrointestinal tract disorders, cancer, cardiovascular diseases, neurological disorders, and diseases related to undesirable angiogenesis using A2B adenosine receptor antagonists having the structure of Formula I or Formula II:... Agent: Cv Therapeutics, Inc.

20080194594 - Use of reversible inhibitors of s-adenosyl-l-homocysteine hydrolase for treating lupus: The present invention provides compositions and methods for reversibly inhibiting S-adenosyl-L-homocysteine (SAH) hydrolase. The compounds of the present invention can be used in combination with an anti-hemorrhagic viral infection agent, an immunosuppressant, a homocysteine lowering agent, or an anti-neoplasm agent. The compositions and methods of the present invention can be... Agent: Morrison & Foerster LLP

20080194597 - Platelet adp receptor inhibitors: Novel compounds of formulae (I) to (VIII), which more particularly include sulfonylurea derivatives, sulfonylthiourea derivatives, sulfonylguanidine derivatives, sulfonylcyanoguanidine derivatives, thioacylsulfonamide derivatives, and acylsulfonamide derivatives which are effective platelet ADP receptor inhibitors. These derivatives may be used in various pharmaceutical compositions, and are particularly effective for the prevention and/or treatment of... Agent: Townsend And Townsend And Crew, LLP

20080194595 - Quinazolinone derivatives useful as vanilloid antagonists: The present invention relates to the use of a quinazolinone compound of the formula (I) wherein R1, R2, R3, R4, R5 and m are as defined in the specification and in the claims, in free form or in salt form, and, where possible, in acid addition salt form, as a... Agent: Novartis Corporate Intellectual Property

20080194596 - Therapeutic combination including a selective erbb2 inhibitor: This invention relates to a method of treatment of cancer with a combination of an additional therapeutic agent in mammals. This invention also relates to a kit useful in the treatment of abnormal cell growth in mammals, especially humans.... Agent: Pfizer Inc

20080194600 - Dihydrogen phosphate salt of a prostaglandin d2 receptor antagonist: a pharmaceutical composition comprising a pharmaceutically effective amount of the compound of Formula (III), and a pharmaceutically acceptable carrier; and a method of treating a patient suffering from a PGD2-mediated disorder including, but not limited to, allergic disease (such as allergic rhinitis, allergic conjunctivitis, atopic dermatitis, bronchial asthma and food... Agent: Andrea Q. Ryan Sanofi-aventis U.s. Llc

20080194599 - Method of mollusc control: A method of Controlling mollusc damage to plants in horticulture or agriculture comprises treating the plant's propagation material with a combination of, as active ingredients, at least (a) clothiainidin and prothioconazole, (b) clothiainidin, fluoxastrobin and prothioconazole, (c) clothiainidin, tebuconazole, triazoxide and prothioconazole, (d) imdiacloprid and prothioconazole, (e) thiamethoxam, tebuconazole and... Agent: Syngenta Crop Protection , Inc. Patent And Trademark Department

20080194598 - Pyrimidine carboxylic acid derivatives and use thereof: The present application relates to pyrimidinecarboxylic acid derivatives, to processes for their preparation, to their use for the treatment and/or prophylaxis of diseases and their use for preparing medicaments for the treatment and/or prophylaxis of diseases, preferably for the treatment and/or prevention of cardiovascular disorders, in particular dyslipidaemias and arteriosclerosis.... Agent: Bayer Health Care Llc

20080194601 - Prevention of hiv-infection with tmc278: This invention relates to the use of a parenteral formulation comprising the NNRTI TMC278 for the long term prevention of HIV infection in a subject at risk of being infected by HIV, which comprises the intermittent administration of the said formulation at long time intervals.... Agent: Philip S. Johnson Johnson & Johnson

20080194605 - (1h-ind0l-7-yl)-(pyrimidin-2-ylamino)methanone derivatives and related compounds as igf-r1 inhibitors for the treatment of cancer: The invention relates to compounds of the formula (I), in which Ar denotes a mono- or bicyclic aromatic homo- or heterocycle having 1 to 4 N, O and/or S atoms and 5 to 10 skeleton atoms, which may be unsubstituted or mono-, di- or trisubstituted by carbonyl oxygen, Hal, A,... Agent: Millen, White, Zelano & Branigan, P.c.

20080194603 - Compositions and methods for inhibition of the jak pathway: The invention encompasses compounds having formula I and the compositions and methods using these compounds in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases are therapeutically useful.... Agent: Rigel Pharmaceuticals Inc.

20080194604 - Crystalline forms of rosuvastatin calcium salt: Bis[(E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl]-(3R,5S)-3,5-dihydroxyhept-6-enoic acid] (also known as rosuvastatin) calcium salt and hydrates can exist in new crystal forms B and C. These crystal forms provide a higher diversity on crystalline materials to optimize manufacture, formulation and biological efficiency.... Agent: Joann Villamizar Ciba Corporation/patent Department

20080194602 - Hiv inhibiting 2-(4-cyanophenylamino) pyrimidine oxide derivatives: HIV replication inhibitors of formula (I) a pharmaceutically acceptable addition salt; or a stereochemically isomeric form thereof, wherein R1 is halo; R2 and R3 each independently are C1-6alkyl. Pharmaceutical compositions containing these compounds as active ingredient and processes for preparing these compounds and compositions.... Agent: Philip S. Johnson Johnson & Johnson

20080194607 - Modulation of pathogenicity: V

20080194606 - Pyrazolyl-amino-substituted pyrimidines and their use in the treatment of cancer: This invention relates to novel compounds having the formula (I), and to their pharmaceutical compositions and to their methods of use. These novel compounds provide a treatment for cancer.... Agent: Astrazeneca R&d Boston

20080194608 - 6-phenylhex-5-enoic acid derivatives, process for the preparation thereof, pharmaceutical compositions comprising them, and therapeutic uses thereof: Compounds of the formula (I): in which R1, R2, R3, R′3 and R4 are as defined in the description, the use thereof for the treatment of dyslipidaemia, atherosclerosis and diabetes, the pharmaceutical compositions comprising them, and the processes for the preparation of these compounds.... Agent: Millen, White, Zelano & Branigan, P.c.

20080194609 - Chemical compound and its use: The present application relates to novel tetrahydroquinoline derivatives, to a process for their preparation, to their use on their own or in combination for treating and/or preventing diseases and to their use for preparing medicaments, in particular as inhibitors of the cholesterol ester transfer protein (CETP) for the treatment and/or... Agent: Bayer Health Care Llc

20080194610 - Spiropiperidine glycinamide derivatives: e

20080194611 - Modulation of cell barrier dysfunction: The invention provides prophylactic and therapeutic methods for administering a μ-opioid receptor antagonist to treat cell barrier diseases and disorders, such as endothelial and epithelial cell barrier diseases and disorders. The diseases or disorders may amenable to the methods include inflammation, such as acute lung injury, atherosclerosis, gut-derived sepsis, a... Agent: Michael Best & Friedrich LLP

20080194612 - Multi-arm polymer prodrugs: Provided herein are water-soluble prodrugs. The prodrugs of the invention comprise a water-soluble polymer having three or more arms, at least three of which are covalently attached to an active agent, e.g., a small molecule. The conjugates of the invention provide an optimal balance of polymer size and structure for... Agent: Nektar Therapeutics

20080194614 - Combination of organic compounds: The invention relates to a pharmaceutical combination comprising an HMG-Co-A reductase inhibitor, especially fluvastatinor pitavastatin or a pharmaceutically acceptable salt thereof and mTOR inhibiting agent, e.g. rapamycin or a rapamycin derivative.... Agent: Novartis Corporate Intellectual Property

20080194613 - P53 wild-type as biomarker for the treatment with mtor inhibitors in combination with a cytotoxic agent: Provided are biomarkers for determining the sensitivity of proliferative diseases such as cancer to therapeutic agents, in particular mTOR inhibitors in combination with a cytotoxic agent, in particular a cytotoxic agent which damages or affects the integrity of DNA.... Agent: Novartis Corporate Intellectual Property

20080194615 - Substituted tetrahydroquinolines: Disclosed are compounds of formula (I), wherein W, R, R1, R2, R3, R4, R5, R6, and R7 have the meanings indicated in claim 1. Said compounds can be used for the treatment of tumors, among other things.... Agent: Baker & Daniels LLP

20080194617 - Fused ring compound: s

20080194616 - Pyridopyrimidinone compounds useful in treating sodium channel-mediated diseases or conditions:

20080194618 - Muscarinic acetylcholine receptor antagonists: Muscarinic Acetylcholine receptor antagonists and methods of using them are provided.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20080194619 - Anti-hiv quinuclidine compounds: The invention provides a therapeutic method for preventing or treating a pathological condition or symptom in a mammal, such as a human, wherein the infectivity of a pathogen such as a retrovirus toward mammalian cells is implicated and inhibition of its infectivity is desired comprising administering to a mammal in... Agent: Schwegman, Lundberg & Woessner, P.a.

20080194621 - Substituted 4-phenyltetrahydroisoquinolines, process for their preparation, pharmaceutical compositions and therapeutic use: e

20080194620 - Use of benzodiazepine receptor ligands for combating signs of ageing: The invention relates to the cosmetic use of at least one benzodiazepine peripheral receptor antagonist in a composition containing a physiologically acceptable medium, as an agent for reducing or preventing cutaneous signs of ageing.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.c.

20080194623 - Method for the synthesis of quinoline derivatives: This invention relates to novel intermediates and processes for preparing pharmaceutically active quinoline compounds, including (−)-(S)—N-(α-ethylbenzyl)-3-hydroxy-2-phenylquinoline-4-carboxamide.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20080194622 - Quinoline 3-sulfonate esters as nk3 receptor modulators: Compounds of Formula I wherein R1, A, R2, R3, R4, R5 n, m and q are as described in the specification, pharmaceutically-acceptable salts, methods of making, pharmaceutical compositions containing and methods for using the same.... Agent: Astra Zeneca Pharmaceuticals Lp Global Intellectual Property

20080194624 - 2-amino-quinoline derivatives useful as inhibitors of beta-secretase (bace): The present invention is directed to 2-amino-quinoline derivatives, pharmaceutical compositions containing them and their use in the treatment of Alzheimer's disease (AD) and related disorders. The compounds of the invention are inhibitors of β-secretase, also known as β-site cleaving enzyme and BACE, BACE1, Asp2 and memapsin2.... Agent: Philip S. Johnson Johnson & Johnson

20080194625 - Tetrahydroquinoline derivatives as cannabinoid receptor modulators: Further provided are methods of using such compounds for the treatment of eating disorders, metabolic disorders, obesity, cognitive disorders, neurological disorders, pain disorders, inflammation disorders, in the promotion of smoking cessation and for the treatment of other psychiatric disorders Also provided are pharmaceutical compositions containing such compounds and pharmaceutical combinations... Agent: Louis J. Wille Bristol-myers Squibb Company

20080194626 - Antihypertensive drug combination: Therapeutic combinations and pharmaceutical compositions are provided comprising darusentan and an inhibitor of renin activity or release in absolute and relative amounts effective to provide a beneficial change in a subject's 24-hour pattern of systolic and/or diastolic blood pressure. There are further provided methods of using such combinations or compositions... Agent: Harness, Dickey, & Pierce, P.l.c

20080194627 - Aryl substituted pyridines and the use thereof: or a pharmaceutically acceptable salt, prodrug or solvate thereof, wherein Ar and R1—R4 are set in the specification. The invention is also directed to the use of compounds of Formula I for the treatment of neuronal damage following global and focal ischemia, for the treatment or prevention of neurodegenerative conditions... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20080194628 - Donepezil salts suitable for the preparation of pharmaceutical compositions: The invention relates to donepezil salts formed with organic acids and a process for the preparation thereof. Said salts can be used for the preparation of pharmaceutical compositions. The invention also relates to a process for the preparation of said salts, pharmaceutical compositions containing them and the use of said... Agent: K.f. Ross P.c.

20080194629 - 3-mono-and 3,5-disubstituted piperidine derivatives as renin inhibitors: The invention relates to 3,5-piperidine compounds, these compounds for use in the diagnostic and therapeutic treatment of a warm-blooded animal, especially for the treatment of a disease (=disorder) that depends on activity of renin; the use of a compound of that class for the preparation of a pharmaceutical formulation for... Agent: Novartis Corporate Intellectual Property

20080194630 - Lta4h modulators and uses thereof: Leukotriene A4 hydrolase (LTA4H) inhibitors, compositions containing them, and methods of use for the inhibition of LTA4H enzyme activity and the treatment, prevention or inhibition of inflammation and/or conditions associated with inflammation.... Agent: Philip S. Johnson Johnson & Johnson

20080194631 - Medicament for the treatment of central nervous system disorders: The invention relates to the use of a molecule, alone or in combination, chosen from the group of molecules having a simultaneous antagonist action on the alpha1-noradrenergic, glutamatergic NMDA and serotoninergic 5HT2 receptors, for the preparation of a medicament intended for treating pathologies of the central nervous system.... Agent: Oliff & Berridge, Plc

20080194632 - Novel piperidine derivatives as chemokine receptor modulators useful for the treatment of respiratory diseases: The invention provides compounds of formula wherein m, R1, R2 and R3 are as defined in the specification, salts and polymorphic forms thereof, processes for the preparation of the compounds, salts and polymorphs, pharmaceutical compositions containing these compounds, salts and/or polymorphic forms and their use in therapy.... Agent: Fish & Richardson P.c.

20080194633 - Certain chemical entities, compositions, and methods: Chemical entities that modulate smooth muscle myosin and/or non-muscle myosin, pharmaceutical compositions and methods of treatment of diseases and conditions associated with smooth muscle myosin and/or non-muscle myosin are described.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080194635 - Crystalline forms of cis-5-fluoro-n-[4-(2-hydroxy-4-methylbenzamido) cyclohexyl]-2-(tetrahydrothiopyran-4-yloxy) nicotinamide: The present invention relates to new crystalline forms of syn-5-Fluoro-N-[4-(2-hydroxy-4-methyl-benzoylamino)-cyclohexyl ]-2-(tetrahydro-thiopyran-4-yloxy)-nicotinamide and to processes for the preparation of, compositions containing and the uses of such crystalline forms.... Agent: Pfizer Inc.

20080194634 - Process for the oxidation of certain substituted sulfilimines to insecticidal sulfoximines: Insecticidal sulfoximines are produced efficiently and in high yield by the oxidation of the corresponding sulfilimine with ruthenium tetraoxide or an alkali metal permanganate.... Agent: Dow Agrosciences Llc

20080194638 - Bioavailable formulations of heterocyclic compounds: The present invention relates to bioavailable pharmaceutical formulations of heterocyclic compounds, such as such as N-(3,5-dichloropyrid-4-yl)-4-difluoromethoxy-8-methanesulfonamido-dibenzo[b,d]furan-1-carboxamide (oglemilast) and pharmaceutically acceptable salts thereof, to processes for their preparation and to methods of treatment using the same. The present invention also relates to substantially pure amorphous forms of heterocyclic compounds, such as... Agent: Forest Laboratories, Inc. Attn: Charles S. Ryan

20080194636 - Enzyme inhibitors and uses thereof: The present invention relates to inhibitors of insulin-regulated aminopeptidase (IRAP) and methods for inhibiting same, as well as compositions comprising said inhibitors. In particular, the inhibitors of the present invention may be useful in therapeutic applications including enhancing memory and learning functions, regulating cellular glucose uptake and homeostasis, inducing labour... Agent: Seed Intellectual Property Law Group Pllc

20080194637 - Small organic molecule regulators of cell proliferation: The present invention makes available methods and reagents for modulating proliferation or differentiation in a cell or tissue comprising contacting the cell with a compound. In certain embodiments, the methods and reagents may be employed to correct or inhibit an aberrant or unwanted growth state, e.g., by antagonizing a normal... Agent: Ropes & Gray LLP

20080194639 - Proton pump inhibitors in the treatment of sleep disturbance due to silent gastroesophageal reflux: The present invention relates to a new method of treatment of sleep disturbance due to silent gastro-esophageal reflux. In particular, the present invention relates to the use of certain proton pump inhibitors (PPIs) in said treatment.... Agent: White & Case LLP Patent Department

20080194642 - High dose, long-acting ectoparasiticide for extended control: The present invention provides a topical, high-dose, long-acting ectoparasiticide composition, kit and method for protecting against ectoparasite infestations in a warm-blooded animal for a period of greater than about 6 weeks.... Agent: Wyeth Patent Law Group

20080194640 - Optically active tetrahydronaphthalene derivative: A compound represented by the following formula (I), a pharmacologically acceptable salt thereof or a hydrate thereof or a solvate thereof, which shows not only a C5a receptor antagonistic activity but also high activity in the biological availability, as compared to its racemate.... Agent: Wenderoth, Lind & Ponack, L.l.p.

20080194641 - Pesticidal mixtures: Pesticidal mixtures comprising, as active components 1) a compound of the formula I wherein W is CI or CF3; X and Y are each independently CI or Br; R1 is alkyl, alkenyl, alkynyl, or cycloalkyl optionally substituted with 1 to 3 halogens, or alkyl which is substituted by alkoxy; R2... Agent: Hutchison Law Group Pllc

20080194643 - Factor xa inhibitor crystalline forms: Disclosed are crystalline forms A, B and C of 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(2-oxo-1(2H)-pyridinyl)phenyl]-4-methoxy-, (2R,4R)-(9Cl). These crystalline forms are characterized by their powder X-ray diffraction, solid-state NMR, as well as methods for the preparation and pharmaceutical compositions of the same which are useful for the treatment of acute, subacute, or chronic thrombotic disorders... Agent: Pfizer Inc.

20080194644 - Method of providing pirfenidone therapy to a patient: The invention relates to methods for decreasing adverse events associated with pirfenidone (5-methyl-1-phenyl-2-(1H)-pyridone) therapy. The invention discloses an optimized dose escalation scheme that results in the patient having increased tolerance to adverse events associated with the administration of pirfenidone. The invention also discloses a starter pack that may be used... Agent: Marshall, Gerstein & Borun LLP

20080194645 - Substituted amides: Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis,... Agent: Merck And Co., Inc

20080194646 - Methods for avoiding edema in the treatment of metabolic, inflammatory, and cardiovascular disorders: Compounds, compositions, and methods of treating or preventing PPARγ-mediated diseases, including cancer, using phenoxy acetic acid derivatives and prodrugs are provided.... Agent: Townsend And Townsend And Crew, LLP

20080194650 - Aryl fluoroethyl ureas acting as alpha 2 adrenergic agents: The invention provides well-defined aryl fluoroethyl ureas that are useful as selective alpha2 adrenergic agonists. As such, the compounds described herein are useful in treating a wide variety of disorders associated with modulation of alpha2 adrenergic receptors.... Agent: Allergan, Inc.

20080194648 - Compounds which potentiate glutamate receptor and uses thereof in medicine: wherein R1 is C1-6alkyl, haloC1-6alkyl, C2-6alkenyl, amino, monoC1-4alkylamino or diC1-4alkylamino; R2 and R3, which may be the same or different, are hydrogen, halogen, C1-6alkyl, haloC1-6alkyl, C1-4alkoxy, haloC1-4alkoxy, cyano, amino, monoC1-4alkylamino or diC1-4alkylamino; each R4, which may be the same or different, is C1-6alkyl, halogen, C1-6alkyl, haloC1-6alkyl, C1-4alkoxy, haloC1-4alkoxy, cyano, nitro,... Agent: Glaxosmithkline Corporate Intellectual Property - Uw2220

20080194652 - Inactive isomer compositions for use as drug-resistance-reversal agents and in prophylactic treatment: A method of using inactive isomer compositions as drug-resistance-reversal agents and in prophylactic treatment includes the steps of selecting an antihistaminically-inactive isomer of a preselected antihistamine, and making stereoselective use of the antihistaminically-inactive isomer for a clinical purposes. The making step includes choosing one of the following clinical purposes for... Agent: David P. Cooper Kolisch Hartwell, P.c.

20080194651 - Nitroderivatives as drugs for diseases having an inflammatory basis: Use for the treatment of diseases having an inflammatory basis of compounds or salts thereof, Having the following general formula (I): A-X1-L-(W)p—NO2 wherein A contains the radical of a drug, X1 and W are bivalent radicals, L is a covalent bond or oxygen, sulphur, NR1e wherein R1e is H or... Agent: Arent Fox LLP

20080194649 - Ophthalmologic compositions and use mode thereof: The invention concerns a pharmaceutical composition characterised in that it contains a combination of a parasympatholytic agent, a sympathomimetic agent and a local anaesthetic. Such a composition may be injected into the anterior chamber of the eye before a cataract operation or instilled on the eye before laser treatment.... Agent: Cantor Colburn, LLP

20080194647 - Pyridyl derivatives and their use as mglu5 antagonists: The present invention is directed toward pyridyl derivatives of formula (I) as antagonists of the mGlu5 receptor. As such the compounds may be useful for treatment or prevention of disorders remedied by antagonism of the mGlu5 receptor, wherein Ar is phenyl or napthyl each of which may be substituted by... Agent: Eli Lilly & Company

20080194654 - Hydroxy-substituted aryl sulfamide derivatives and methods of their use: or a pharmaceutically acceptable salt, stereoisomer or tautomer thereof, which are monoamine reuptake inhibitors, compositions containing these derivatives, and methods of their use for the prevention and treatment of conditions, including, inter alia, vasomotor symptoms, sexual dysfunction, gastrointestinal disorders and genitourinary disorder, depression disorders, endogenous behavioral disorders, cognitive disorders, diabetic... Agent: Wyeth Patent Law Group

20080194653 - Therapeutic agent for solid tumor: [wherein, n represents an integer of 1 to 3, R1 represents a hydrogen atom, R2 represents lower alkyl, or R1 and R2 are combined together to represent alkylene, R3 represents lower alkyl, R4 represents NHSO2R6 (wherein R6 represents hydroxy or the like) or the like, and R5 represents aryl or... Agent: Greenblum & Bernstein, P.L.C

20080194655 - Zero order controlled release compositions of tizanidine: The present invention relates to a novel controlled release formulations of tizanidine. The invention also provides methods of using novel controlled release formulations of tizanidine to treat a patient.... Agent: Philip S. Johnson Johnson & Johnson

20080194656 - Benzotriazole derivatives as cannabinoid receptor antagonists: Het represents a monocyclic 5 or 6 membered partially saturated or aromatic heterocycle selected from furanyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, triazolyl, thiadiazolyl, pyrimidinyl, pyridinyl, pyrazinyl, triazinyl, pyridazinyl, 2H-pyranyl or 4H-pyranyl wherein said heterocycle is optionally substituted with C1-6alkyl;... Agent: Philip S. Johnson Johnson & Johnson

20080194657 - Thiazole derivatives for treating restless legs syndrome: The invention relates to the use of derivatives of thiazoles having general formula (I) for the preparation of a medicament for the treatment or prevention of restless legs syndrome, also known as Ekbom syndrome. The invention also relates to a combination of thiazole derivatives having general formula (I) and at... Agent: Hunton & Williams LLP Intellectual Property Department

20080194658 - Sterol carrier protein-2 inhibitors for lowering cholesterol and triglyceride levels in mammals: Methods of treating high serum levels of total cholesterol, low density lipoprotein and triglycerides in a mammal by administering therapeutically effective doses of N-(4-{[4-(3,4-dichlorophenyl)-1,3-thiazol-2-yl]amino}phenyl)acetamide or a salt thereof such as a hydrochloride or hydrobromide salt.... Agent: Quarles & Brady LLP

20080194659 - Cinnamic, phenylpropiolic and phenylpropanoic acid derivatives useful as anti-tumor agents: Cinnamic and phenylpropiolic acid derivatives of formula (I) having antitumour and chemo sensitizing activity are described. Also described are pharmaceutical compositions containing the above-mentioned compounds, for the treatment of tumours.... Agent: Lucas & Mercanti, LLP

20080194660 - Angiotensin ii receptor antagonists: wherein R is an angiotensin receptor antagonist active group, Y is -Y1-Y2-Y3-Y4-Y5-; Y1 is C(R1R2); R1 is selected from the group consisting of hydrogen and C1-4 alkyl; R2 is selected from the group consisting of hydrogen, C1-4 alkyl, and —OC(O)C1-4 alkyl; Y2 is O or CH2; Y3 is C(O) or... Agent: Covington & Burling, LLP Attn: Patent Docketing

20080194661 - Antifungal triazole derivatives: Disclosed herein are antifungal triazole derivatives or pharmaceutically acceptable salts thereof, a preparation method thereof, and a pharmaceutical composition comprising the same.... Agent: Sughrue Mion, Pllc

20080194662 - Cleanser composition: A cleanser composition composed of purified water, sodium laureth sulfate, zinc pyrithione, cocamidopropyl betaine, glycerol cocoate, polyquaternium-7, and a cross-linked polyacrylic acid polymer for topical application to an area affected by a skin disorder such as seborrheic dermatitis, perioral dermatitis, rosacea, acne, tinea versicolor, eczema and psoriasis.... Agent: Husch Blackwell Sanders LLP

20080194663 - Novel sustained release polymer: A polymer and a method for its preparation are provided. The polymer comprises poly(lactide), poly(lactide/glycolide) or poly(lactic acid/glycolic acid) segments bonded by ester linkages to both ends of an alkanediol core unit. The polymer is for use in a controlled release formulation for a medicament, preferably leuprolide acetate. The controlled... Agent: Schwegman, Lundberg & Woessner, P.a.

20080194664 - Avermectin/metronidazole compositions for treating afflictions of the skin, e.g., rosacea: Pharmaceutical/dermatological compositions containing at least one avermectin compound, e.g., ivermectin and metronidazole or salt, ester or derivative thereof, are useful for treating afflictions of the skin, especially rosacea.... Agent: Buchanan, Ingersoll & Rooney Pc

20080194665 - Compositions based on amino acids for improving the myocardial ventricular function in patients suffering from diabetes: Compositions based on amino acids are described, for improving the myocardial ventricular function in patients suffering from diabetes, particularly but not exclusively II type diabetes. The compositions according to the invention comprise up to 75% of the branched chain amino acids leucine, isoleucine and valine, as active ingredients. Preferably, the... Agent: Sughrue, Mion, Zinn, Macpeak & Seas

20080194666 - Combination treatment methods: A method of treating an individual with a condition which condition is one wherein the individual with the condition benefits from the administration of GnRH and/or a GnRH analogue, the method comprising administering to the individual GnRH and/or a GnRH analogue and an inhibitor of prostaglandin synthesis and/or a prostaglandin... Agent: Nixon Peabody LLP - Patent Group

20080194667 - Compositions for treating amyloid associated diseases: Indole derivatives, compositions including same, and methods utilizing same for the treatment of amyloid associated diseases, such as type II diabetes mellitus, Alzheimer's dementia or diseases, systemic and localized amyloidosis, and prion-related encephalopathies are provided.... Agent: Martin D Moynihan Prtsi, Inc.

20080194668 - Compounds and compositions as tpo mimetics: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated TPO activity, particularly diseases or disorders that involve thrombocytopenia.... Agent: Genomics Institute Of The Novartis Research Foundation

20080194669 - T type calcium channel blockers and the treatment of diseases: The present invention provides a method for treating a disease or condition in a mammal associated with influx of extracellular calcium via T type calcium channels, which comprises administering to the mammal a therapeutically effective amount of a T type calcium channel inhibitor, a prodrug thereof, or a pharmaceutically acceptable... Agent: Scully Scott Murphy & Presser, Pc

20080194670 - Novel thiophene derivatives as spingosine-1-phosphate-1 receptor agonists: The invention relates to novel thiophene derivatives, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunosuppressive agents.... Agent: Dickstein Shapiro LLP

20080194671 - Method for treating atherosclerosis or restenosis using microtubule stabilizing agent: The present invention is a method of preventing or reducing atherosclerosis or restenosis, and a pharmaceutical preparation used therefore. In particular, it is a method of preventing or reducing atherosclerosis or restenosis after arterial injury by treatment with a low dose of a microtubule stabilizing agent such as taxol or... Agent: Klarquist Sparkman, LLP

20080194672 - Macrocyclic ghrelin receptor modulators and methods of using the same: The present invention provides novel conformationally-defined macrocyclic compounds that can function as selective modulators of the ghrelin receptor (growth hormone secretagogue receptor, GHS-R1a and subtypes, isoforms and variants thereof). Methods of synthesizing the novel compounds are also described herein. These compounds are useful as agonists of the ghrelin receptor and... Agent: Myers Bigel Sibley & Sajovec

20080194673 - Environment-friendly pollution-proof agent: The present invention relates to an environmental friendly antifouling agent, and more particularly, to a novel Sargassum-derived antifouling agent which is harmless to environment, has antifouling activity against a broad spectrum of fouling organisms, can be extracted from nature, resulting in a relative reduction in production cost as compared with... Agent: Ronald R. Santucci

20080194674 - Cb2 receptors blocks accumulation of human hepatic myofibroblasts: a novel antifibrogenic pathway in the liver: Methods for treating diseases of the livers mediated by CB2 receptors are described. The methods may include administering an effective amount of a cannabinoid, an agent that activates a CB2 receptor, a composition that includes a non-selective agonist of CB2 and a selective antagonist of CB1, a composition that includes... Agent: Townsend And Townsend And Crew, LLP

20080194676 - Formulations for oral administration of cromolyn sodium: An oral dosage form comprises cromolyn sodium (sodium or disodium cromoglycate), and an acylated amino acid delivery agent.... Agent: Pearl Cohen Zedek Latzer, LLP

20080194675 - Mixture of catechins or rather polyphenols extracted from chinese green tea or other vegetables for the prevention of prostate cancer and for the treatment of prostate hypertrophy (bph): The formulation and modality of use of a pharmaceutical preparation having the properties described below is described. This preparation is a product comprising a mixture of catechins or polyphenols extracted from chinese green tea or other vegetables that has proven to be efficacious in the chemical prevention of prostate cancer... Agent: Jacobson Holman Pllc

20080194677 - Transdermal fluid: The present invention relates to a transdermal fluid. The transdermal fluid containing an active amount of a tocotrienol is described, useful for the treatment or prevention of a cancer or a tumour or an inflammatory disorder, particularly breast cancer. The fluid can be used either in combination with known medication... Agent: Maier & Maier, Pllc

20080194678 - Process to obtain synthetic and semi-synthetic lignan derivatives, their antiparasitic activities and corresponding pharmaceutical formulations, including the therapeutic method using said lignan for the treatment of parasitosis: A process to obtain synthetic and semi-synthetic derivatives of lignans, especially dibenzylbutyrolactonic, tetrahydrofuranic, aryltetralynic, furofuranic and dibenzocyclooctanic lignans obtained by means of partial synthesis and/or full synthesis or also by isolation from plant extracts. It refers to a process to obtain synthetic and semi-synthetic derivatives of (−)-cubebin, such as: (−)-O-acetylcubebin;... Agent: Volpe And Koenig, P.c.

20080194679 - Compositions and methods for increasing metabolic activity in animal tissue: The present invention is directed to methods and compositions which include high nitrogen metal amino acid chelates that can increase the metabolic activity or metal concentration in animals. In one embodiment, an amino acid composition can comprise an amino acid chelate with a first metal and first amino acid ligand,... Agent: Thorpe North & Western, LLP.

20080194680 - Platinum analogs with bis-nitrile-containing ligands: Disclosed herein are novel platinum-based analogs possessing two nitrile substituent groups (bis-nitrile) covalently-bonded to the platinum. Also disclosed herein are the reaction schemes for the synthesis of said platinum complexes, as well as quantitative in vitro IC50 data.... Agent: Scott A. Whitaker, Ph.d., J.d. Senior Intellectual Property Counsel

20080194681 - Novel inhibitors of histone deacetylase for the treatment of disease: Disclosed herein are carbonyl compounds of Formula: (I) as described herein. Compounds as modulators of his-tone deacetylase (HDAC), pharmaceutical compositions comprising the same, and methods of treating disease using the same are disclosed.... Agent: Global Patent Group - Kal Attn: Ms Lavern Hall

20080194682 - Method and composition for treatment of skeletal dysplasias: The present invention discloses pharmaceutical compositions for the treatment of skeletal dysplasias, comprising as an active ingredient at least one natriuretic peptide. Unexpectedly, it has been shown that the natriuretic factors may be effective for bone elongation in situations of abnormal bone growth especially for achondroplasia. The effects of the... Agent: Winston & Strawn LLP Patent Department

20080194683 - Medicament for preventing and/or treating peripheral neuropathies: This invention disclosed the use of acetyl L-carnitine or of a pharmaceutically acceptable salt thereof for the preparation of a medicament for preventing and/or treating peripheral neuropathies induced by the administration of a peripheral neuropathy—inducing anticancer agent. In particular said anticancer agent is selected from the group consisting of the... Agent: Nixon & Vanderhye, Pc

20080194685 - Production of arachidonic acid in oilseed plants: Oilseed plants which have been transformed to produce arachidonic acid, recombinant constructs used in such transformations, methods for producing arachidonic acid in a plant are described and uses of oils and seeds obtained from such transformed plants in a variety of food and feed applications are described.... Agent: E I Du Pont De Nemours And Company Legal Patent Records Center

20080194684 - Treatment of neurodegenerative conditions: A method is provided for treating a patient in need of therapy for a neurodegenerative disease comprising administering to that patient a therapeutically effective dose of a lipid glyceride comprising a glycerol moiety and a fatty acid moiety, the fatty acid moiety being selected from the group consisting of γ-linolenic... Agent: Nixon & Vanderhye, Pc

20080194686 - Induction of betaine-homocysteine s-methyltransferase to elevate apolipoprotein b and very-low-density lipoprotein: Methods for use in mobilizing triacylglycerol (TAG) in order to elevate apoliprotein B and Very-Low-Density Lipoprotein (VLDL) are described. In some embodiments, the method involves providing betaine in an amount of about 3 gm/kg of body weight per day in order to mobilize TAG. In some embodiments, serum VLDL is... Agent: Mcdermott Will & Emery LLP

20080194687 - Pharmaceutical preparation containing gabapentin: A gabapentin granulate obtained by granulating gabapentin with PEG having a melting point comprised between 50 and 80° C. and pharmaceutical compositions containing it, are described.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.c.

20080194688 - Process for producing 1,4-dihydroxy-2-naphthoic acid: A composition containing 1,4-dihydroxy-2-naphthoic acid at a high concentration is obtained by intracellularly and extracellularly producing 1,4-dihydroxy-2-naphthoic acid using a bacterium belonging to the genus Propionibacterium and collecting it. This composition is efficacious in improving intestinal flora, alleviating abdominal ailments in association with the intake of milk, and preventing metabolic... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.c.

20080194689 - Disinfectant and germicidal agent: c

20080194691 - Apoptosis promoters: Compounds of formula (I), in which B1 and X1 are together alkylene which is unsubstituted or substituted with ═O and having one CH2 moiety unreplaced or replaced with CH═CH, O, NH or N(alkyl), which inhibit the activity of antiapoptotic Bcl-2 family protein members, compositions containing the compounds and methods of... Agent: Paul D. Yasger Abbott Laboratories

20080194690 - Pharmaceutical formulations of hdac inhibitors: This invention pertains to pharmaceutical compositions comprising certain carbamic acid compounds (e.g., which inhibit HDAC (histone deacetylase) activity) (e.g., PXD-101, N hydroxy-3-(3-phenylsulfamoyl-phenyl)-acrylamide)) and one or more additional ingredients selected from cyclodextrin, arginine, and meglumine. The present invention also pertains to the use of such compositions, for example, in the inhibition... Agent: Michael Best & Friedrich LLP

20080194692 - Polymorphs of suberoylanilide hydroxamic acid: The present invention provides methods of selectively inducing terminal differentiation, cell growth arrest and/or apoptosis of neoplastic cells, and/or inhibiting histone deacetylase (HDAC) by administration of pharmaceutical compositions comprising potent HDAC inhibitors. The oral bioavailability of the active compounds in the pharmaceutical compositions of the present invention is surprisingly high.... Agent: Ivor R. Elrifi Mintz, Levin, Cohn, Ferris,

20080194693 - Aminoacetonitrile derivatives and their use for controlling parasites on warm-blooded animals: The invention relates to compounds of the general formula (I) wherein Ar, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, W, a, b, m, n, o and p are as defined in claim 1, and to any enantiomers thereof. The active ingredients have advantageous pesticidal for controlling parasites... Agent: Novartis Animal Health Us Inc.

20080194694 - Antiparasitic agents: e

20080194695 - Pharmaceutical composition containing sibutramine free base and manufacturing method thereof: The present invention relates to a composition comprising sibutramine free base. The present invention provides a solid dispersion wherein sibutramine free base, acid and hydrophilic polymer are uniformly dispersed and a manufacturing method thereof. The composition of the present invention has improved dissolution rate compared to conventional compositions containing sibutramine... Agent: Stroock & Stroock & Lavan LLP

20080194696 - Novel arylbicyclo[3.1.0]hexylamines and methods and compositions for their preparation and use: The invention provides novel arylbicyclo[3.1.0]hexylamines, and related processes and intermediates for preparing these compounds, as well as compositions and methods employing these compounds for the treatment and/or prevention of central nervous system (CNS) disorders, including but not limited to depression and anxiety.... Agent: Jeffrey J. King, Esq. Black Lowe & Graham Pllc

20080194697 - Novel polyamine analog conjugates and quinone conjugates as therapies for cancers and prostate diseases: Peptide conjugates in which cytostatic and cytostatic agents, such as polyamine analogs or naphthoquinones, are conjugated to a polypeptide recognized and cleaved by enzymes such as prostate-specific antigen (PSA) and cathepsin B are provided, as well as compositions comprising these conjugates. Methods of using these conjugates in the treatment of... Agent: Morrison & Foerster LLP

20080194698 - Nmda receptor antagonists in the medical intervention of metabolic disorders: The present invention provides for the use of an NMDA receptor antagonist, preferably memantine or neramexane or a pharmaceutical acceptable salt or a prodrug of said antagonists, in the preparation of a pharmaceutical composition for the prevention, amelioration and/or treatment of disorders of metabolism influencing body weight, in particular obesity,... Agent: Mueting, Raasch & Gebhardt, P.a.

20080194699 - Stabilized compositions of volatile alkylating agents and methods of using thereof: A composition and method for treatment of cancer. The composition for treating a skin disorder, comprising: a Nitrogen Mustard or an HX salt of the Nitrogen Mustard, wherein the Nitrogen Mustard or the HX salt of the Nitrogen Mustard is in a non-aqueous vehicle or carrier that does not include... Agent: Gfd Patents, Llc

20080194700 - Use of paeonol for inhibiting angiogenesis or for enhancing radiosensitization: The present invention relates to a composition comprising paeonol of formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient for inhibiting angiogenesis, or for enhancing radiosensitization. The present invention also relates to novel use of paeonol of formula (I) or a pharmaceutically acceptable salt thereof for the... Agent: Jhk Law

20080194701 - Bifunctional enzyme with y-glutamylcysteine synthetase and glutathione synthetase activity and uses thereof: Disclosed herein are DNA molecules isolated from Streptococcus agalactiae and other bacterial species encoding a bifunctional enzyme with γ-glutamylcysteine synthetase and glutathione synthetase activities. Also disclosed are bifunctional enzymes with γ-glutamylcysteine synthetase and glutathione synthetase activities, uses of bifunctional enzymes with γ-glutamylcysteine synthetase and glutathione synthetase activities, uses of inhibitors... Agent: Bacon & Thomas, Pllc

20080194702 - Obovatol having anti-anxiety activity: The present invention relates to obovatol compound isolated from Magnolia obovata Thunb. for the prevention and treatment of anxiety disorders involved with CNS. The obovatol compound isolated from Magnolia obovata Thunb. have potent anti-anxiety activity, verified by an increased percentage of time on the open arms, an increased number of... Agent: Kirk Hahn

20080194704 - Composition of an agricultural spray oil: The invention relates to an agricultural spray oil composition comprising paraffinic base oil and emulsifiers for controlling pests and diseases in tea gardens, various plantations, fruit orchards etc. The said composition is based on C16-C18 alcohol poly glycol ether along with other emulsifiers.... Agent: Frommer Lawrence & Haug

20080194703 - Method of preparing lycopene-enriched formulations that are free of organic solvents, formulations thus obtained, compositions comprising said formulations and use of same: The present invention refers to a process to obtain a lycopene-enriched formulation free of organic solvents that comprises: (a) mixing a lycopene source with an extractant lipid, and (b) separating the lipidic phase obtained in step (a) to obtain the lycopene-enriched formulation free of organic solvents; in which the mixture... Agent: Katten Muchin Rosenman LLP

20080194705 - Lotion composition for personal use: This invention relates to emulsion compositions that can warm on contact with ambient moisture and can be used as lubricants on the skin of a person. They may be formulated in the form of a lotion.... Agent: Philip S. Johnson Johnson & Johnson

20080194706 - Modified open-cell foams and method for production thereof: i

20080194707 - Medical devices: According to the invention there is provided a medical device capable of releasing a medically active ingredient, said device including a blend of: (i) a carrier polymer or a blend of carrier polymers; (ii) a medically active ingredient; and, optionally, (iii) a water sensitive polymer for releasing said medically active... Agent: Mcdermott, Will & Emery LLP

20080194708 - Cationic polymers as thickeners for aqueous and alcoholic compositions: The present invention relates to the use of a water-soluble or water-dispersible crosslinked polymer obtainable by the polymerization of a mixture comprising 99.99 to 10% by weight of at least one α,β-ethylenically unsaturated compound having at least one cationogenic and/or cationic group per molecule, 0 to 90% by weight of... Agent: Connolly Bove Lodge & Hutz LLP

20080194709 - Dried emulsion, method for preparing same and uses thereof: Dried emulsions suited for formulation into, e.g., plant protection and detergent compositions comprise a matrix of a water-soluble or water-dispersible polymer, in which is dispersed a hydrophobic phase, and also containing a non-polyalkoxylated surfactant, the water-soluble or water-dispersible polymer being a polycarboxylate including hydrophobic units.... Agent: Buchanan, Ingersoll & Rooney Pc

20080194711 - Cx3cr1 as a marker which correlates with both disease and disease activity in multiple sclerosis patients: Multiple sclerosis (MS) is an autoimmune disease of the central nervous system (CNS) characterized by an enormous variability in its clinical presentation and course, in which clear diagnostic parameters are lacking. Here, the inventors performed an RNA screen, which indicated a role for the chemokine receptor CX3CR1 as diagnostic marker... Agent: Millen, White, Zelano & Branigan, P.c.

20080194710 - Prostatic stem cells, isolation and uses: Prostatic stem cells have been isolated. Benign prostatic hyperplasia and other proliferative diseases of the prostate may arise in prostatic stem cells. The prostatic stem cells are used as a research tool for studying cancer and other proliferative diseases of the prostate, and for developing diagnostics and therapeutics for proliferative... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20080188401 - Compounds: Binding members, e.g. human antibody molecules, which bind interleukin-6 (IL-6) and neutralise its biological effects. Use of binding members for IL-6 in medical treatment e.g. for treating inflammatory diseases and tumours associated with IL-6.... Agent: Cooley Godward Kronish LLP Attn: Patent Group

20080188399 - Drug-polymer conjugates coupled to a peptidic carrier: Monodisperse macromolecular conjugate compositions of a peptidic carrier irreversibly or reversibly conjugated with one or more effectors and one or more therapeutic agents, wherein at least one effector or therapeutic agent is attached to a pendant reactive group on said peptidic carrier via a water-soluble polymer. Monodispersity is obtained through... Agent: Synnestvedt Lechner & Woodbridge LLP

20080188400 - Methods for treating bleeding: Methods for the treatment of various bleeding disorders using variants of human Factor VII (hFVII) or activated FVII (FVIIa) having an altered activity compared to 5 recombinant FVIIa with the native human sequence.... Agent: Maxygen, Inc. Intellectual Property Department

20080188402 - Novel heterocyclic compounds, their preparation, pharmaceutical compositions containing them and their use in medicine: t

20080188403 - Parenteral combination therapy for infective conditions with drug resistant bacterium: The invention describes a pharmaceutical composition to combat multiple-drug-resistant bacteria in non-ocular infective conditions. Compositions comprising glycopeptides, in particular vancomycin, and cephalosporins, in particular ceftriaxone, are disclosed. Such compositions are found to be useful for parenteral administration for hospitalized patients with serious infections. Specifically, this invention also discloses a pharmaceutical... Agent: Amin Hallihan, LLC

20080188410 - Apoptosis-inducing polypeptides: An isolated water-soluble VP1 polypeptide of foot-and-mouth disease virus and a nucleic acid encoding the polypeptide. Also disclosed are a pharmaceutical composition containing the polypeptide or nucleic acid and related methods of inducing apoptosis and treating an apoptosis-related disorder.... Agent: Occhiuti Rohlicek & Tsao, LLP

20080188412 - Bcl-2 promoted cell death: The invention is directed towards a method of screening compounds that disrupt Bcl-2/FKBP38 binding and thereby induce apoptosis. The invention is also directed towards a method of promoting apoptotic cell death in Bcl-2 producing cells or tissues by contacting the cells or tissues with a sufficient amount of BH4 peptide... Agent: Gordon & Rees LLP

20080188417 - Beta-like glycoprotein hormone polypeptide and heterodimer: Novel β10 polypeptides and heterodimers thereof, and nucleic acid molecules encoding the same are disclosed. The invention also provides vectors, host cells, selective binding agents, and methods for producing β10 polypeptides and heterodimeric forms thereof, specifically α2/β10. Also provided for are methods for the treatment, diagnosis, amelioration, or prevention of... Agent: Amgen Inc.

20080188405 - Cancer markers: The invention related to methods of diagnosis and prognosis of cancer, the methods comprising determining the level of one or more gene products. In addition, the invention relates to modulators of the gene products for use in treatment of cancer. The genes include EIA-induced genes and Numb.... Agent: Morgan Lewis & Bockius LLP

20080188415 - Composition of matter containing harmonized hydroxyl modified fullerene substance: The present invention provides a composition of matter having a harmonized form (Φ/φ) of a hydroxyl modified fullerene having a molecular formula of C60(OH)xHy∀z (where x is from 10 to 36, and y is from 0 to 24 and z is from 0 to 12) the composition of matter having... Agent: Joseph A. Fuchs Rockey, Depke & Lyons, LLC

20080188413 - Disintegrin variants and pharmaceutical uses thereof: Disintegrin variants and pharmaceutical uses thereof are disclosed. The disintegrin variant includes an isolated polypeptide that has integrin αvβ3 receptor-antagonist activity and substantially reduced integrin αllbβ3 and/or α5β1 receptor-blocking activity as compared to a wild-type disintegrin. The variant is encoded by a modified disintegrin nucleotide sequence that encodes a modified... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080188414 - Factor ix moiety-polymer conjugates having a releasable linkage: The present invention provides Factor IX moiety-polymer conjugates having a releaseable linkage. Methods of making conjugates, methods for administering conjugates, are also provided.... Agent: Nektar Therapeutics

20080188404 - Hybrid and chimeric polypeptides that regulate activation of complement: A hybrid complement-regulating protein comprises a first functional unit of a first complement regulatory protein having complement regulating properties, a first spacer sequence of at least about 200 amino acids encoding a polypeptide that does not exhibit complement regulating properties and at least a second functional unit attached to the... Agent: Hahn Loeser & Parks, LLP

20080188409 - Kallikrein inhibitors and anti-thrombolytic agents and uses thereof: Methods, kits and compositions are described that include a non-naturally occurring kallikrein inhibitor and an anti-thrombolytic agent, e.g., an anti-fibrinolytic agent, for preventing or reducing blood loss and/or ischemia, e.g., ischemia associated with perioperative blood loss and cerebral ischemia, the onset of systemic inflammatory response, and/or reperfusion injury, e.g., reperfusion... Agent: Lowrie, Lando & Anastasi, LLP

20080188418 - Method of administering and using vegf inhibitors for the treatment of human cancer: A method of treating a human patient suffering from cancer, comprising administering an effective amount of a vascular endothelial growth factor (VEGF) trap antagonist to the human patient, the method comprising: (a) administering to the patient an initial dose of at least approximately 0.3 mg/kg of the VEGF antagonist; and... Agent: Regeneron Pharmaceuticals, Inc

20080188419 - Method of administering and using vegf inhibitors for the treatment of human cancer: A method of treating a human patient suffering from cancer, comprising administering an effective amount of a vascular endothelial growth factor (VEGF) trap antagonist to the human patient, the method comprising: (a) administering to the patient an initial dose of at least approximately 0.3 mg/kg of the VEGF antagonist; and... Agent: Regeneron Pharmaceuticals, Inc

20080188420 - Method of administering and using vegf inhibitors for the treatment of human cancer: A method of treating a human patient suffering from cancer, comprising administering an effective amount of a vascular endothelial growth factor (VEGF) trap antagonist to the human patient, the method comprising: (a) administering to the patient an initial dose of at least approximately 0.3 mg/kg of the VEGF antagonist; and... Agent: Regeneron Pharmaceuticals, Inc

20080188406 - Methods and reagents for treating glucose metabolic disorders: The invention relates to methods for potentiating, enhancing or restoring glucose responsivity in pancreatic islets or cells. The methods can be used as therapies for diseases caused by, or coincident with, aberrant glucose metabolism, such as Type II Diabetes Mellitus.... Agent: Ropes & Gray LLP

20080188408 - Protein and preventive/remedy for neurodegenerative diseases such as polyglutamine diseases by utilizing the same: e

20080188411 - Reducing myelin-mediated inhibition of axon regeneration: Oligodendrocyte-myelin glycoprotein (OMgp)-specific binding agents are used to reduce OMgp-mediated axon growth inhibition. Mixtures of axons and OMgp and mixtures of Nogo receptor (NgR) and OMgp are used in pharmaceutical screens to characterize agents as inhibiting binding of NgR to OMgp and promoting axon regeneration.... Agent: Richard Aron Osman

20080188416 - Tissue fillers and methods of using the same: The invention relates to tissue filler compositions that are alterable or removable on demand. Also provided are methods for filling or augmenting tissue using the tissue fillers described herein, and correcting such tissue implants as required.... Agent: Fish & Richardson PC

20080188407 - Treating cerebrovascular diseases with erythropoietin and granulocyte-colony stimulating factor jointly: A method for treating a cerebrovascular disease with erythropoietin (EPO) and granulocyte-colony stimulating factor (G-CSF) jointly by first identifying a subject in need of the treatment and then administering to the subject an effective combined amount of EPO and G-CSF. Also disclosed is a method for increasing in a subject... Agent: Occhiuti Rohlicek & Tsao, LLP

20080188421 - Hunter-killer peptides and methods of use: The present invention provides homing conjugates containing an antimicrobial peptide and a tumor homing molecule, wherein the tumor homing molecule comprises a dimer of two endothelium-homing peptide monomers, wherein the conjugate homes to and is internalized by a tumor cell type or tissue comprising angiogenic endothelial cells and exhibits high... Agent: Mcdermott, Will & Emery

20080188422 - Ligands having metal binding ability and targeting properties: Ligands having a metal binding domain and a targeting domain are provided. The ligands can be used to target, inhibit, and catalytically degrade or inactivate a desired target. Methods of treating a disease or condition using the ligands are also provided.... Agent: Calfee Halter & Griswold, LLP

20080188423 - Pi-3 kinase inhibitor prodrugs: The invention provides novel prodrugs of inhibitors of PI-3 kinase. The novel compounds are LY294002 and analogs thereof comprising a reversibly quaternized amine.... Agent: Polsinelli Shalton Flanigan Suelthaus PC

20080188424 - Topical non-pharmaceutical cosmetic, personal and pet care products with chiral technology and methods of formulating and manufacturing the same: As disclosed herein, a series of compounds that are not generally intended for internalization such as cosmetic, skin and pet care products are formulated using chirally correct ingredients, organic ingredients, and natural or naturally derived ingredients. In this fashion, certain deleterious biological effects due to inadvertent or incidental internalization may... Agent: Wright Law Group, PLLC Attn: Mark F. Wright

20080188425 - Dihydroouabain-like factor and diagnostic & therapeutic compositions and methods: A novel mammalian dihydroouabain-like factor is disclosed which substantially fails to cross-react with mammalian ouabain-like factor (OLF) for binding to anti-OLF antibody, but cross-reacts with plant-related dihydroouabain (dho) for binding to anti-dho antibody, has maximal u.v. absorbance at 196 nm, has a non-peptidic, non-lipidic chemical structure and a fully hydrogenated... Agent: Viksnins Harris & Padys Pllp

20080188426 - Nitrogenous fused-ring derivatives, medicinal compositions containing the derivatives, and use thereof as drugs: The present invention provides nitrogen-containing fused-ring derivatives represented by the following general formula, or pharmaceutically acceptable salts thereof, or prodrugs thereof, which exhibit an excellent inhibitory activity in human SGLT and are useful as agents for the prevention or treatment of a disease associated with hyperglycemia such as diabetes, postprandial... Agent: Sughrue Mion, PLLC

20080188427 - Fish production: This invention is directed to the use of spinosyn or a physiologically acceptable derivative or salt thereof for improved production of fish; controlling ectoparasite infestations in aquaculture raised fish; and fish feed formulations. X-17187... Agent: Eli Lilly & Company

20080188428 - Bioinformatically detectable group of novel hiv regulatory genes and uses thereof: The present invention relates to a group of novel viral RNA regulatory genes, here identified as “viral genomic address messenger genes” or “VGAM genes”, and as “viral genomic record” or “VGR genes”. VGAM genes selectively inhibit translation of known host target genes, and are believed to represent a novel pervasive... Agent: Rosetta-genomics C/o Psws

20080188437 - Compositions and methods for sirna inhibition of angiogenesis: RNA interference using small interfering RNAs which are specific for the vascular endothelial growth factor (VEGF) gene and the VEGF receptor genes Flt-1 and Flk-1/KDR inhibit expression of these genes. Diseases which involve angiogenesis stimulated by overexpression of VEGF, such as diabetic retinopathy, age related macular degeneration and many types... Agent: Pepper Hamilton LLP

20080188438 - Fra-1 expression in brain cancer: Fra-1 serves as a target for diagnosing and treating glioblastoma multiforme and related brain cancers. Cancer in a brain tissue sample is detected by analyzing expression of Fra-1 in the sample. Brain cancer is treated by modulating Fra-1 gene expression in cells of the cancer, and by inhibiting angiogenesis associated... Agent: Akerman Senterfitt

20080188436 - Intact minicells as vectors for dna transfer and gene therapy in vitro and in vivo: A composition comprising recombinant, intact minicells that contain a therapeutic nucleic acid molecule is disclosed. Methods for purifying a preparation of such minicells also are disclosed. Additionally, a genetic transformation method is disclosed, which comprises (i) making recombinant, intact minicells available that contain a plasmid comprised of a first nucleic... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20080188433 - Methods of diagnosis of spinal muscular atrophy and treatments thereof: Methods for treating SMA in a subject comprise administering to the subject a recombinant genetic vector comprising at least one copy of a Stathmin inhibitor. The inhibitor can be a Stathmin expression inhibitor. The inhibitor can be or can encode an antisense or RNAi nucleic acid, such as a siRNA... Agent: King & Spalding LLP

20080188435 - Methods of dignosing or treating depression on basis of increased cerebrospinal fluid levels of neurotrodhin 3: t

20080188432 - Oligomeric compounds for the modulation ras expression: Oligonucleotides directed against the Ha-ras gene are provided for modulating the expression of Ha-ras. The compositions comprise oligonucleotides, particularly antisense oligonucleotides, targeted to nucleic acids encoding the Ha-ras. Methods of using these compounds for modulation of Ha-ras expression and for the treatment of diseases associated with either overexpression of Ha-ras,... Agent: Edwards Angell Palmer & Dodge LLP

20080188430 - Rna interference mediated inhibition of hypoxia inducible factor 1 (hif1) gene expression using short interfering nucleic acid (sina): This invention relates to compounds, compositions, and methods useful for modulating hyproxia inducable factor (e.g., HIF1) gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of HIF1 gene... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20080188434 - Role of fgf-20 in cancer diagnosis and treatment: The invention provides methods for diagnosing cancers in humans by detecting DNA amplifications in chromosomal region 8p22, which encompasses the FGF-20 gene and the EFHA2 gene. Also provided are cancer treatment methods using inhibitors of FGF-20 and EFHA2. The invention also provides methods for promoting successful regeneration of liver function.... Agent: Ropes & Gray LLP

20080188429 - Synthetic sirna compounds and methods for the downregulation of gene expression: This invention relates to the design and synthesis of chemically modified short interfering nucleic acid (siNA) compounds capable of mediating RNA interference (RNAi) against target genes.... Agent: Elmore Patent Law Group, PC

20080188431 - Transcytosis of adeno-associated viruses: The present invention provides methods of transcytosing barrier epithelial cells using adeno-associated virus-4 (AAV4), adeno-associated virus-5 (AAV5), adeno-associated virus-7 (AAV7), bovine adeno-associated virus (BAAV), and vectors and particles derived therefrom. In addition, the present invention provides methods of delivering a nucleic acid across the barrier epithelia using the AAV4, AAV5,... Agent: Needle & Rosenberg, P.C.

20080188439 - Directed metabolism of compounds by glucuronidation and sulfonation donors to decrease toxicity: Disclosed are compositions and methods of treatment with uridine-based and phosphoadenosine-based cofactors for the prevention and treatment of toxicity associated with compounds such as acetaminophen, which undergo Phase II glucuronidation and sulfonation in the liver. Uridine diphosphoglucose, phosphoadenosine-phosphosulfate, and their derivatives can be administered exogenously either to prevent their depletion... Agent: Mark J. Pandiscio Pandiscio & Pandiscio, P.C.

20080188440 - Beta-l-2'-deoxy-nucleosides for the treatment of hepatitis b: wherein R is selected from the group consisting of H, straight chained, branched or cyclic alkyl, CO-alkyl, CO-aryl, CO-alkoxyalkyl, CO-aryloxyalkyl, CO-substituted aryl, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, amino acid residue, mono, di, or triphosphate, or a phosphate derivative; and BASE is a purine or pyrimidine base which may be optionally substituted. The... Agent: Jones Day

20080188441 - Composition for treating inflammatory diseases: The present invention relates to the use of hyaluronic acid for treating inflammatory diseases, in particular skin or mucous membrane diseases.... Agent: Millen, White, Zelano & Branigan, P.C.

20080188442 - Pyrazole-4-carboxamide derivatives as microbiocides: Compounds of the formula I in which the substituents are as defined in claim 1 are suitable for use as microbiocides.... Agent: Syngenta Crop Protection , Inc. Patent And Trademark Department

20080188443 - Tricyclic compound, compositions, and methods: m

20080188444 - Methods of treating various diseases using carnitine conjugates as dual prodrugs:

20080188445 - Tetracycline compositions for topical administration: Multi-part pharmaceutical formulations containing tetracycline for topical administration, as well as methods of making and administering the same, are disclosed.... Agent: Fitzpatrick Cella Harper & Scinto

20080188446 - Tetracycline compositions for topical administration: Pharmaceutical formulations containing tetracycline for topical administration, as well as methods of making and administering the same, are disclosed.... Agent: Fitzpatrick Cella Harper & Scinto

20080188447 - Glucocorticoid-lowering composition: This disclosure relates to a composition comprising pregnane derivatives according to Formula (I), or a salt, solvate or hydrate thereof, and to a pharmaceutically acceptable carrier or excipient. The composition may be used to lower glucocorticoid level in a human or animal. It may also be used tor modulate activity... Agent: Mathews, Shepherd, Mckay, & Bruneau, P.A.

20080188448 - Non-steroidal progesterone receptor modulators: i

20080188449 - Treatment of conditions caused by calcium abnormalities: In certain aspects, the invention relates to use of PKD2 agonists, such as triptolide and triptolide derivatives, to regulate calcium release. In other aspects, the invention relates to use of PKD2 agonists to treat or aid in the treatment of any condition in which a calcium channel, such as the... Agent: Wolf Greenfield & Sacks, P.C.

20080188450 - Macrolactams by engineered biosynthesis: Macrolactams are made by feeding aromatic amino acids as replacement starter units to a mutant strain of the geldanamycin-producing microorganism Streptomyces hygroscopicus var. geldanus NRRL 3602, wherein the gene cluster encoding enzymes for the biosynthesis of the natural starter unit 3-amino-5-hydroxybenzoic acid has been deleted.... Agent: Kosan Biosciences, Inc

20080188452 - Macrocyclic benzofused pyrimidine derivatives: Macrocyclic benzofused pyrimidine compounds, compositions comprising such compounds, methods for making the compounds, and methods of treating and preventing the progression of diseases, conditions and disorders using such compounds and compositions are described herein.... Agent: Paul D. Yasger Abbott Laboratories

20080188453 - Mapk/erk kinase inhibitors: c

20080188451 - Inhibitors of tyrosine kinases: wherein the substituents R1, R2 and R4 have the meaning as set forth and explained in the description of the invention, to processes for the preparation of these compounds, pharmaceutical compositions containing same, the use thereof optionally in combination with one or more other pharmaceutically active compounds for the therapy... Agent: Novartis Corporate Intellectual Property

20080188454 - Bicyclic aryl and bicyclic heteroaryl substituted triazoles useful as axl inhibitors: Bicyclic aryl substituted triazoles or heteroaryl substituted triazoles and pharmaceutical compositions containing the compounds are disclosed as being useful in inhibiting the activity of the receptor protein tyrosine kinase Axl. Methods of using the compounds in treating diseases or conditions associated with Axl activity are also disclosed.... Agent: Seed Intellectual Property Law Group PLLC

20080188455 - Polycyclic heteroaryl substituted triazoles useful as axl inhibitors: Polycyclic heteroaryl substituted triazoles and pharmaceutical compositions containing the compounds are disclosed as being useful in inhibiting the activity of the receptor protein tyrosine kinase Axl. Methods of using the compounds in treating diseases or conditions associated with Axl activity are also disclosed.... Agent: Seed Intellectual Property Law Group PLLC

20080188456 - Methods and compositions for repelling arthropods: wherein X is O, S, NH, N-NH2, N-CH3 or CH2, R′ is H or alkyl, R″ is alkyl, n is 0, 1, 2, 3 or 4, and mixtures thereof, optionally including a carrier material or canier. The compound is preferably selected from homopiperazine, 1-methylhomopiperazine, 1-methylpyrrolidine, (R)-(−)-2-methylpiperazine, (S)-(+)-2-methylpiperazine, 2-methylpiperazine, 1-methylpiperazine, pyrrolidine,... Agent: Usda, Ars, Ott

20080188457 - Modulation of neurogenesis with biguanides and gsk3-beta agents: The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The disclosure includes compositions and methods based on use of one or more biguanides in combination with one or more GSK3-β agents, to stimulate or activate the formation... Agent: Townsend And Townsend And Crew, LLP

20080188458 - Compounds for the treatment of hepatitis c: The invention encompasses compounds of formula I as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.... Agent: Louis J. Wille Bristol-myers Squibb Company

20080188459 - Non-steroidal compounds useful as glucocorticoid receptor modulators: This invention relates to novel amino acid derivatives of formula (I) wherein the R groups have the following meanings: —R1 is —H or -(1-4C)alkyl; —R2 is —C(O)R15 or —S(O)2R15; —R3 is —H, -(1-4C)alkyl or —OR16; —R4 is —H, -(1-4C)alkyl or —OR16; —R6 is —H or —C(R16)NOR16; —R7 is —H, -halogen,... Agent: Organon Usa, Inc. C/o Schering-plough Corporation

20080188460 - Tricyclic compounds, a process for their preparation and pharmaceutical compositions containing them: i

20080188463 - 6-oxo-6,7-dihydro-5h-dibenzo[b,d]azepin-7-yl derivatives:

20080188464 - Combinations of dopamine d2 receptor blockade with norepinephrine reuptake inhibition and with norepinephrine alpha 2 receptor blockade: Methods of treating and or preventing substance abuse/dependence, and alcohol abuse/dependence in particular. Combinations of medications are also disclosed.... Agent: Fish & Richardson PC

20080188461 - Compositions and methods for detecting, preventing and treating seizures and seizure related disorders: The present invention relates to compositions and methods for the detecting, preventing, treating, and empirically investigating seizures and seizure related disorders (e.g., West syndrome, TSC, childhood absence epilepsy, benign focal epilepsies of childhood, juvenile myoclonic epilepsy (JME), temperol lobe epilepsy, frontal lobe epilepsy, Lennox-Gastaut syndrome, occipital lobe epilepsy). In particular,... Agent: Casimir Jones, S.c.

20080188462 - Quinoline derivatives and uses thereof: This disclosure provides a new class of compounds referred to as “reversed chloroquines” (RCQs), which are highly effective against CQR and CQS malaria parasites. RCQs are hybrid molecules, which include an antimalarial quinoline analog (such as chloroquine) moiety and a CQR reversal moiety. Exemplary RCQ chemical structures are provided. Also... Agent: Klarquist Sparkman, LLP

20080188465 - Process of preparation of olanzapine form i: A process for the preparation of polymorph Form I of 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2.3-b][1,5]benzodiazepine, or olanzapine.... Agent: Sandoz Inc

20080188466 - Pyridazinone compounds: The invention is directed to pyridazinone compounds and pharmaceutical compositions containing such compounds that are useful in treating infections by hepatitis C virus.... Agent: Connolly Bove Lodge & Hutz LLP

20080188467 - Compounds for the prevention and treatment of cardiovascular diseases: The present disclosure relates to compounds, which are useful for regulating the expression of apolipoprotein A-I (ApoA-I), and their use for treatment and prevention of cardiovascular disease and related disease states, including cholesterol- or lipid-related disorders, such as, for example, atherosclerosis.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080188468 - Substituted para-trifluoromethyl phenylate compounds and its preparation and use thereof: The compounds of present invention have broad-spectrum activity, and may be used to control diseases in all sorts of plants caused by oomycete, basidiomycete, ascomycete pathogens and deuteromycete, and it may also provide good control efficacy at very low dosage because of the high activity. The compounds of the invention... Agent: Smith, Gambrell & Russell

20080188469 - Vaccination: The present invention relates to improvements in DNA vaccination and in particular, methods of vaccinating a mammal against disease states, and to the use of imidazo[4,5-c]quinolin-4-amine derivative adjuvants in the manufacture of medicaments for boosting previously vaccinated individuals.... Agent: Glaxosmithkline Corporate Intellectual Property - Uw2220

20080188470 - Oxazolidinone derivatives as antimicrobials: Provided herein are novel substituted phenyl oxazolidinones and to processes for the synthesis thereof. Also provided are pharmaceutical compositions comprising one or more compounds described herein The compounds described can be useful antimicrobial agents, which can be effective against a number of human and veterinary pathogens, including gram-positive aerobic bacteria... Agent: Ranbaxy Inc.

20080188471 - Dipeptidyl peptidase-iv inhibiting compounds, method of preparing the same, and pharmaceutical compositions containing the same as an active agent: The present invention relates to novel compounds exhibiting good inhibitory activity versus Dipeptidyl Peptidase-IV (DPP-IV), methods of preparing the same and pharmaceutical compositions containing the same as an active agent.... Agent: Cantor Colburn, LLP

20080188472 - Indole-2-carboxylic acid hydrazides: Compounds of formula (I) or pharmaceutically acceptable salts thereof, are inhibitors of glycogen phosphorylase and are useful in the prophylactic or therapeutic treatment of diabetes, hyperglycemia, hypercholesterolemia, hyperinsulinemia, hyperlipidemia, hypertension, atherosclerosis or tissue ischemia, e.g. myocardial ischemia, or as cardioprotectants or inhibitors of abnormal cell growth.... Agent: Osi Pharmaceuticals, Inc.

20080188473 - Indoles useful in the treatment of inflammation: There is provided a compound of formula: (I) wherein X, R1, R2, R3, R4, R5, R6, R7 and R8 have meanings given in the description, and pharmaceutically-acceptable salts thereof, which compounds are useful in the treatment of diseases in which inhibition of the activity of microsomal prostaglandin E synthase-1 is... Agent: Morgan Lewis & Bockius LLP

20080188474 - Substituted triazoles useful as axl inhibitors: Substituted triazoles and pharmaceutical compositions containing the compounds are disclosed as being useful in inhibiting the activity of the receptor protein tyrosine kinase Axl. Methods of using the compounds in treating diseases or conditions associated with Axl activity are also disclosed.... Agent: Seed Intellectual Property Law Group PLLC

20080188475 - Novel interleukin-1 and tumor necrosis factor-alpha modulators, syntheses of said modulators and their enantiomers and methods of using said modulators: Disclosed herein are novel tricyclic diterpene compounds. These compounds, including their prodrug esters and acid-addition salts, are useful as Interleukin-1 and Tumor Necrosis Factor-alpha modulators, and thus useful in the treatment of various diseases. Pharmaceutical compositions comprising, and uses of, theapeautically effective amounts of the above compounds and their prodrug... Agent: Knobbe Martens Olson & Bear LLP

20080188476 - Method for treating obesity: The present invention relates, in general, to obesity, and, in particular, to a method of treating obesity and minimizing metabolic risk factors associated therewith using, for example, zonisamide or other weight-loss promoting anticonvulsant either alone or in combination with bupropion or other compound that enhances the activity of norepinephrine and/or... Agent: Nixon & Vanderhye, PC

20080188477 - Substituted heterocycles, their use as medicament, and pharmaceutical preparations comprising them: e

20080188478 - Compounds useful in therapy:

20080188479 - Methods to treat cancer with 10-propargyl-10-deazaaminopterin and methods for assessing cancer for increased sensitivity to 10-propargyl-10-deazaaminopterin: The present invention relates to a method for assessing the sensitivity of a patient's cancer to treatment with 10-propargyl-10-deazaaminopterin and a method for selecting a patient for treatment of cancer with 10-propargyl-10-deazaaminopterin, by determining the amount of a selected polypeptide expressed by the cancer and comparing the amount with the... Agent: Marina Larson & Associates LLC Re: Msk

20080188480 - Use of sildenafil, vardenafil and other 5-phosphodiesterase inhibitors to enhance permeability of the abnormal blood-brain barrier: This invention relates to compositions, methods and kits for enhancing the permeability of the blood-brain barrier. Particularly, compositions comprising 5-phosphodiesterase inhibitors, such as sildenafil, vardenafil, or tadalafil, when administered to a mammal, will selectively enhance the permeability of the blood-brain barrier in abnormal brain tissue. This selective enhancement allows for... Agent: Davis Wright Tremaine LLP/los Angeles

20080188481 - Indole, azaindole and related heterocyclic 4-alkenyl piperidine amides: i

20080188483 - Compounds and compositions as protein kinase inhibitors: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the Abl, Bcr-Abl, BMX, BTK, CHK2, c-RAF, CSK,... Agent: Genomics Institute Of The Novartis Research Foundation

20080188482 - [1h-pyrazolo[3, 4-d]pyrimidin-4-yl]-piperidine or -piperazine compounds as serine-theoronine kinase modulators (p70s6k, atk1 and atk2) for the treatment of immunological, inflammatory and proliferative diseases: The invention provides compounds of formula (I) and methods for inhibition of kinases, more specifically p70S6 kinases, and more preferably p70S6, Akt-1 and Akt-2 kinases. The invention provides compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration, chemoinvasion and metabolism.... Agent: Mcdonnell Boehnen Hulbert @ Berghoff LLP

20080188484 - Indol-2-yl-piperazin-1-yl-methanone derivatives: e

20080188485 - Piperidine derivatives useful as ccr5 antagonists: for the treatment of HIV, solid organ transplant rejection, graft v. host disease, arthritis, rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, psoriasis, asthma, allergies or multiple sclerosis is disclosed, as well as novel compounds, pharmaceutical compositions comprising them, and the combination of CCR5 antagonists of the invention in combination with... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20080188486 - (indol-4-yl) or (indol-5-yl)-piperazinylmethanones: r

20080188487 - 5-amido-(1h-indol-2-yl)-piperazin-1-yl-methanone derivatives:

20080188488 - Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors: Methods of treating an SCD-mediated disease or condition in a mammal, preferably a human, are disclosed, wherein the methods comprise administering to a mammal in need thereof a compound of formula (I) where x, y, J, K, W, V, R3, R4, R5, R5a, R6, R6a, R7, R7a, R8 and R8a... Agent: Seed Intellectual Property Law Group PLLC

20080188489 -